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ABSTRACT 
DEVELOPMENT OF CLINICALLY RELEVANT IN VITRO PERFORMANCE TESTS FOR 
POWDER INHALERS 
By Xiangyin Wei, M.S. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2015 
Major Director: Peter R. Byron, Ph.D. 
Professor, Department of Pharmaceutics 
While realistic in vitro testing of dry powder inhalers (DPIs) can be used to establish 
in vitro–in vivo correlations (IVIVCs) and predict in vivo lung doses, the aerodynamic 
particle size distributions (APSDs) of those doses and their regional lung deposition 
remains unclear. Four studies were designed to improve testing centered on the behavior 
of Novolizer®. Different oropharyngeal geometries were assessed by testing different 
mouth-throat (MT) models across a realistic range of inhalation profiles (IPs) with 
Salbulin® Novolizer®. Small and large Virginia Commonwealth University (VCU) and 
Oropharyngeal Consortium (OPC) models produced similar ranges for total lung dose in 
vitro (TLDin vitro), while results for medium models differed significantly. While either group
xxiv 
 
may be selected to represent variations in oropharyngeal geometry, OPC models were 
more difficult to use, indicating that VCU models were preferable. To facilitate simulation 
of human IPs through DPIs, inhalation profile data from a VCU clinical trial were analyzed. 
Equations were developed to represent the range of flow rate vs. time curves for use with 
DPIs of known airflow resistance. A new method was developed to couple testing using 
VCU MT models and simulated IPs with cascade impaction to assess the APSDs of TLDin 
vitro for Budelin® Novolizer®. This method produced IVIVCs for Budelin’s total lung dose, 
TLD, and was sufficiently precise to distinguish between values of TLDin vitro and their 
APSDs, resulting from tests using appropriately selected MT models and IPs. For 
example, for slow inhalation, TLD values were comparable in vivo and in vitro; TLDin vitro 
ranged from 12.2±2.9 to 66.8±1.7 mcg aerosolized budesonide while APSDs in vitro had 
mass median aerodynamic diameters of 3.26±0.27 and 2.17±0.03 µm, respectively. To 
explore the clinical importance of these variations, a published computational fluid 
dynamic (CFD) model was modified and coupled to accept the output of realistic in vitro 
tests as initial conditions at the tracheal inlet. While simplified aerosol size metrics and 
flow conditions used to shorten CFD simulations produced small differences in theoretical 
predictions of regional lung deposition, the results broadly agreed with the literature and 
were generally consistent with the median values reported clinically for Budelin. 
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CHAPTER 1 
INTRODUCTION 
1.1  BACKGROUND 
The history of inhalation therapy can be traced back some 4,000 years, when 
ancient Indian herbal smoke preparations with bronchodilating properties were used to 
treat asthma and other respiratory conditions (Anderson, 2005). But it was not until 1956, 
and the launch of the first pressurized metered dose inhaler (pMDI), that the modern era 
of pulmonary drug delivery began (Sanders, 2007). In the last 60 years we have seen 
great advances in aerosol delivery technology, and the emergence of safer and more 
effective drugs to treat pulmonary diseases like asthma and chronic obstructive 
pulmonary disease (COPD). At the time of this thesis, there are 32 branded orally inhaled 
drug products covering 19 active pharmaceutical ingredients (APIs) approved by the U.S. 
Food and Drug Administration (FDA) for treatment of asthma and COPD (U.S. Food and 
Drug Administration, 2015a). With the exception of some nebulizer solutions however, 
none of these products have generic competitors in the USA. Patients are forced to pay 
for branded inhalers and unless they have top-notch insurance or high income, disease 
treatment can be difficult to maintain due to the high cost of these combination products 
that combine a drug formulation with a device to deliver it as an aerosol (Rosenthal, 2013). 
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Ideally, as products come off patent, the launch for cheaper generic equivalents 
should alleviate the problem. Unfortunately, even though a number of patents for inhaled 
drugs are expiring [e.g. Advair® Diskus®, U.S. patent 5,873,360 expires on Feb 23, 2016; 
(U.S. Food and Drug Administration, 2015b)], product development scientists and the 
regulators experience problems proving that a new inhaler delivers drug in the same way 
as the “innovator”.  
 
1.2  DRY POWDER INHALER 
Dry powder inhalers (DPIs) are a major developing platform for aerosol drug 
delivery that has been replacing propellant based devices in recent years, in part because 
of the environmental effects of chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) 
propellants. Most commercial DPIs are passive DPIs that require the patient’s inhalation 
power to generate the drug aerosol cloud. Passive DPIs can be classified into three 
categories: (a) unit dose, where the drug formulation is stored in a single capsule, blister 
or cartridge (e.g. Foradil® Aerolizer®); (b) multiple unit dose, where the drug formulation 
is stored in blisters fixed on strips or disks (e.g. Advair® Diskus®); (c) multi-dose, where 
the drug formulation is stored in a reservoir (e.g. Budelin® Novolizer®) and the powder 
metered by the device itself.  
A typical powder formulation contains micronized drugs milled to a respirable 
particle size (usually 1–5 µm), blended with larger carriers (e.g. α-lactose monohydrate) 
to facilitate flow and reduce the aggregation of micronized drug powders (Telko & Hickey, 
2005). When a patient activates a DPI and inhales, air is introduced into the device that 
causes the drug-carrier blend to be dispersed and to deaggregate due to air turbulence 
3 
 
and mechanical impaction with the device (Telko & Hickey, 2005). The extent of powder 
dispersion and the efficiency in generating small particles for pulmonary delivery from a 
DPI is dependent on device design (which determines powder dispersion mechanism), 
drug formulation (which determines the cohesive and adhesive forces between particles), 
and the patient’s inhalation maneuver (which determines the forces available for 
aerosolization). General principles of powder metering and dispersion from a typical DPI 
are illustrated in Figure 1.1.  
 
Figure 1.1. General principles of powder metering and dispersion from a DPI (Telko & 
Hickey, 2005). A typical powder formulation contains micronized drugs blended with much 
larger carrier particles that when inhaled, deaggregate to generate small respirable 
particles for pulmonary delivery.  
 
Although different DPIs adopt similar principle for powder dispersion (Figure 1.1), 
their device design and powder dispersion mechanisms differ significantly. For example, 
Aerolizer® contains pre-metered drug in a single hard capsule. The patient activates the 
inhaler by piecing the capsule ends with eight pins at the device base (four pins on each 
side). Upon inhalation, the capsule spins in the capsule chamber and releases powder 
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into the airstream due to vibration and centrifugal forces; drug-carrier deaggregation 
occurs largely through particle-device collisions and air turbulence (Coates et al., 2005). 
Novolizer® contains drug formulations in a cartridge that may or may not be replaceable 
and may deliver up to 200 metered doses (Fenton et al., 2003). The device uses “Air 
Classifier Technology (ACT)” that enables collisions to occur within a “cyclone” inside the 
device so that during inhalation, tangential air is introduced at different point inside a multi-
channel classifier which consequently, causes the drug-carrier agglomerates to 
deaggregate under centrifugal, collision and frictional forces (de Boer et al., 2003). The 
device is designed to favor the retention of large carrier particles within the classifier, 
while small drug particles are easily released from the device (de Boer et al., 2003). In 
vitro testing under compendial conditions (see section 1.4) showed that Novolizer delivers 
consistent doses in the early, middle, and late stages of cartridge emptying with a 
comparatively small relative standard deviation (RSD) of 5.56% (de Boer et al., 2004). 
More detailed reviews on this topic and recent advances can be found at (Chan et al., 
2014; Son & McConville, 2008; Zhou et al., 2014).  
Of the many variations in DPI design, airflow resistance across the device is an 
important factor that affects a patient’s inhalation maneuver. Clark and Hollingworth (1993) 
found that the mean peak inhalation flow rate (PIFR) generated by healthy volunteers at 
their maximum inhalation efforts reached over 150 L/min for a low resistance DPI device 
(Rotahaler®), while the value was only 50 L/min for a high resistance DPI device 
(Inhalator®). In the same study, the authors also found that PIFR dropped to 80 L/min 
and 30 L/min respectively for the two DPIs when subjects reduced their inhalation efforts 
to a “comfortable level” (Clark & Hollingworth, 1993). As passive DPIs rely upon a 
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patient’s inhalation to disperse the formulation and deliver drug to the lung, changes in 
inhalation effort through a DPI can significantly affect drug deposition in the airways. 
Borgström et al. (1994) reported that total lung deposition of budesonide inhaled via 
Turbuhaler® reached 27.7% of the metered dose when subjects inhaled at a PIFR of 60 
L/min, while the value decreased to 14.8% for a lower PIFR of 35 L/min. Similarly, 
Newman et al. evaluated budesonide deposition from “ASTA Medica”, a prototype inhaler 
that became the commercially available Budelin® Novolizer®, and found on average, 
using gamma scintigraphy, that this inhaler delivered higher doses to the lung at a PIFR 
of 99 L/min (32.1% of the metered dose) than at 65 L/min or 54 L/min (25.0% and 19.9% 
of the metered dose, respectively) (Newman et al., 2000). To ensure optimal drug delivery, 
patients are usually instructed to inhale fast and deeply through a DPI, and training tools 
such as In-Check Dial™ (a peak flow meter integrated with different resistance orifices to 
mimic DPI resistances) may be used to help patients reach a desired PIFR for a given 
device (Chrystyn, 2003; Lavorini et al., 2010). Even with trained inhalation maneuvers 
however, large inter-subject variations are still observed in the clinical lung deposition 
studies (Borgström et al., 2006). Because of this variability, and because powder inhalers 
are likely to dominate the aerosol marketplace of the future, this thesis is focused on the 
development and application of realistic (“bio-relevant”) testing of DPIs. Indeed, most of 
the work in this thesis seek to explain the variability seen in lung deposition for “ASTA 
Medica”, the Budelin prototype. Newman et al. (2000) explained the wide variations in 
drug delivery to the lung based on variations in the way normal subjects inhaled. In this 
thesis, experiments and results are presented that offer insights both to the effects of 
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inhalation profiles and orphyaryngeal geometry on pulmonary drug deposition from the 
same inhaler.  
 
1.3  INHALER BIOEQUIVALENCE: STATUS AND CHALLENGES 
FDA approval of generic products requires that bioequivalence be demonstrated 
between the proposed drug product and the “innovator” or reference listed drug (RLD) 
(U.S. Food and Drug Administration, 2013). This requires comparative testing between 
the generic and the RLD, where the applicants must prove “no significant difference in 
the rate and extent to which the active ingredient or active moiety in pharmaceutical 
equivalents or pharmaceutical alternatives becomes available at the site of drug action 
when administered at the same molar dose under similar conditions in an appropriately 
designed study” ("Code of Federal Regulations," 2015). While pharmacokinetic (PK) 
studies alone are usually considered sufficient for establishing bioequivalence of orally 
administered drugs with systemic action (Saluja et al., 2014), situations are far more 
complex for pulmonary delivered drugs with local or “topical” activity. As illustrated in 
Figure 1.1, aerosolized drugs from an inhaler are designed to be delivered via oral 
inhalation. Because the mouth is the conduit, the drug deposits in both the oropharynx 
and lung. Drug depositing in the oropharyngeal region will be swallowed into the 
gastrointestinal (GI) tract, and only the dose entering the lung can induce local therapeutic 
effects. Furthermore, because local effects in the airways depend on regional dose and 
distribution (Anderson & Newman, 2009; Usmani, 2015; Usmani & Barnes, 2012; Usmani 
et al., 2005), the way in which an aerosol deposits in the lung can influence product and 
drug efficacy. Given that the aerosols produced from inhalers may vary in size depending 
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on drug formulation, device design and patient-related human factors, this “proof of 
similarity” or bioequivalence becomes quite a challenge, especially because some 
inhalers contain multiple drugs with different aerosol characteristics (Daley-Yates et al., 
2014; Daley-Yates et al., 2009; Tarsin et al., 2006). Taken overall, because drug 
concentration at the “site of action” does not rely upon the systemic circulation (the plasma 
is “downstream” of drug absorption from either the GI tract or the lung; Figure 1.2), PK 
studies alone are not considered adequate to establish bioequivalence of orally inhaled 
drug products in the USA (Saluja et al., 2014). In practice, PK may assure equivalent 
systemic exposure but it fails to assure local exposure in the airways.  
 
Figure 1.2. Schematic of drug deposition and disposition in the human body after 
delivery through the pulmonary route. Figure was redrawn  from (Anderson & Newman, 
2009). 
 
FDA’s current thinking about inhaler bioequivalence is based on an aggregate 
“weight of evidence” approach (Lee et al., 2009; Saluja et al., 2014); for DPIs, this includes 
demonstration of comparative in vitro performance [single actuation content and 
aerodynamic particle size distribution (APSD) tests], comparative systemic exposure (PK 
studies), comparative local action (clinical end point studies), and comparative device and 
Inhaler 
Oropharyngeal 
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Lung 
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Gastrointestinal Tract Systemic Circulation
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formulation design (Figure 1.3). Product-specific draft guidance has also been released 
for DPIs containing fluticasone propionate and salmeterol xinafoate based on this 
approach (U.S. Food and Drug Admiistration, 2013).  
 
Figure 1.3. FDA’s aggregate “weight of evidence” approach for establishing 
bioequivalence of dry powder inhalers. Figure was redrawn from (Lee et al., 2009). 
 
Of the two major types of multi-dose inhalers, DPIs are arguably a greater 
challenge to regulators because they rely on the patient’s inhalation to produce the 
aerosol, and aerosol properties can depend on the way the patient inhales (Tarsin et al., 
2006). Even for low-variance inhalers [e.g. Novolizer®, (Delvadia et al., 2012)], it appears 
to be difficult to select individuals that even when trained, inhale in such a way that the 
lung dose in vivo is reproducible. In practice, topical delivery from DPIs is variable even 
in normal trained subjects (Newman et al., 2000), and this variability needs to be 
recognized when attempting to assess the equivalence of two inhalers. In addition to this, 
when comparing in vitro properties, a performance characteristic should be chosen that 
has a proven relationship to efficacy in the clinic. In short, it is necessary to show an  in 
vitro–in vivo correlation (IVIVC) for example, between inhaler in vitro attributes (e.g. 
APSDs) and in vivo drug deposition in the lung (Newman & Chan, 2008), before using 
Comparative 
In Vitro Studies 
Comparative 
Pharmacokinetic Studies
Comparative 
Clinical Endpoint Studies 
Bioequivalence 
Device and Formulation Design 
9 
 
the in vitro attribute to judge the similarity of two devices. This raises uncertainties for 
product development scientists and the regulators concerning the meaningful definition 
of in vitro equivalence between the test and reference products. In short, the answer to 
the question “If the two products show equivalence in vitro, will they have potentially 
equivalent in vivo performance?” is presently unknown. A good example to illustrate the 
complexity of this topic is the studies published by Daley-Yates et al. (2014; 2009), where 
test and reference DPIs showed comparable in vitro performance, but in vivo PK studies 
suggested significant differences in systemic exposure and lung absorption of fluticasone 
between the two inhalers. One possible reason for those discrepancies is that compendial 
(e.g. United States Pharmacopeia, or USP) in vitro test methods for measurement of 
APSDs (U.S. Pharmacopeial Convention, 2013) do not readily reflect the real situation of 
inhaler use in the clinic (see section 1.4), so that apparent “equivalence” in vitro does not 
necessarily relate to the clinical performance of the inhalers (Daley-Yates et al., 2014). 
As we enter an era where generic inhalers are needed, it will be necessary and beneficial 
for both drug developers and regulators if more predictive in vitro test methods are 
researched and established for orally inhaled drug products.  
 
1.4  IN VITRO PREDICTION OF AEROSOL DEPOSITION IN THE HUMAN LUNG 
The study of aerosol deposition in the human lung dates back to the 1950s, when 
the deposition of hazardous environmental aerosols in the lung were of major concerns 
to the public. Specifically, the dosimetry, proportion and position of aerosol deposition 
and how the human lung could remove certain aerosols, after deposition had occurred 
were studied for humans breathing tidally (Gerrity, 1989). In those studies, human 
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subjects were instructed to inhale radiolabeled, monodisperse, insoluble particles through 
a large mouthpiece using required breathing patterns. Subsequently, aerosol deposition 
and clearance in the lung were monitored externally using scintillation detectors. A large 
meta-analysis of these deposition studies was performed by Stahlhofen et al. (1989) in 
the late 1980s with the goal of reducing discrepancies in existing deposition data and 
providing reliable, less variable, empirical equations for predicting aerosol dosimetry in 
different regions of the respiratory tract. Factors including particle characteristics, subjects’ 
breathing patterns and airway geometries were considered important determinants of 
aerosol deposition in the human lung.  
Table 1.1. Aerosol deposition study characteristics: Environmental aerosols vs. drug 
aerosols delivered from DPIs.  
Environmental Aerosols Drug Aerosols from DPIs 
a. Monodisperse dilute aerosols a. Polydisperse concentrated aerosol 
clouds 
b. Particles are insoluble b. Particles are soluble and absorbable  
c. Particle size do not change – aerosols 
are stable 
c. Drug-carrier deaggregation and APSDs 
depends on patient-device interactions 
– aerosols are not stable; 
deagglomeration and/or hygroscopic 
effects may occur during administration 
d. Subjects inhale tidally from a stable 
aerosol reservoir 
d. Subjects inhale once only, fast and 
deeply through the inhaler; aerosols 
are created during this process 
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The semi-empirical models developed by Stahlhofen et al. (1989) and others [e.g. 
the ICRP model (International Commission on Radiological Protection (ICRP), 1994)] 
provided valuable information for pharmaceutical scientists wishing to study aerosol drug 
deposition in the human lung. However, caution should be applied when using these 
models to predict drug deposition from inhalers. Stahlhofen’s work (Stahlhofen et al., 
1989) generally employed insoluble dilute stable aerosols that did not change size during 
entry into the human subjects following or during tidal inhalation in each study. DPIs on 
the other hand involve single deep inspirations of powder mixtures; such concentrated 
aerosols are created and administered at the same time. That situation is far more 
complex than those involved in early lung deposition studies (Table 1.1).  
The present compendial methods (U.S. Pharmacopeial Convention, 2013) 
determine the APSD of the drug leaving a powder inhaler under fixed conditions (airflow 
rate and volume are specified). Often the data is processed to yield the mass of drug 
exiting the inhaler with aerodynamic diameters smaller than about 5 µm because this is 
often construed as most likely to penetrate the lung. Indeed, the “fine particle fraction” 
(FPF, designated as drug fraction with particle size < ~5 µm) is usually considered to be 
an important in vitro parameter that predicts inhaler performance in vivo. The 
pharmacopeial methods were initially designed for quality control (QC) and batch release 
purposes, while offering an approximation of inhaler use in the clinic to capture key 
performance characteristics. For example, with DPIs, APSD is tested at a constant flow 
rate equivalent to the maintenance of a 4 kPa pressure drop across the inhaler (to 
approximate the inhalation effort that humans can potentially achieve), with 4 L air (to 
approximate the vital capacity of a human adult). The aerosol exiting the inhaler is then 
12 
 
passed through the 90° bent induction port into a standardized, calibrated cascade 
impactor (U.S. Pharmacopeial Convention, 2013) (Figure 1.4). While the methods are still 
far from realistic, as human oropharyngeal geometries are much more complex than the 
induction port (Swift, 1994), and the square wave profile during testing does not resemble 
a patients’ breath profile, attempts have been made to correlate the particle size 
distribution data collected from DPIs with the human lung deposition results in vivo.  
 
Figure 1.4. Illustration of compendial (pharmacopeial) methods to determine 
aerodynamic particle size distributions (APSDs) for DPIs at a fixed air flow rate and 
volume. Aerosol exiting the inhaler is passed through the 90° bent induction port into a 
standardized, calibrated Next Generation Pharmaceutical Impactor (NGI; a commonly 
used cascade impactor for testing pharmaceutical aerosols). A pre-separator is used to 
remove large particles in the aerosol cloud before it enters NGI.  
 
Newman and Chan (2008) performed a meta-analysis of the literature data on this 
topic and found that in general, FPF6.8µm appeared to over-predict the fraction of the drug 
dose depositing in the lung tested using gamma scintigraphy, while FPF3µm appeared to 
produce a correlation with the mean in vivo lung deposition data  (Figure 1.5). The study 
was a nice exploration of the use of convential APSD data (collected during QC testing) 
to predict the mean in vivo lung dose. In spite of those findings however, clinical variations 
in lung deposition, which may even exceed 100% coefficient of variation (CV) for low dose 
Vacuum Pump 
(Constant Flow) 
USP Induction Port
DPI 
Pre-separator
Next Generation Pharmaceutical Impactor 
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DPIs (Borgström et al., 2006), shows that DPI deposition remains “patient specific” and 
unpredictable.  
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Figure 1.5. Correlations between mean total lung deposition (by gamma scintigraphy) 
and the mean drug fraction with aerodynamic diameters smaller than 6.8 µm (left panel) 
and 3 µm (right panel), respectively. Figures were redrawn from Newman and Chan 
(2008). Only data for DPIs were included. Individual variations between subjects were not 
shown.  
 
Other than trying to correlate particle size distribution with total lung deposition, a 
lot of efforts have been devoted to developing more realistic in vitro test methods and 
improve our ability to predict inhaler in vivo performance. These studies have been mainly 
focused on developing realistic human mouth-throat (MT) models and inhalation profiles 
(IP) to mimic inhaler use in the clinic, with the ultimate goal of achieving better in vitro–in 
vivo correlations (IVIVCs). Recent advances relevant to DPI testing in this area are 
summarized below. 
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Realistic Mouth-Throat Models 
The human upper airway has long been recognized as a barrier to sucessful 
pulmonary drug delivery, where aerosolized drugs must bypass the right-angled 
oropharyngeal region in order to reach the lung (Swift, 1994). Borgström et al. (2006) 
found that throat deposition was the major source of inter-subject variations observed in 
clinical lung deposition studies. They suggested that upper airway geometries may 
significantly affect aerosol deposition in the lung. Three dimensional (3D) geometries of 
the oropharyngeal region can be obtained from cadaver casts or medical imaging like 
computed tomography (CT) using scans from x-ray or magnetic resonance imaging (MRI); 
the latter has become the major tool for studying airway geometries because cadaver 
casts usually suffer from distortion from postmortem tissue shrinkage (Byron et al., 2010). 
While individual upper airway geometries have been studied and used to improve IVIVCs 
(Olsson et al., 1996), more “representative” human oropharyngeal geometries and the 
corresponding physical models remain uncertain. Questions like, “What is the most 
representative geometry?” and “Can the model(s) cover inter-subject variations?”, remain 
difficult to answer and controversial. Different approaches have been proposed regarding 
this topic (Burnell et al., 2007; Delvadia et al., 2012; Olsson et al., 2013; Stapleton et al., 
2000; Xi & Longest, 2007; Zhang et al., 2007) and three main types of realistic MT models 
developed based on oropharyngeal geometry studies of healthy human adults (Figure 
1.6). MT models for children and infants have also been developed (Carrigy et al., 2014; 
Ruzycki et al., 2014), but the topic of pediatric models is beyond the scope of this thesis 
and will not be discussed.  
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(c) Internal Geometry or Diagram 
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*Determined experimentally using water 
(d) Internal Volume (cm3) 
Figure 1.6. Realistic mouth-throat (MT) models developed for inhaler in vitro testing: 
Oropharyngeal Consortium (OPC) Large (OPCL), OPC Medium (OPCM), OPC Small 
(OPCS) (Burnell et al., 2007; Oropharyngeal Consortium, 2013), Virginia Commonwealth 
University (VCU) Large (VCUL), VCU Medium (VCUM), VCU Small (VCUS) (Delvadia et 
al., 2012; Longest, 2012), Alberta Idealized Throat (AIT; Medium) (Stapleton et al., 2000).  
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Small, medium and large Virginia Commonwealth University (VCU) MT models 
(Longest, 2012) were designed and built in our laboratories using well-documented 
anatomical data from the literature. In brief, the VCU medium MT model (Figure 1.6) is a 
geometrically realistic physical model of the mouth-throat that was constructed by rapid 
prototyping (Byron et al., 2010). The model is derived from CT imaging of a male human 
oropharynx as described by Xi and Longest (2007) and Xi et al. (2008). The imaging data 
was processed and simplified by computer-aided design (CAD) to preserve important 
anatomical details but enable reliable prototyping. VCU small and VCU large MT models 
(Figure 1.6) were scaled by volume to cover approximately 95% of the volumetric 
variations seen in mixed gender healthy human adults as described in Delvadia et al. 
(2012). The internal MT volumes for the VCU small, medium and large models of 26.6, 
61.6, and 96.1 cm3, respectively, were consistent with 95% confidence intervals (CI) 
derived from Burnell et al.’s values for mean±2SD (Burnell et al., 2007). 
Small, medium and large Oropharyngeal Consortium (OPC) MT models 
(Oropharyngeal Consortium, 2013) were also developed by an industry consortium 
(AstraZeneca, GlaxoSmithKline and sanofi-aventis) to represent the medium and 
extremes for in vitro aerosol drug capture in mixed gender human subjects inhaling 
through different mouthpieces (Burnell et al., 2007). OPC models were constructed using 
real human oropharyngeal geometries produced from MRI imaging, with slight 
modifications of the mouth opening of each geometry to facilitate in vitro testing 
(Oropharyngeal Consortium, 2013). Notably, the selection of the small, medium and large 
OPC models was based on the Consortium’s assessment of aerosol deposition, not on 
measurements of the internal geometries of the models themselves (Burnell et al., 2007). 
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The Alberta Idealized Throat (AIT) is an idealized model developed (a) to represent the 
“average geometry” of the human mouth-throat and its major fluid dynamic properties 
(with respect to aerosol capture) and (b) enable ease of manufacturing in metal (Stapleton 
et al., 2000). The 3D geometry of AIT was designed based on dimensions from MRI 
images, CT images, and visual observations to mimic those features in a real human 
mouth-throat that cause aerosol deposition (Warren H Finlay et al., 2010). Currently only 
a medium AIT model is available, although a ±30% scaling factor was proposed to cover 
inter-subject variability in aerosol deposition (Warren H Finlay et al., 2010). All models 
shown in Figure 1.6 are geometrically different and tailored in different ways to enable 
their manufacture and use. One feature in common, however, is that the interior surfaces 
of all models are unrealistically smooth, and they also neglect the entry of the 
nasopharyngeal airways into the back of the throat. Additionally, these models require an 
airtight adapter to locate and to angle an inhaler “correctly” into the mouth opening of the 
model.  
Inhalation Profiles 
The commercially available DPIs for treatment of asthma and COPD are all breath 
actuated, which requires a patient’s inhalation to disperse powdered drug formulations. 
These formulations usually contain micronized drugs blended with lactose as the carrier. 
Different types of lactose are employed that result in different lactose and drug aerosols 
for lung delivery. The extent of drug-carrier de-aggregation, and thereafter the size 
distribution of drug aerosols, depends on the combined effects of inhaler design, powder 
formulation, and patient’s inhalation maneuver (Telko & Hickey, 2005). While inhaler 
design is important however, it is likely that the patient’s inhalation profile (IP) is the most 
18 
 
significant feature defining pulmonary drug delivery from DPIs. Aerosol dispersion and 
release from a selected DPI is known to be affected by many factors like a patient’s peak 
inhalation flow rate (PIFR), flow increase rate (FIR; the rate at which the air flow 
accelerates to PIFR) and inhaled volume (V) (Chavan & Dalby, 2002; de Boer et al., 1997). 
Realistic IPs therefore, if appropriately collected and chosen, are likely to enable studies 
that provide more complete information on DPI performance than we presently see from 
compendial tests alone (Burnell et al., 1998a).  
The general method to collect IPs from a group of healthy subjects or patients is 
to use an “inhalation flow rate recorder”, where a flow meter and/or flow-calibrated 
pressure transducer is attached to a placebo DPI or an orifice plate with equivalent 
resistance to the test inhaler (Azouz et al., 2015b; Harris & Willoughby, 2010; Tiddens et 
al., 2006; Weers et al., 2013). Each subject’s inhalation can then be recorded, after 
instruction, as flow rate vs. time or pressure drop vs. time profiles using methods 
described by Clark and Hollingworth (1993). While the methods for collecting inhalation 
profiles are generally similar across different research groups, variable approaches have 
been used to select “representative” IPs from each group’s database for inhaler in vitro 
testing. Weers et al. (2013) chose four individual IPs with peak pressure drop 
representing the ranges of patients’ inhalation efforts in their study. A similar approach 
was applied by Casaro et al. (2014) where five individual IPs were selected to cover the 
medium and ranges of PIFRs in the database. Olsson et al. (2013) proposed select IPs 
representative of the medium and 95 percentile variations for both PIFR and PIF; this 
method was adopted by Chrystyn et al. (2015) in a recent study. Besides using individual 
IPs, well simulated IPs based on measured key inhalation parameters also show great 
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potential for use in vitro tests to predict lung deposition (Delvadia et al., 2013a; Delvadia 
et al., 2012).  
 
1.5  CURRENT STATUS AND CHALLENGES 
Realistic in vitro testing of DPIs can be performed essentially by coupling well-
designed MT models to selected IPs that mimic inhaler use in the clinic or in practice. The 
approach has already been found helpful while building IVIVCs for inhaled drug products. 
The system most typically employed is shown in Figure 1.7.  
 
Figure 1.7.  Experimental setup for realistic in vitro testing. A DPI is primed and inserted 
into a realistic mouth-throat (MT) model. Internal surface of the MT is coated to retain 
powder particles. A breath simulator with sufficient capacity is programmed to withdraw 
realistic inhalation profiles (IPs) through a low resistance filter. The mass of drug that 
reaches the filter, TLDin vitro, depends on the product, and the MT-IP combinations.  
 
The in vitro predicted lung dose (TLDin vitro; designated as the drug dose exiting the 
MT model; Figure 1.7) can be compared with the in vivo lung deposition data for the same 
inhaler obtained either from gamma scintigraphy studies (Delvadia et al., 2013a; Delvadia 
et al., 2012; Zhang et al., 2007), or from PK studies performed using a charcoal block 
DPI 
Pulmoguard II™ Filter 
Mouth-Throat (MT) Model 
ASL 5000-XL Breath Simulator 
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technique to prevent drug absorption from the GI tract (Olsson et al., 2013; Weers et al., 
2014). The test methods have also been used as predictive tools to estimate the drug 
dose likely to penetrate patients’ lungs as part of the product development process 
(Chrystyn et al., 2015; Pitcairn et al., 2012; Weers et al., 2013). Although such methods 
are more clinically relevant and shown to produce better IVIVCs than the standard 
compendial methods, their application remains challenging. At this stage, industry 
scientists and regulators are left to debate which MT models to select and how to choose 
representative IPs. No effort has yet been made to standardize the approach.  
Another question relates to the importance of regional drug distribution in the lung; 
this may well be relevant to the therapeutic effects of certain inhaled drugs (Anderson & 
Newman, 2009; Usmani et al., 2005), but in vitro methods have yet to be developed that 
are predictive of regional drug deposition from DPIs in vivo. Recent advances on the topic 
have been to couple realistic in vitro testing with compendial cascade impactor methods 
to measure the size distribution of aerosol drugs leaving the MT model. These require the 
use of flow-balancing devices like the Nephele Mixing Inlet (NMI) or Electronic Lung™ to 
enable particle size distributions for drugs exiting the MT model to be measured at 
constant cascade impactor flow rates, following aerosol dispersion and release from an 
inhaler under realistic (variable flow) inhalation conditions (Casaro et al., 2014; Chrystyn 
et al., 2015; Olsson et al., 2013; Tarsin et al., 2006). But it remains unclear (a) how to 
measure APSDs under all inhalation conditions and (b) how even “realistic” size 
distribution data could be used to predict regional drug deposition in the lung. Overall, 
methods need to be developed, validated, standardized and improved to better evaluate 
DPI performance under realistic conditions. Emergent modeling approaches like CFD 
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simulations (Longest & Holbrook, 2012; Wong et al., 2012), that allow the motion of air 
flow and inhaled particles in human airways to be predicted based on principles of fluid 
mechanics, have been shown to be promising for aerosol deposition predictions in the 
lung. If these methods are to be used in bridging lung doses and particle size distribution 
data with in vivo regional lung deposition data, considerable method development and 
improved lung modeling is needed.  
 
1.6  PROJECT AIM 
This thesis is designed to further our understanding of DPI performance in vitro 
and in vivo. It describes efforts to improve realistic in vitro test methods for DPIs to explore 
the truth about the ranges of total lung dose and the particle size distributions of drugs 
that are likely to enter the lung from a marketed DPI. Methods have been developed to: 
(a) compare and select MT models for realistic in vitro testing (Chapter 3); (b) choose 
appropriate IPs for realistic testing of a wide range of DPIs (Chapter 4); (c) measure 
APSDs for DPIs across a range of IPs that extends beyond the currently permitted 
maximum flow rate for compendial cascade impactors (Chapter 5); (d) evaluate one 
proposed CFD method for its ability to predict regional lung depositions for a single inhaler 
based both on realistic APSD data for the inhaler and the in vivo data for regional drug 
distribution in the lung taken from the literature (Chapter 6).  
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CHAPTER 2 
HYPOTHESES AND SPECIFIC AIMS 
The goal of this research was to develop clinically relevant in vitro performance 
test methods for powder inhalers that enable variations in aerodynamic particle size 
distributions (APSDs) of drug aerosols to be characterized at the exit of selected mouth-
throat (MT) models, across the range of breath profiles likely to be used by healthy human 
adults. To accomplish this objective, the project was subdivided into a series of 
hypotheses and specific aims: 
Hypothesis I. Representative MT models with human oropharyngeal geometries 
can be selected from the literature, manufactured and evaluated experimentally for use 
in realistic in vitro performance tests for DPIs.  
Specific Aim I. Different types of MT models and the USP cascade impactor 
induction port will be compared for ease of use and drug retention when tested across a 
realistic range of inhalation profiles (IPs) with Salbulin® Novolizer®. Values for total lung 
dose in vitro (TLDin vitro, or the dose exiting each internally-coated MT model) will be 
compared statistically across MTs, and the practical advantages and disadvantages of 
different models will be explored. 
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Hypothesis II.  A general method for simulating a range of representative IPs for 
use with any powder inhaler of known air flow resistance can be derived from existing 
Virginia Commonwealth University (VCU) clinical trial data for healthy adults, provided 
the general instructions for inhalation from the chosen device during use are consistent 
with those that normally accompany passive powder inhalers. 
Specific Aim II. VCU clinical trial data collected from healthy adults by Delvadia 
(2012) will be analyzed further. A statistically valid range of IPs and associated algorithms 
will be tested for their ability to adequately fit the experimentally generated IP data across 
a population of mixed gender normal human adult volunteers inhaling through a range of 
air flow resistances typical of those in marketed DPIs. 
 
Hypothesis III. When realistic IPs are used to generate aerosol drugs from a 
typical DPI, Budelin® Novolizer® (budesonide 200 mcg/dose), reliable methods can be 
developed to determine the APSD of TLDin vitro, the dose exiting the MT model. 
Specific Aim III. The Pharmacopeial Next Generation Pharmaceutical Impactor 
(NGI) will be modified and recalibrated to enable its use at high air flow rates consistent 
with the measurement of the budesonide APSD exiting MT models in excess of 100 L/min. 
The modified, recalibrated NGI will be used to characterize the drug clouds from Budelin® 
Novolizer® exiting each MT model across a range of realistic IPs, by using an aerosol 
mixing inlet supplied with dilution air to maintain constant air flow through the impactor.  
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Hypothesis IV. Computational fluid dynamic (CFD) modeling can be employed 
with initial conditions that describe the APSD of drug aerosols exiting MT to predict 
regional lung deposition of budesonide aerosols from Budelin® Novolizer® and the 
results can be compared with clinical data.  
Specific Aim IV. The stochastic individual pathway (SIP) lung model and 
associated CFD methods, as developed by Tian et al. (2015a) for use with realistic IPs, 
will be evaluated for its ability to predict regional budesonide deposition in the lung from 
Budelin® Novolizer® following (a) experimental APSD characterization of TLDin vitro and 
(b) assumed entry of the APSD to the trachea of Tian et al.’s model at the chosen IPs. 
The predicted regional deposition results from CFD will be compared with those reported 
in the literature for the same inhaler following its collection based on two dimensional (2D) 
gamma scintigraphy (Newman et al., 2000). 
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CHAPTER 3 
SELECTING REPRESENTATIVE HUMAN MOUTH-THROAT MODELS FOR 
REALISTIC DPI TESTING 
3.1  INTRODUCTION 
Realistic in vitro testing methods that are able to discriminate between inhalers and 
inhaler formulations and predict drug doses likely to deposit in the human lung (total lung 
dose; TLD) should offer significant benefits to personnel involved in clinical planning for 
inhaled product development. Such predictions can be made by collecting and analyzing 
the aerosol drug escaping a realistic mouth-throat (MT) model following delivery from an 
inhaler using inhaled flow rate vs. time profiles (IPs) likely to be used by the relevant 
patient population. At this time, three main types of MT models have been developed and 
all have shown promising in vitro–in vivo correlations (IVIVCs) (Delvadia et al., 2013a; 
Delvadia et al., 2012; Olsson et al., 2013; Weers et al., 2014; Zhang et al., 2007). 
However, there are significant differences in their development philosophies, geometries 
and manufacture. Product developers wishing to predict TLD values in humans are left to 
select an MT model (perhaps in several sizes) and couple these to a range of IPs that are 
expected to span the likely inspiratory maneuvers to be used with their chosen inhaler.
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This chapter is an attempt to describe the issues that are currently associated with 
these choices, with the ultimate view of rationalizing the selection of the Virginia 
Commonwealth University (VCU) MT models used in the remainder of this thesis to 
describe the further development of in vitro performance test methods for dry powder 
inhalers (DPIs). Salbulin® Novolizer® (Meda Pharmaceuticals, Hertfordshire, U.K.) was 
selected and used as the test inhaler in this chapter to compare drug retention across MT 
models with different geometries. Budelin® Novolizer® (Meda Pharmaceuticals, 
Hertfordshire, U.K.) was selected as the test inhaler in the remainder of the thesis to 
compare drug retention in VCU MT models.  
 
3.2  MATERIALS AND METHODS 
Mouth-Throat Models 
Small, medium and large VCU models (Delvadia et al., 2012) were made from 
ultraviolet-laser-cured resin (Accura® 60, 3D System, Valencia, CA) using a rapid 
prototyping process of stereolithography (Viper si2™ SLA® system, 3D Systems, 
Valencia, CA), with vertical layer thickness of 0.1 mm. The three dimensional (3D) 
geometries of VCU models are available to download at www.rddonline.com (Longest, 
2012). Small, medium and large Oropharyngeal Consortium (OPC) models (Burnell et al., 
2007) were purchased from Emmace Consulting AB (Södra Sandby, Sweden). These 
models were designed by the Oropharyngeal Consortium (AstraZeneca, GlaxoSmithKline 
and sanofi aventis) and manufactured using polyamide, also by rapid prototyping. The 3D 
geometries of OPC models are available to download at www.isam.org (Oropharyngeal 
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Consortium, 2013). The medium Alberta Idealized Throat (AIT) (Warren H Finlay et al., 
2010) and the USP inlet (U.S. Pharmacopeial Convention, 2013) were purchased from 
Copley Scientific (Nottingham, U.K.). Unlike VCU and OPC models that are constructed 
from plastic, AIT model and USP inlet are manufactured in aluminum. The three types of 
realistic MT models and the USP inlet are shown Figure 3.1; further detail and 
descriptions of these models was provided in Chapter 1 and Figure 1.6.  
 
Figure 3.1. Realistic mouth-throat (MT) models developed for inhaler in vitro testing. 
From Left: Oropharyngeal Consortium (OPC) Large, OPC Medium, OPC Small (Burnell 
et al., 2007; Oropharyngeal Consortium, 2013), Virginia Commonwealth University (VCU) 
Large, VCU Medium, VCU Small (Delvadia et al., 2012; Longest, 2012), Alberta Idealized 
Throat (AIT; Medium) (Stapleton et al., 2000) and USP Inlet (U.S. Pharmacopeial 
Convention, 2013).  
 
Inhalation Profiles 
The clinical study data and methods described by Delvadia to simulate IPs for 
realistic DPI testing (Delvadia, 2012) was used to simulate IPs suitable for test of Salbulin 
Novolizer (airflow resistance = 0.0241 kPa0.5L-1min) as shown in Figure 3.2. Three IPs 
representing the typical range of these DPI-trained profiles were determined based on 
Delvadia’s statistical treatment where individual flow rate (FR) profiles were ranked at 
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each time point, and the 10, 50 and 90 percentile values selected to produce the three 
red inhalation profiles (Figure 3.2).  
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Figure 3.2. Individual flow profiles (gray; volumetric flow rates entering mouth vs. time) 
from DPI-trained normal adult volunteers inhaling through an inhalation flow recorder with 
an identical airflow resistance to Novolizer [data from (Delvadia, 2012)]. Red profiles are 
the 10, 50 and 90 percentile results that illustrate the range of profiles seen across this 
population. The smoothed profiles shown in black are the simulated profiles used to 
program the breath simulator for the in vitro MT model comparisons described below 
following simulation according to Delvadia using Equations 3.1 to 3.4 with parameters 
described in Table 3.1 (Delvadia, 2012; Delvadia et al., 2012). 
 
The red FR vs. time, t, profiles were then simulated using Equations 3.1 to 3.3 
below (Delvadia, 2012; Delvadia et al., 2012) to produce the black profiles shown in the 
figure. Values for the inhalation parameters used in the equations are shown in Table 3.1, 
where peak inhalation flow rate (PIFR), time at which PIFR occurs (TPIFR), and total 
inhaled volume (V, area under the curve) were obtained directly from the red profiles, and 
duration of inhalation (T) was calculated from Equation 3.4. The three simulated IPs were 
used for the realistic in vitro testing of Salbulin with each of the MT models shown in 
Figure 3.1.  
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Table 3.1. Peak inhalation flow rate, PIFR, time at which PIFR occurs, TPIFR, total inhaled 
volume, V and duration of inhalation, T values for 10, 50 and 90 percentile simulated IPs 
according to the method described by Delvadia (Delvadia, 2012; Delvadia et al., 2012) 
and shown in Figure 3.2.  
IPa PIFR (L/min) TPIFR (sec) V (L) T (sec) 
10 Percentile 76.9 0.550 1.43 1.667 
50 Percentile 98.2 0.450 2.72 2.525 
90 Percentile 126.2 0.610 4.64 3.380 
aFigure 3.2, black profiles 
 
Experimental Setup for Realistic In Vitro Testing  
Figure 3.3 is a schematic of the experimental apparatus to evaluate aerosol drug 
deposition and the in vitro total lung dose (TLDin vitro) for a powder inhaler under realistic 
conditions. Salbulin® Novolizer® (label claim: 120 mcg albuterol sulfate per delivered 
dose) was donated by Meda Pharmaceuticals (Hertfordshire, U.K.) and used to compare 
the eight MT models shown in Figure 3.1.  
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Figure 3.3. Schematic of experimental setup for measurement of total lung dose in vitro 
(TLDin vitro), or the dose exiting the MT model, under simulated, realistic human inhalation 
conditions.  
 
During testing, the inhaler was primed and inserted into an adapter manufactured 
to form an airtight junction between the inhaler mouthpiece and the MT model. Adapters 
for VCU MT models are described at www.rddonline.com (Longest, 2012), and were 
identical to those used previously (Delvadia et al., 2012). Adapters for OPC MT models 
were obtained from Emmace Consulting AB, while those for the AIT and USP inlet were 
manufactured in-house from Ten-to-One / High Tear Strength Mold Rubber (Micro-Mark, 
Berkeley Heights, NJ) positioned to site the inhaler exit at the center of the opening to the 
chosen MT model. During each simulated IP, air was drawn through the newly primed 
inhaler (single actuation) and MT model into a low resistance filter (Pulmoguard IITM, 
Queset Medical, North Easton, MA) capable of retaining all of the aerosolized drug that 
passed through the model. The filter was connected to a programmable breath simulator 
(ASL 5000-XL, IngMar Medical, Pittsburgh, PA) to produce the standard IP at the mouth 
opening of the MT model. The internal surfaces of the VCU and OPC models were coated 
using two applications of 2% (w/v) Brij™ 35 (ACROS Organics™, Thermo Fisher 
DPI 
Pulmoguard II™ Filter 
Mouth-Throat (MT) Model 
ASL 5000-XL Breath Simulator 
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Scientific, Waltham, MA) in glycerol followed by allowing excess solution to drip and 
evaporate from the model for at least 2 h (Mitchell, 2003; Olsson et al., 2013). Because 
Brij solutions failed to adequately wet the metal surfaces of the AIT model and the USP 
inlet port, those models were coated instead using two spray applications of Molykote® 
316 Silicone Release Spray (Dow Corning, Midland, MI) followed by solvent evaporation 
prior to each experiment (Hindle et al., 1996). A randomized experimental design was 
implemented to vary the MT models and recover the drug from the filter (TLDin vitro; Figure 
3.3) following withdrawal of individual actuations (doses) by triggering the breath 
simulator programmed for the black IPs shown in Figure 3.2. The apparatus was 
disassembled after each dose, and albuterol sulfate was recovered by rinsing the inhaler 
(with drug cartridge removed), MT and filter using known volumes of 65% methanol: 35% 
20mM ammonium formate buffer (v/v) and analyzed using high-performance liquid 
chromatography (HPLC). Albuterol sulfate assay was performed using Allure® PFP 
Propyl column (5µm, 3.2×150mm, Restek Corporation, Bellefonte, PA), 65% methanol: 
35% 20mM ammonium formate buffer (v/v) as mobile phase (flow rate: 0.75 mL/min), and 
UV detection at 276 nm (2998 Photodiode Array Detector, e2695 Seperation Module, 
Waters, Milford, MA). Injection volume was 100 µL and calibration curves were linear in 
the range of 0.2–10.0 mcg/mL (r2 > 0.999). Each experiment was performed at least 9 
times. Statistical analyses were performed for drug doses retained on and delivered from 
the inhaler, and TLDin vitro using one-way ANOVA and Tukey’s HSD in JMP Pro 11 (SAS 
Institute Inc., Cary, NC). Further analyses to evaluate the effects of the MT models, IPs, 
and model sizes on values for mean TLDin vitro were performed by two-way ANOVA (MT 
models and IPs) and three-way ANOVA respectively.   
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3.3  RESULTS 
Effects of IP Selection on Inhaler Performance 
Drug doses retained on and delivered from the Novolizer device were analyzed for 
the 10, 50 and 90 percentile IPs. Data were pooled across the eight MT models for each 
IP (n≥72), and were presented as percent of manufacturer’s label claim (120 mcg 
albuterol sulfate per delivered dose) in Figure 3.4.  
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Figure 3.4. Percent of manufacturer’s label claim (120 mcg albuterol sulfate per delivered 
dose) for drugs retained in the mouthpiece or delivered from the Novolizer device (device 
retention and delivered dose, respectively) for the 10, 50 and 90 percentile IPs. Data were 
pooled across eight MT models for each IP and presented as mean±SD (n≥72). 
Statistically significant differences were observed for both the mean device retention and 
mean delivered dose between different IPs in all cases (Student’s t-test, p<0.05). 
 
The 10 percentile IP produced the highest value for mean device retention (31.0% 
label claim), while this value reduced to 10.2% label claim for the 50 percentile IP and 
3.4% label claim for the 90 percentile IP. Most notably, when tested with the 10 percentile 
IP, Salbulin only delivered a mean of 81.3% of label claim. Statistically significant 
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differences were observed for both the mean device retention and mean delivered dose 
between different IPs (one-way ANOVA, p<0.05), consistent with the literature reports for 
this device (Delvadia et al., 2012). 
 
Effects of IP Selection on TLDin vitro 
Values for TLDin vitro, designated as the drug dose escaping the MT model and 
collected on the filter from Salbulin, are shown in Figure 3.5 for each MT model tested 
using the 10, 50 and 90 percentile IPs typical of trained adults inhaling through a 
resistance equivalent to that of Novolizer.  
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Figure 3.5. Percent of manufacturer’s label claim (120 mcg albuterol sulfate) exiting the 
MT model (TLDin Vitro) from Salbulin Novolizer after randomized testing using the 10, 50 
and 90 percentile IPs. The subscripts L, M and S represent Large, Medium and Small MT 
models, respectively (Figure 3.1). 
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Notably, the change of test IPs produced large variations in TLDin vitro for each MT 
model, and the larger MTs generally produced a larger range of results for TLDin vitro than 
was seen for smaller MTs. For a selected MT model, the 90 percentile IP produced 
highest values for TLDin vitro, while the 10 percentile IP produced the lowest values. The 
effects of IP variations on TLDin vitro indicate that more efficient drug-carrier deaggregation 
occurred when larger IPs were used for Salbulin testing; for this inhaler and others, the 
effects of improved powder deaggregation seen with larger flow rates may be expected 
to exceed the effects of the increased inertia of drug particles passing into the MTs (i.e. 
impacting and depositing in MT) due to the higher values of TLDin vitro seen with larger IPs.  
While the approach used to generate the 10, 50 and 90 percentile flow rate vs. 
time curves in Figure 3.2 will be analyzed more thoroughly in Chapter 4 that describes an 
improved simulation technique for a spectrum of standard IPs for use with DPIs of 
different airflow resistances, the significant variations in TLDin vitro observed in this study 
suggested that it is important to include both the medium (the 50 percentile IP) and the 
extremes (the 10 and 90 percentile IPs) to fully evaluate the likely clinical performance of 
a powder inhaler like Salbulin Novolizer. Powder inhaler performance, even for a well-
designed DPI like Salbulin Novolizer, was highly dependent on the selected IP. The 
ranges with which TLDin vitro could be determined when using a single IP in these models 
was of the order of 5–12% of label claim (Figure 3.5); this increased to 15–30% of label 
claim when Novolizer was tested at the extremes (the 10 or 90 percentile IP), even though 
these simulated IPs were based on the inhalation maneuvers recorded following 
Delvadia’s study of trained adult subjects of both genders (Delvadia, 2012). 
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Effects of MT Model Selection on TLDin vitro 
This investigation showed that the choice of MT model clearly impacts the value 
of TLDin vitro and thus the anticipated values for TLD in the clinic (Figure 3.6). Statistical 
differences between the mean values are illustrated in Figure 3.6. Perhaps most 
surprising from Figure 3.6, was the finding of a statistical difference between the results 
shown among the three “medium” models (VCU medium, OPC medium and AIT). Notably, 
for all three IPs, the VCU medium and AIT models produced statistically comparable 
results while the OPC medium model produced a value for TLDin vitro that was significantly 
smaller than its counterparts. The USP inlet also produced statistically comparable results 
to VCU medium and AIT models in all three cases, illustrating that this pharmacopeial 
standard conduit (used to connect an inhaler to a cascade impactor) can sometimes 
produce comparable results with MT models that were designed with “realistic 
geometries”, provided its internal surfaces are coated to ensure impacted powder 
retention. The comparison of two “small” models also showed statistical differences for 
the 50 and 90 percentile IPs, where OPC small produced a significantly smaller value for 
TLDin vitro than VCU small. Notably however, these two models produced comparable 
results for the 10 percentile IP. The two “large” models, in contrast, showed statistically 
comparable results for all three IPs.  
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Figure 3.6. Percent of manufacturer’s label claim (120 mcg albuterol sulfate) escaping 
the MT model (mean TLDin Vitro) from Salbulin Novolizer after randomized testing using 
10, 50 and 90 percentile IPs. Results are presented as mean±SD (n≥9). The subscripts 
L, M and S represent large, medium and small MT models, respectively. Statistically 
significant differences () in mean values are shown after one-way ANOVA (p<0.05) and 
Tukey’s HSD. Further statistical analyses following two- and three-way ANOVA to 
evaluate the effects of the MT models, IPs and model sizes on values for mean TLDin Vitro 
are described in the text.  
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The direct one-way ANOVA comparisons (above and Figure 3.6) were mirrored by 
two-way ANOVA to evaluate the effects of MTs (VCU vs. OPC vs. AIT vs. USP) and IPs 
(10 percentile vs. 50 percentile vs. 90 percentile) on TLDin vitro. The following hypotheses 
were tested: 
H1: MTs have no effect on TLDin vitro 
H2: IPs have no effect on TLDin vitro 
H3: There is no interaction between MTs and IPs 
The results showed that both MTs and IPs had significant effects on TLDin vitro 
(p<0.0001 in both cases; H1 and H2 were rejected), while no significant interaction was 
observed between the two factors (p=0.6523>0.05; H3 was not rejected). Tukey’s HSD 
indicated that effects of MT on TLDin vitro appeared to be: VCU = AIT = USP > OPC, while 
effects of IP on TLDin vitro showed that: 90 percentile IP > 50 percentile IP > 10 percentile 
IP.  
Three-way ANOVA was used to compare the VCU and OPC MTs. The effects of 
MTs (VCU vs. OPC), model sizes (small vs. medium vs. large) and IPs (10 percentile vs. 
50 percentile vs. 90 percentile) on TLDin vitro were evaluated by testing the following 
hypotheses: 
H4: MTs have no effect on TLDin vitro 
H5: Model sizes have no effect on TLDin vitro 
H6: IPs have no effect on TLDin vitro 
H7: There is no interaction between MTs and model sizes 
H8: There is no interaction between MTs and IPs 
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H9: There is no interaction between model sizes and IPs 
H10: There is no interaction between MTs, model sizes and IPs 
The results showed that there was no significant interaction between the three 
factors (MT*size*IP, p=0.8812>0.05; H10 was not rejected), while significant interactions 
were observed for MTs and model sizes (MT*size, p<0.0001; H7 was rejected), MTs and 
IPs (MT*IP, p=0.0419<0.05; H8 was rejected), and model sizes and IPs (size*IP, 
p<0.0001; H9 was rejected). Tukey’s HSD indicated that effects of MT*size on TLDin vitro 
appeared to be: VCU Large MT = OPC Large MT, VCU Medium MT > OPC Medium MT, 
VCU Small MT > OPC Small MT. Tukey’s HSD furthermore showed the effects of MT*IP 
on TLDin vitro appeared to be: VCU > OPC for both the 50 and 90 percentile IPs while VCU 
= OPC for the 10 percentile IP. Effects of size*IP on TLDin vitro appeared to be: Large MT > 
Medium MT > Small MT, and Large IP > Medium IP > Small IP.  
 
3.4  DISCUSSION 
The TLDin vitro results of Delvadia et al. (2012) for Budelin Novolizer (200 mcg 
budesonide per delivered dose) appeared to correlate well with reported literature values 
for TLDin vivo when experiments were conducted in VCU MT models and the simulated IPs 
were based on those used in the clinic (Newman et al., 2000). Most notable from that 
work (Delvadia et al., 2012), was the apparent agreement between the overall range of 
results for TLDin vitro when the results were derived from tests across IPs using the small, 
medium and large VCU MT models, compared with the literature values for TLDin vivo (for 
example, TLDin vivo ranged from 9.4–41.0% of the metered dose for fast inhalation, while 
that of in vitro spanned 9.7–40.4%). In the work discussed in this chapter, the 
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experimental range of TLDin vitro in VCU models was 22–59% label claim, while in OPC 
models it was 21–63% label claim. In these terms, VCU and OPC models were similar. 
Because in vivo results are not available for Salbulin however, there was no way that a 
preference can be stated for either model on this basis. Nevertheless, the medium VCU 
and OPC geometries produced statistically significant differences in values for TLDin vitro 
from Salbulin Novolizer at all tested inhalation profiles. While the meaning of this 
difference in “medium result” needs to be further explored, the predicted range of possible 
deposition results across an adult population was more consistent between the differently 
sized VCU and OPC models, indicating that a much smaller number of in vitro 
experiments than those described in this paper may be sufficient to provide reliable 
estimates of TLDin vitro at the extremes (e.g. small IP–small MT to large IP–large MT, from 
either model series). Figure 3.7 and Table 3.2 show the range of results for TLDin vitro from 
all the tests conducted with Salbulin Novolizer.  
 
Figure 3.7. The range of mean results for Salbulin Novolizer’s TLDin vitro (% label claim) 
tested across all MT Models using 10, 50 and 90 percentile IPs. Results for the single 
geometry AIT and USP models show the range of results due solely to the change in IP. 
Results are percent of manufacturer’s label claim (120 mcg albuterol sulfate as delivered 
dose). Upper and lower error bars are SD values from the large IP–large model and small 
IP–small model, respectively, as shown numerically in Table 3.3. 
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Table 3.2. Numerical results from Figure 3.7; a statistically significant difference between 
VCU and OPC model results (p<0.05; n=18) occurred when testing to determine the value 
for the mean minimum TLDin vitro. 
 Mean (SD)a 
 Small Large 
VCU 27.0 (3.5) 55.5 (2.2) 
OPC 23.8 (2.6) 54.3 (3.6) 
AIT 33.9 (2.1) 51.9 (1.8) 
USP 34.8 (3.6) 49.9 (1.8) 
a Mean and standard deviations (SD) of TLDin vitro following testing with small model and 
10 percentile IP (“Small”) vs. large model and 90 percentile IP (“Large”). For AIT and USP, 
where only a single model is available, “Small” and “Large” refer to the results from testing 
with 10 and 90 percentile IPs, respectively.  
 
 
The colored portion in each of the bar graphs of Figure 3.7 shows the range 
between the mean results when the 10 percentile IP was tested with the small MT model 
(mean minimum TLDin vitro) and the 90 percentile IP was tested with the large MT model 
(mean maximum TLDin vitro); the error bars in Figure 3.7 show a single standard deviation 
about those means in each case. While the means for minimum TLDin vitro showed 
statistically significant differences (Student’s t test, p<0.05; Table 3.3), there was a distinct 
overlap in the experimental results (Figure 3.7) and no statistically significant difference 
between each model series for mean maximum TLDin vitro. Clearly, this range of values 
could be collected using only the small and large versions of each set of MT models, at 
least as far as this inhaler was concerned. Moreover, because the experimental range of 
results for TLDin vitro seen by Delvadia et al. (2012) was much more representative of the 
results seen in vivo, there is good evidence to suggest that DPI testing needs to be 
41 
 
conducted across a range of MT geometries (and not a single model as seen with either 
AIT or USP; Figure 3.7).  
The choice between the three VCU and three OPC MT models became one in 
which the advantages and disadvantages of these models needed to be compared in 
order to practically justify the use of one over the other. While further studies are possibly 
needed to thoroughly compare values of in vitro lung doses for the different models, the 
practical advantages and disadvantages of these MT models were listed in Table 3.3 to 
facilitate selection of the MT models for realistic in vitro testing. As shown in this table, 
OPC models are not provided with a standardized mouth opening. Moreover, their 
complex internal structure (Figure 1.6) required solvent based drug extraction for periods 
up to 10 minutes, in order to ensure complete drug recovery (for albuterol sulfate in this 
study, VCU models could be extracted in less than 1 minute). In this thesis therefore, the 
VCU models were selected for all further studies because their advantages outweighed 
their disadvantages, the models were readily available, and they had already been shown 
to produce an apparent IVIVCs with Budelin Novolizer and four other marketed DPIs 
(Delvadia et al., 2013a; Delvadia et al., 2012). In addition, the results from the VCU 
models were similar to those from the OPC models when tested with Salbulin Novolizer. 
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Table 3.3. Practical advantages and disadvantages of the test MT models.  
 Advantages Disadvantages 
VCU  Small, medium and large MTs are 
available 
 Polyurethane versions are now 
available for use with an attached NGI 
adapter 
 Constructed in one piece for ease of 
use 
 Clear and easy to observe particle 
deposition 
 Geometrically validated via the 
literature (Delvadia et al., 2012) 
 IVIVC validated to five marketed DPIs 
 Accura 60 is not resistant to use of all 
solvents 
OPC  Small, medium and large MTs are 
available 
 Constructed in one piece for ease of 
use 
 Universal outer geometry allows a 
single mouth-piece adapter to be 
used 
 NGI/ACI adapter attached 
 Chunky and less easy to handle 
 Internal volumes inconsistent with 
those reported in the literature* 
(Burnell et al., 2007); not 
geometrically validated 
 Mouth entrance arbitrarily occluded 
due to selection of individual subject 
geometries (Oropharyngeal 
Consortium, 2013) 
AIT  Robust construction in polished 
aluminum 
 Particle deposition site can be 
observed after splitting into two-
halves 
 NGI/ACI adapter attached 
 Only the medium model is available 
 Constructed in two-halves with a 
gasket that can leak 
 Not easy to handle 
USP  Constructed in one piece for ease of 
use 
 NGI/ACI adapter attached 
 Geometry is not realistic 
 Only one model is available 
*The internal volumes of the small, medium and large OPC models (constructed from 
sintered polyamide) were determined experimentally to be 27.6, 91.7 and 84.4 cm3, 
respectively, compared to reported internal volumes of 25.8 (small), 78.1 (medium) and 
71.0 cm3 (large) (Burnell et al., 2007).  
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CHAPTER 4 
SIMULATING VARIATIONS IN HUMAN BREATH PROFILES FOR REALISTIC DPI 
TESTING 
This Chapter is in press. It is to be published in the Journal of Aerosol Medicine 
and Pulmonary. Drug Delivery. In the Journal it carries the title and authors: In Vitro Tests 
for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for 
Realistic DPI Testing. Renishkumar R. Delvadia, Xiangyin Wei, P. Worth Longest, 
Jurgen Venitz and Peter R. Byron. Renishkumar Delvadia performed the clinical trial with 
assistance from Xiangyin Wei. The raw breath profile data and statistical analyses of the 
descriptive inhalation parameters (PIFR, V, etc.) were performed by Renishkumar 
Delvadia with the assistance of Jurgen Venitz and included in his thesis in 2012 (Delvadia, 
2012). In this thesis, Peter Byron and Worth Longest advised Xiangyin Wei during her 
reanalysis, simulation and curve fitting of the data describing the 10, 50 and 90 percentile 
inhalation profiles under the various conditions described in full below. The chapter is 
reproduced entirely as it is to be published below. 
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4.1  INTRODUCTION 
In this series of publications on realistic inhaler testing we sought to offer improved, 
clinically-relevant test methods for aerosol drugs and possible in vitro-in vivo correlations 
(IVIVC) for lung deposition (Delvadia et al., 2013a; Delvadia et al., 2012; Delvadia et al., 
2013b). The experimental setup and brief description of the test method is shown in 
Figure 4.1.  
 
Figure 4.1. Experimental setup for realistic in vitro testing. A passive powder inhaler 
with known airflow resistance, R, is primed and inserted into small, medium or large 
mouth-throat (MT) model(s) that span 95% of the volumetric range seen in human 
adults. Internal surfaces of MT are coated to retain powder particles. A breath simulator 
with sufficient capacity is programmed to withdraw a volume V through a low resistance 
filter using a range of simulated IPs, as described in this paper. The mass of drug that 
reaches the filter, TLDin vitro, depends on the product, and the MT-IP combination (Byron 
et al., 2010; Byron et al., 2013; Delvadia et al., 2013a; Delvadia et al., 2012; Delvadia 
et al., 2013b; Longest, 2012; Olsson et al., 2013; Wei et al., 2014). 
 
By assessing the aerosol drug dose exiting small, medium and large realistic 
mouth-throat (MT) models (Longest, 2012) while using inhalation profiles (IPs) believed 
to simulate the breathing maneuvers used during clinical testing, we found that (a) the 
mean value for TLDin vitro, from several different dry powder inhalers (DPIs) was consistent 
with literature values for lung deposition following clinical testing (Delvadia et al., 2013a) 
and (b) the range of values from a single DPI agreed with the published range of values 
Powder Inhaler 
Pulmoguard IITM Filter 
Mouth-Throat (MT) Model 
ASL 5000-XL Breath Simulator 
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for TLDin vivo following gamma-scintigraphic testing in a mixed-gender adult population 
(Delvadia et al., 2012). It is well known that performance of passive DPIs is air flow rate 
dependent; indeed the seminal work of Clark and Hollingworth (1993), led to compendial 
test methods requiring that dose emissions and size distributions be determined at flow 
rates that maintain an appropriate pressure drop across each inhaler (U.S. 
Pharmacopeial Convention, 2013). It is also well known that DPI performance depends 
on the way that patients use these inhalers. While this can be influenced by instruction 
leaflets, training and of course, the subject’s lung capacity, present DPI development is 
largely empirical and often retrospective because of in vitro performance testing that fails 
to concern itself with the way that patients actually inhale through a chosen device. 
Reports that a large proportion of patients fail to use DPIs correctly are common; failure 
to exhale before inhalation, failure to inhale rapidly and deeply, as well as incorrect 
mouthpiece positioning may all influence regional drug deposition and clinical outcome 
(Broeders et al., 2009; van Beerendonk et al., 1998). 
In this article we report the results of a clinical study that enabled us to document 
the variability in the IPs of inhaler-naïve normal adults inhaling through a series of air flow 
resistances typical of those used in commercial DPIs. The study enabled us to 
recommend a range of IPs for testing DPIs with different airflow resistances. The IPs may 
be simulated using sinusoidal equations that adequately describe the flow rate vs. time 
profiles spanning the 10 through 90 percentile values for a mixed-gender, lung-normal, 
adult population. Because inhaler-naïve volunteers were recruited for the study, it was 
also possible to compare the effectiveness of “training by package insert” to formalized 
training from a pharmacist in the use of passive DPIs; this by comparing the different IPs 
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elicited by the two procedures in the same subjects. Use of the protocol described here 
should enable IPs to be selected for inhaler testing to span those likely to be used by 
normal human volunteers in clinical trials. While recognizing that inhalation profiles may 
differ in patient groups with different demographics and lung disease (Baba et al., 2011; 
Broeders et al., 2004; Malmberg et al., 2010; Sarinas et al., 1998), the approach to data 
analysis and IP simulation that is described here can likely be generalized to cover 
different populations so that product development scientists can select IPs for inhaler 
testing in vitro that are realistic and representative of the way new inhalers should 
eventually be used. 
 
4.2  MATERIALS AND METHODS 
A protocol was designed to document the IPs commonly used by healthy 
volunteers inhaling through powder inhalers. Volunteers were trained first by reading the 
directions for use provided in a typical package insert, and second, by receiving a 
demonstration and direct oral instructions from a pharmacist. The objectives were (a) to 
collect a range of typical flow rate vs. time profiles from normal adult subjects inhaling 
through air flow resistances that mimicked those seen in commercial DPIs, (b) curve-fit 
and analyze those IPs before and after receipt of training and thus, (c) establish a data 
base and equations for simulation of typical IPs used by normal subjects inhaling through 
different air flow resistances. We envisaged the use of these equations by inhaler 
designers seeking to optimize product performance in vitro, in advance of clinical trials. 
As it is well known that aerosol drug delivery performance of passive DPIs is dependent 
on air flow rate and air flow resistance (Clark & Hollingworth, 1993; U.S. Pharmacopeial 
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Convention, 2013), a drug-free “inhalation flow cell (IFC)” with a disposable mouthpiece 
and variable airflow resistances was constructed and instrumented with a digital 
volumetric flow meter, as shown in Figure 4.2, to record the air flow rate vs. time profiles 
used by each of the volunteers.  
         
Figure 4.2. The inhalation flow cell (IFC) with top views of two “Resistance Tubes” with 
identical external, but different internal, dimensions. Six IFC resistances were chosen for 
IP recordings in the clinic: 0.0179, 0.0200, 0.0241, 0.0344, 0.0432 and 0.0462 kPa0.5 L-1 
min. These values were determined experimentally from the slope of plots measured 
pressure drop0.5 (flowmeter inlet to mouthpiece) vs. the volumetric airflow rate exiting the 
mouthpiece (ASL 5000-XL, Ingmar Medical, Pittsburgh, PA). In the clinic, flow rates 
entering IFC were recorded every 50msec using a calibrated digital flow meter (EM1, 
Sensirion Inc., CA). All flow rates in this paper are expressed as the volumetric flow rate 
exiting the mouthpiece and are identical to those used to program the breath simulator 
(Figure 4.1). 
 
Each recorded flow rate value was converted to the volumetric flow rate exiting the 
mouthpiece using an algorithm to account for the change in the volumetric gas flow into 
and out of the IFC with variations in pressure and resistance (Delvadia, 2012). All of the 
IPs and flow rates described in this paper are flow rates exiting the mouthpiece. 
Therefore, all IP data can be used directly to program breath simulators in the “realistic” 
in vitro tests we described elsewhere (Byron et al., 2010; Byron et al., 2013; Delvadia et 
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al., 2013a; Delvadia et al., 2012; Delvadia et al., 2013b; Olsson et al., 2013; Wei et al., 
2014). Air flow resistance values [kPa0.5.L-1 min] for the IFC were determined from the 
slope of experimental plots of (pressure drop across IFC)0.5 vs. volumetric flow rate out of 
the mouthpiece, by linear regression. 
 
Clinical Study: Collection of inhalation profiles (IPs) 
Adult human volunteers were recruited from the general population of Richmond, 
Virginia, via advertisements. Healthy, non-pregnant, non-smoking subjects were recruited 
who were 18 to 65 years old, above 147 cm in height, 50 to 120 kg in weight,  without 
history of recent congestion, lung disease and/or inhaler use. Volunteers had never used, 
or been trained to use, a DPI before admission to the study. The study was approved by 
VCU’s Institutional Review Board and entered on www.clinicaltrials.gov. Eligible subjects 
were enrolled; twenty (10M, 10F) completed the study. None had evidence of acute 
medical or psychiatric illness and all were found to have FEV1 > the predicted lower limit 
of normal (LLN) after spirometric screening performed during an initial visit.(Marion et al., 
2001; M. R. Miller et al., 2005) On the second visit, each volunteer was asked to inhale 
approximately 18 times through the IFC (Figure 4.2). Individual IPs were recorded digitally 
every 50 msec as the volumetric flow rate vs. time profile of air exiting the mouthpiece of 
the calibrated inhalation cell after Instruction A and B were provided, sequentially, to each 
volunteer.  
Instruction A. Each volunteer was asked to read the instructions shown in Figure 
4.3. Those written instructions were based on leaflets, supplied as package inserts with 
marketed powder inhalers, showing patients how to inhale from a primed DPI. After 
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reading the instructions, volunteers were asked to inhale through the drug-free IFC, as if 
they were conforming to the written instructions. Inhalation profiles were recorded for 
each of six different resistance tubes placed in the IFC in random order. Subjects were 
allowed to rest between inhalations to avoid fatigue. 
Instruction B. Verbal instruction and a practical demonstration of how to use a 
powder inhaler correctly was then delivered individually to each volunteer by a pharmacist 
trained and experienced in the use of powder inhalers. The same pharmacist provided 
the same demonstration and instructions to each volunteer that emphasized: (Step 1) 
breathe out completely, (Step 2) ensure good lip closure around the IFC mouthpiece, 
(Step 3) inhale as fast and deep as possible through the mouth; and to continue until 
replete, (Step 4) hold breath and remove IFC from mouth.  
Following this formal training, volunteers were again asked to inhale through the 
IFC in the way they had been instructed and, during each inhalation, they were 
encouraged to continue inhaling as they began to show signs of reduced effort. IPs were 
recorded for each of the six different resistance tubes placed in the IFC in random order. 
Each flow profile was repeated to give a second IP, or flow rate exiting the mouthpiece 
vs. time, for each subject and resistance. The results from these duplicate experiments 
were designated “Instruction B1” and “Instruction B2”.  
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Figure 4.3. Written instructions for inhalation. Instruction A (Artwork adapted from 
patient information leaflets). 
 
 
Data Analysis and Statistics 
Overall, the trial produced a series of 20 IPs per air flow resistance (total = 120) 
for each of three instruction conditions: A, B1 and B2. These IPs were analyzed to 
determine their overall dependence on airflow resistance, R, and training status. In order 
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to do this, the parameters defined in Figure 4.4 were extracted from each IP and 
tabulated. The descriptive statistics: mean, median, standard deviation, minimum and 
maximum values, coefficient of variation [CV (%) = 100*standard deviation/mean] were 
estimated for each of the inhalation variables (PIFR, TPIFR`, V and T; Figure 4.4) by gender 
and across gender. Further inferential statistics were estimated as follows: for each 
individual dataset (Instruction A, B1 or B2) for a given volunteer, the quantitative 
relationship between each inhalation variable and air flow resistance (R) was assessed 
by linear regression analysis. Four functions of R, [f(R)], were explored in this way: R, 
1/R, LogR and R0.5. Best f(R) was selected based on the best fit (e.g. the coefficient of 
determination, r2, that was largest). To assess the effects of training on IP statistically 
(e.g. comparing instruction A, B1 or B2) it was necessary to pool the results for each 
training condition. Accordingly, secondary variables were derived that were resistance-
independent: in cases where significant relationships existed between the inhalation 
variable and R (e.g. PIFR), the values of that variable were normalized by resistance and 
averaged across all resistances in order to obtain a secondary, resistance-independent, 
normalized, inhalation variable. In case of insignificant relationships between a variable 
and R, the inhalation variables were averaged across resistances, without normalization, 
again to obtain a secondary, resistance-independent, inhalation variable. The effect of 
formal training (Instruction B1 and B2) on these secondary inhalation variables was 
assessed using repeated-measures ANOVA. The level of significance was preset at 0.05. 
Normality of the residuals was judged by normal quantile plots and visual inspection of 
the distribution of residuals. JMP 8.0 (SAS Corp, RTP, NC) was used for all statistical 
analyses. 
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Figure 4.4. Idealized IP and the primary variables: PIFR = peak inspiratory flow rate; 
TPIFR, the time at which PIFR occurs; AUC = Area Under the Curve = Inhaled Volume, 
V. Total inhalation time, T, is a secondary variable, dependent on PIFR and V. 
 
4.3  RESULTS 
Air flow resistances of the Inhalation Flow Cell (Figure 4.2) were 0.0462, 0.0432, 
0.0344, 0.0241, 0.0200 and 0.0179 kPa0.5 L-1 min. These were comparable with the 
values 0.0467, 0.0435, 0.0352, 0.0241, 0.0198 and 0.0176 kPa0.5 L-1 min, determined 
from linear regression of pressure drop0.5 vs. flow rate data for Spiriva® HandiHaler®,   
Salbutamol Easyhaler®, Pulmicort® Turbuhaler®, Budelin® Novolizer®, Relenza® 
Diskhaler® and Foradil® Aerolizer®, respectively. Twenty (10F, 10M) of an initial 22 
volunteers, with the demographics and pulmonary function results shown in Table 4.1, 
completed the study. Each subject followed the instructions and inhaled through the six, 
randomly-presented, airflow resistances that are typical of those in marketed DPIs, using 
the apparatus shown in Figure 4.2.  The resulting IPs are used in the discussion to provide 
data on the type and range of inspiratory maneuvers that need to be catered for by powder 
inhaler designers seeking to deliver aerosol drug clouds to the lungs of inhaler-naïve 
human adults with essentially normal pulmonary function, and where the subjects 
PIFR 
AUC = V
TPIFR T
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selected for product development trials have either been given written instructions on how 
to inhale or received formal training in DPI use by a professional. 
Table 4.1. Summary of subject demographics and pulmonary function tests (mean±SD). 
aPulmonary function tests 
 
Dependence of inhalation variables on air flow resistance and training 
A complete and detailed description of the analyses performed on the inhalation 
variables collected clinically is available in Delvadia (2012); the thesis included analyses 
of residual distributions, normal quantile plots, statistical evaluation of gender effects, 
 Males Females Overall 
Total 10 10 20 
Caucasian 6 3 9 
African 1 3 4 
Asian 1 2 3 
Hispanic 0 1 1 
Others 2 1 3 
Age [yrs] 31.1 ± 10.31 34.0 ± 8.81 32.6±9.23 
Height [cm] 176.6 ± 5.64 161.8 ± 6.49 169.2±9.40 
Weight [kg] 81.7 ± 16.75 60.7 ± 7.29 71.2±16.16 
PFTa    
FVC [L] 5.02 ± 0.60 3.31 ± 0.35 4.15±0.98 
FEV1 [L] 4.23 ± 0.41 2.81 ± 0.32 3.51±0.80 
FEV1/FVC 0.84 ± 0.04 0.85 ± 0.06 0.85±0.05 
FEF 25-75% [L/s] 4.72 ± 0.70 3.29 ± 0.87 3.99±1.03 
PEF [L/s] 10.08 ± 1.28 7.12 ± 0.77 9.15±1.92 
FET [s]  6.46 ± 1.01 6.91 ± 3.77 6.69±2.63 
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assessment of interactions between training status, gender and data from pulmonary 
function tests and a complete compilation of all numerical data on which the analyses in 
this paper are based. While those results enable us to present IP data, conclusions and 
equations for IP simulation at each resistance and training condition, the material is too 
lengthy to present in its entirety. Therefore, essential material in Delvadia (2012) is 
presented to justify our recommendations to test dry powder inhalers in vitro, using the 
apparatus shown in Figure 4.1, with a range of differently simulated IPs that describe the 
pooled data including confidence limits at each resistance and training condition. 
The experimental values for PIFR, TPIFR and V (Figure 4.4) were assessed for 
functional dependence on airflow resistance, R. The results showed that 1/R gave the 
best fit for PIFR from the four functions tested, while TPIFR and V showed no detectable 
dependence on resistance. Accordingly, the statistics describing the mean, median, 
standard deviation, minimum and maximum values and coefficient of variation [CV (%) = 
100*standard deviation/mean] for each “resistance-normalized” variable (Figure 4.4; 
R*PIFR, TPIFR and V) are presented in Table 4.2 by gender, across gender and by training 
status to show the effects of gender and training.  
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While the move from Instruction A to Instruction B1 or B2 showed the importance 
of formal training, the data from the duplicate IPs designated “Instruction B1” or 
“Instruction B2” showed no statistical difference between the pooled first or second 
measurement sets. Accordingly, data from B1 and B2 were pooled for further analysis 
and designated “Instruction B”. 
Gray profiles in Figures 4.5 and 4.6 show the IP results from all subjects (M and 
F) following Instructions A and B, respectively. The profiles shown in red at each 
resistance and training condition, are taken from the gray profiles after processing to show 
the 10, 50 and 90 percentile flow rate for the population at each 50 msec sampling time. 
The functional dependence of the 10, 50 (median) and 90 percentile PIFR values 
(Figures 4.5 and 4.6) on reciprocal resistance is plotted in Figure 4.7 for this population. 
Figure 4.7 is valid for values of R in the range 0.018 – 0.046 kPa0.5 L-1 min although 
beyond this range, curvature of PIFR vs. 1/R is expected (in order to meet a zero intercept 
as R tends to infinity). There was no need to explore curvature at impractically large 
resistance values however, as the selected linear functions were clearly appropriate for 
resistances that are encountered practically. 
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(a) Instruction A (Reading Only) (b) Instruction B (Training by Professional)  
Figure 4.7. PIFR vs. I/R from pooled data collected after (a) Instruction A (reading only) 
and (b) Instruction B (training by professional; r2>0.995). 10, 50 and 90 percentile values 
can be predicted based on a pre-selected value for R in the range of 0.018–0.046 kPa0.5.L-
1 min.  
 
 
Inhalation profiles were less erratic after subjects received professional training 
(Instruction B) and values for PIFR appeared to increase. Equations 4.1–4.3 and Figure 
4.7a describe the 90, 50 and 10 percentile values for PIFR in this population due to 
Instruction A; Equations 4.4–4.6 and Figure 4.7b apply to Instruction B. 
 
Instruction A: 
PIFR90% = 2.48 (1/R) + 19.1    Equation 4.1 
PIFR50% = 1.52 (1/R) + 21.1    Equation 4.2 
PIFR10% = 0.58 (1/R) + 18.6    Equation 4.3 
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Instruction B: 
PIFR90% = 2.56 (1/R) + 19.3    Equation 4.4 
PIFR50% = 1.82 (1/R) + 21.0    Equation 4.5 
PIFR10% = 1.44 (1/R) + 17.7    Equation 4.6 
 
Where R < 0.046 > 0.018 kPa0.5.L-1 min and PIFR and R have units of L min-1 and kPa0.5.L-
1 min, respectively. Overall (Table 4.2), males had higher mean PIFR compared to 
females and volunteers inhaled at larger flow rates with lower inter-subject variability 
when formally trained (Instruction B; there was no significant difference between 
normalized PIFR values for Instruction B1 and B2). Residuals from plots of PIFR vs. 1/R 
were randomly distributed and the observed positive linear relationship between PIFR 
and 1/R was consistent with the physiological literature where the slope of the regression 
line of PIFR vs. 1/R has been reported to give the square root of the “maximum” pressure 
drop across an inhaler for a given volunteer; this pressure drop reportedly stays 
approximately constant across the air flow resistances seen in marketed DPIs (Smutney 
et al., 2009). 
Values for inhaled volume, V, and the time to the peak inspiratory flow rate, TPIFR, 
(Table 4.2) were resistance-independent. As expected however, V was clearly influenced 
by gender. Consistent with their larger total lung capacity (Hankinson et al., 1999) males 
had a mean value for V = 3.009 L after Instruction A. This was 1.45 L more than females 
(mean V = 1.562 L). After Instruction B, these values increased to 3.787 and 2.063 L, 
respectively. Formal training (Instruction B), caused a statistically significant improvement 
in V across gender (n = 20); mean V overall was 0.64 L greater than that seen after 
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Instruction A (p < 0.0001). There was no apparent effect of gender on TPIFR but training 
once again was influential. A significant reduction of 0.3 seconds in mean TPIFR was 
observed after formal training (p < 0.0001).  
 
4.4  DISCUSSION 
This study describes the data resulting from a clinical study of the breath profiles 
produced by differently trained, inhaler-naïve, normal human adults inhaling through 
variable resistances typical of those seen in marketed DPIs (Delvadia et al., 2013a; 
Delvadia et al., 2012). Because the leaflets supplied with different powder inhalers use 
different phrases to describe the actual inhalation maneuver, we adopted a standardized 
phrase for Step 3 of our written Instruction A: “breathe in as quickly and as deeply as you 
can” (Figure 4.3). Our choice of phrase may have influenced the profiles shown in Figure 
4.5 given that the respective phrases in leaflets for Aerolizer®, Diskhaler®,  Novolizer®, 
Turbuhaler®, Easyhaler® and HandiHaler® were: “breathe in quickly and deeply”, 
“breathe in through your mouth steadily and as deeply as you can” “inhale the powder 
with a deep breath”, “breathe in as deeply and as hard as you can”, “take a strong and 
deep breath” and “breathe in deeply until your lungs are full”. Nevertheless, volunteers 
inhaled faster and deeper when they were trained using written instructions in 
combination with formal training from a pharmacist skilled in the use of inhalers, 
compared to the use of written instructions alone. The study showed that formal training 
helped to reduce inter-subject variability in inhalation flow rate vs. time profiles; an 
observation that may translate into reduced variability in aerosol drug deposition in the 
lung. IP analysis showed that decreased air flow resistance produced increases in PIFR 
62 
 
while V was unchanged. The results also showed that males inhaled faster and more 
deeply than females although no significant relationships were observed between the 
spirometric results (Table 4.1) of volunteers and their observed inhalation variables 
(Figure 4.4). Because the scope of the present study was limited to 20 healthy volunteers, 
most of whom were in their prime, the reported IPs probably do not reflect those for 
subjects with significant reductions in lung capacity. While the time of PIFR, TPIFR, and 
the total inhaled volume V were unrelated to R in this study, the findings may not hold in 
all subjects. Sarinas et al. (1998), for example, showed that in CF, COPD and asthma, V 
fell as resistance was increased. Gender and age, that influence mouth inspiratory 
pressure, MIP, have also been shown to influence inspiratory flow (Baba et al., 2011; 
Broeders et al., 2004; Malmberg et al., 2010). In spite of this limitation, the analysis below 
shows a general way of selecting standard IPs for use in realistic in vitro tests of inhalers 
during development. Indeed, because many drug and device development efforts, 
including aerosol deposition studies used for bridging purposes, begin with normal 
volunteers or largely asymptomatic patients, the present study was designed to ensure 
that the equations and general procedures for IP simulation that were developed could 
span the likely range of “normal” IPs needed to program a breath simulator for use with a 
realistic in vitro test method (Figure 4.1). In addition we sought to offer IP ranges for 
volunteers who were representative of patients who had to teach themselves how to 
inhale after reading an instruction leaflet.  
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Simulating Inhalation Profiles for DPIs with Different Airflow Resistances 
Even though it is possible to program breath simulators with IPs that are almost 
identical to the individual breath profiles of volunteers, or the 10, 50 and 90 percentile IPs 
shown in red in Figures 4.5 and 4.6, and this is practiced by some scientists (Olsson et 
al., 2013), profiles that are statistically representative of groups of subjects, that can be 
selected a priori, seem preferable for testing and development purposes.  
To program a breath simulator to mimic IPs that were representative of those 
shown in Figures 4.5 and 4.6, we sought suitable equations and functions able to 
adequately describe the red profiles representing the 10, 50 and 90 percentile flow rate 
vs. time curves shown in each panel. Ideally, parameters in the resulting equations should 
have physiologic meanings that relate to the variables shown in Figure 4.4. While we and 
others have described and used alternate methods previously,(Delvadia et al., 2013a; 
Delvadia et al., 2012; Delvadia et al., 2013b; Longest et al., 2012a; Longest et al., 2012b) 
we sought a simplified approach for use in future research with DPIs, in which it was only 
necessary to select the inhaler resistance, R, in order then to be able to define ranges of 
PIFR, TPIFR and V; whence to generate a fan of appropriate IPs with which to test a new 
DPI. Because the approach and algorithm is simple, we hope that the method proposed 
here can be generalized to include realistic tests that extend to treatment of different 
patient groups with differently designed inhalers and use instructions. 
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The black curves in Figure 4.8 are the simulated flow rate vs. time profiles that 
resulted from the following routine. They are clearly good descriptions of the real profiles 
(reproduced from Figure 4.6) that represent the 10, 50 and 90 percentile IPs (Instruction 
B). The same approach can be used to generate curves that follow the red profiles in 
Figure 4.5 (Instruction A; not shown), while intermediate curves, for testing inhalers with 
different resistances can also be generated. Each panel of IPs (black curves; Figure 4.8) 
was generated as follows from Equations 4.7–4.10: 
  ( ) sin 0
2 PIFRPIFR
t
FR t PIFR t T
T
 
    
 
                      Equation 4.7 
    
 
 
( ) cos
2
PIFR
PIFR
PIFR
t T
FR t PIFR T t T
T T
 
      
            Equation 4.8 
Because AUC = V (Figure 4.4) is given by integrating and adding Equations 4.7 and 4.8, 
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[ ]
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PIFR L T s
V L

 
                                 Equation 4.9 
Therefore, 
                     1
30 [ ]
[ ]
[ min ]
V L
T s
PIFR L





                                         Equation 4.10 
 
First, PIFR90%, PIFR50%, PIFR10% was calculated based on the DPI resistance, R 
(quoted in panel of Figure 4.8) using Equations 4.4, 4.5, 4.6, respectively, assuming that 
we were concerned with well-trained normal subjects. Second, a median value for 
TPIFR50% = 0.49 sec was selected and held constant; if required however, alternate values 
for TPIFR50% may be employed to produce different values for airflow acceleration (see 
distribution and legend in Figure 4.9). Notably, TPIFR was independent of R and log-
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normally distributed across the 240 IPs from this population. In spite of that observation, 
because the rising slope d(FR)/dt falls with decreasing PIFR (Figure 4.6) and PIFR 
decreases with increasing R (Figure 4.7), de Boer et al.’s reported relationship between 
the “flow increase rate (FIR)” and device resistance (de Boer et al., 1997) still holds.  
 
Figure 4.9. Distribution of values for TPIFR (seconds) across genders after Instruction B. 
The 10, 50 and 90 percentile values were 0.28, 0.49 and 0.88 seconds, respectively. 
Instruction A yielded a similar distribution with 10, 50 and 90 percentile values of 0.43, 
0.66 and 1.68 seconds, respectively. Selection of the values for TPIFR and PIFR permits 
the study of device behavior at different flow accelerations according to Equation 4.7. 
 
Third, V90%, V50% and V10% values were assigned (4.6, 2.7 and 1.4 L, respectively), 
based on “across gender” data for V (Table 4.2; because values for V in males and 
females differ significantly, IPs simulated for single gender studies should be adjusted). 
Fourth, values were calculated for the inhalation time T90%, T50% and T10% from Equation 
4.10. Coupling the calculated and assigned values for PIFR, TPIFR, V and T at their chosen 
percentiles, enables the calculation of flow rates leaving the mouthpiece at each value of 
time, t, from Equations 4.7 (t<TPIFR) and 4.8 (t≥TPIFR). These simulated profiles were 
plotted as the large, medium and small profiles shown in black on Figure 4.8. In practice, 
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breath simulators, such as the ASL 5000-XL can be programmed directly using these 
sine wave equations, or data may be supplied directly in the form of a spreadsheet of 
simulated flow rates over time. An example of the use of these IPs to test a DPI with 
known resistance was described previously (Byron et al., 2014). 
 
4.5  CONCLUSION 
A general method of selecting and simulating a range of inhaled flow rate vs. time 
profiles for use in the realistic testing of powder inhalers has been described. Equations 
and an algorithm are presented that enable simulation of the range of inhalation flow rate 
vs. time curves used by normal human adult volunteers of both genders both before and 
after formal training in the use of powder inhalers. The approach enables the product 
designer to select breath profiles with which to study aerosol device performance across 
the likely inter-subject variability seen with DPIs of different resistances following either 
leaflet training alone, or formal training from a professional in addition to leaflet training. 
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CHAPTER 5 
DETERMINING AERODYNAMIC PARTICLE SIZE DISTRIBUTIONS OF IN VITRO 
LUNG DOSES FOR BUDELIN® NOVOLIZER® UNDER REALISTIC INHALATION 
CONDITIONS 
5.1  INTRODUCTION 
Coupling realistic mouth-throat (MT) models with simulated, but representative 
human inhalation profiles (IP) that mimic inhaler use in the clinic (as described in Chapter 
4) has been found to be promising when building in vitro–in vivo correlations (IVIVCs) for 
orally inhaled drug products. Studies of several inhalers have shown that the in vitro 
measured lung doses (designated as the drug doses exiting the MT models) appear to 
predict the mean and extreme values for the in vivo total lung deposition data obtained 
from gamma scintigraphic or pharmacokinetic (PK) methods (Delvadia et al., 2013a; 
Delvadia et al., 2012; Olsson et al., 2013; Weers et al., 2014; Zhang et al., 2007). While 
total lung dose (TLD) is important in evaluating inhaler in vivo performance, regional drug 
deposition in the lung may also be a determinant of the therapeutic effects of inhaled 
drugs, especially for compounds intended for topical activity like budesonide (Anderson 
& Newman, 2009; Usmani & Barnes, 2012; Usmani et al., 2005).  
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As particle size is one of the major factors affecting aerosol drug deposition, and it 
is known to be influenced significantly by the airflow through Novolizer (de Boer et al., 
2004), evaluating size distribution of drug aerosols able to enter the lung, following 
deaggregation and dispersion under realistic inhalation conditions, is an essential part of 
realistic in vitro testing. We may expect that the drug deposition patterns in gamma 
scintigraphy studies, usually reported as P/C ratios [designated as radioactive counts in 
the peripheral (P) to central (C) lung ratio] are some function of the aerodynamic particle 
size distribution (APSD) of the TLD. A summary of the mean values and variations for 
P/C ratio obtained from gamma scintigraphy studies in the literature for different DPIs is 
provided in Appendix I. While variations in regional deposition may be caused by 
combined effects of variations in APSDs, inhalation flow rates, and airway geometries, if 
we are to fully evaluate the variations in regional drug distribution in the lung using 
modeling approaches like computational fluid dynamic (CFD) simulations (Longest & 
Holbrook, 2012), it is necessary to evaluate the possible ranges of APSDs of drugs exiting 
the MT models during realistic testing.  
The challenge of coupling realistic IP conditions for aerosol generation with the 
constant flow demand of cascade impactor testing can be overcome by using devices like 
the Electronic Lung™ (Burnell et al., 1998b) or the Nephele Mixing Inlet (N. C. Miller, 
1997; N. C. Miller et al., 2000). The Electronic Lung™ was developed by GlaxoSmithKline 
scientists who created powder aerosols using different IPs in a large chamber; aerosols 
were subsequently drawn into a calibrated cascade impactor at a fixed flow rate (Brindley 
et al., 1994; Burnell et al., 1998a; Burnell et al., 1998b). The method, that generates an 
apparent APSDs of the sampled drug cloud, suffers from a significant problem because 
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of settling and drug losses in the sample chamber (Burnell et al., 1998b). The use of the 
Nephele Mixing Inlet to provide variable aerosol dilution over time in a “flow balancing” 
set up (described in Figure 5.3 later in this chapter) can overcome this difficulty under 
certain circumstances. Several examples of using this approach to measure particle size 
distributions exiting MT models have been reported (Below et al., 2013; Casaro et al., 
2014; Chrystyn et al., 2015; Olsson et al., 2013). Because the method is obliged to use 
additional makeup air to create the constant air flow required by the cascade impactor, 
the highest flow rate possible for a test IP, i.e. peak inhalation flow rate (PIFR), is presently 
limited by the upper flow limit of the calibration range of the chosen cascade impactor. 
The most accepted cascade impactor for pharmaceutical studies of inhalers with a high 
flow rate calibration is the Next Generation Pharmaceutical Impactor [NGI; Apparatus 5, 
USP (U.S. Pharmacopeial Convention, 2013)]. The NGI is calibrated for use at air flow 
rates between 15 and 100 L/min, so that presently, the maximum usable PIFR in the set 
up used in the literature is 100 L/min (Below et al., 2013; Casaro et al., 2014; Chrystyn et 
al., 2015; Olsson et al., 2013). This is a big limitation of the method given that Chapter 4 
and other studies have reported that both healthy subjects and patients may generate 
PIFRs much greater than 100 L/min through DPIs, especially when the inhalers in use 
are low resistance devices (Azouz et al., 2015a; Azouz et al., 2015b; Virchow et al., 2014). 
The present study sought to develop and evaluate methods for measuring APSDs 
of drug aerosols from Budelin® Novolizer® 200 mcg (Meda Pharmaceuticals, 
Hertfordshire, U.K.) exiting the Virginia Commonwealth University (VCU) MT models 
under a range of realistic IPs. While Budelin was chosen for this study in part because its 
regional distribution in the lung has been reported in the literature (Newman et al., 2000), 
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the method sought to extend the range of testable IPs to allow the assessment of APSDs 
of TLDin vitro from Budelin at flow rates over 100 L/min. The chapter describes methods of 
extending the test limit of NGI to allow the APSDs of the in vitro lung doses to be 
determined across a range of realistic IPs. A recalibration of NGI using polydisperse 
budesonide aerosols is also described. The details of Budelin Novolizer 200 mcg regional 
distribution are summarized from the literature (Newman et al., 2000) in Appendix I. 
 
5.2  MATERIALS AND METHODS 
Mouth-Throat Models 
Small, medium and large Virginia Commonwealth University (VCU) MT models 
[(Longest, 2012); noted as VCU-MTs, VCU-MTM, VCU-MTL in the following text], 
previously designed and validated to describe the geometric variations seen in adult 
humans (Delvadia et al., 2012), were externally modified to improve connectivity to the 
NGI and Nephele Mixing Inlet (NMI) (N. C. Miller, 1997; N. C. Miller et al., 2000) (Figure 
5.1). Internal dimensions of these models were not changed. The three-dimensional (3D) 
geometry of the MT models were altered in Autodesk® Inventor® 2014 (Autodesk, Inc., 
San Rafael, CA), and a quick-fit adapter to NGI was added to the trachea of each model 
to ensure an airtight connection between MT, NGI and NMI. The tapered “quick-fit” female 
dimensions atop the NGI inlet and NMI inlet are identical. The NMI outlet also has a 
tapered male connection designed to mate with the NGI inlet. Dimensions of the modified 
MT geometry can be found in Appendix II. Physical models were constructed in 
ultraviolet-laser-cured resin (Accura® 60, 3D System, Valencia, CA) using a rapid 
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prototyping process of stereolithography (Viper si2™ SLA® system, 3D Systems, 
Valencia, CA), with vertical layer thickness of 0.1 mm.  
 
Figure 5.1. Small, medium and large Virginia Commonwealth University (VCU) mouth-
throat (MT) models [(Longest, 2012); noted as VCU-MTs, VCU-MTM, VCU-MTL in the 
following text] with quick-fit adapters to fit the Next Generation Impactor (NGI) and 
Nephele Mixing Inlet (NMI). Dimensions of the modified MT geometries are described in 
Appendix II.  
 
Inhalation Profiles 
IPs were simulated using the sinusoidal waveforms described in Chapter 4 
(Equations 4.7–4.10) to represent the fast, moderate and slow inhalation used by subjects 
in a lung scintigraphy study of Budelin Novolizer 200 mcg (Newman et al., 2000). 
Variations in subjects’ inhalation maneuvers were estimated by adding and subtracting 
two standard deviations (SD) from the mean values for peak inhalation flow rate (PIFR) 
and inhaled volume (V) (Newman et al., 2000) to represent the 95% conference intervals 
around each of the reported means. These values were paired (Table 5.1) to generate 
the small, medium and large volume IPs for each inhalation condition (Figure 5.2).  
 
Small 
Medium
Large
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Table 5.1. Mean and likely confidence intervals for peak inhalation flow rate (PIFR) and 
inhaled volume (V) at each of the reported inhalation conditions (Newman et al., 2000).  
Inhalation 
Condition 
Inhalation Profile 
 PIFRa (L/min) Va (L) 
Fast 
Small 
73 
(Mean–2SD) 
1.11 
(Mean–2SD) 
Medium 
99 
(Mean) 
3.13 
(Mean) 
Large 
125 
(Mean+2SD) 
5.15 
(Mean+2SD) 
Moderate 
Small 
59 
(Mean–2SD) 
1.30 
(Mean–2SD) 
Medium 
65 
(Mean) 
2.96 
(Mean) 
Large 
71 
(Mean+2SD) 
4.62 
(Mean+2SD) 
Slow 
Small 
40 
(Mean–2SD) 
0.83 
(Mean–2SD) 
Medium 
54 
(Mean) 
2.77 
(Mean) 
Large 
68 
(Mean+2SD) 
4.71 
(Mean+2SD) 
aMean values for PIFR and V for each inhalation condition were as reported (Newman et 
al., 2000), whereas the ranges (large and small values) were estimated by adding and 
subtracting two standard deviations [SD; also reported by Newman et al. (2000)] from the 
mean.  
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Figure 5.2. The small, medium and large simulated test IPs used to represent the median 
and extremes (95% confidence intervals; see IP definition page xix) for the (a) fast, (b) 
moderate and (c) slow inhalations described in the clinical study (Newman et al., 2000).  
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Mixing Inlet–Cascade Impactor System 
Apparatus 
The NMI (Model III for NGI; RDD Online, Richmond, VA) is a precisely engineered 
and patented tool for mixing high density, non-homogeneous aerosol clouds, like those 
from inhalers, with variable volumes of dilution air. It contains a central tube for receiving 
the aerosol clouds and an outer inlet for receiving and introducing dilution air; the design 
enables a sheath air flow to be created around the aerosol flow to minimize wall losses 
due to impaction. Losses within the NMI have been reported to be <2% (N. C. Miller, 1997; 
N. C. Miller et al., 2000). The NGI (MSP Corporation, Shoreview, MN) was modified by 
replacing the jets and orifice plates with those from the Westech W7 Cascade Impactor 
(Westech Scientific Inc., Marietta, GA), a precisely-engineered copy of the original NGI 
and purchased with detailed mensuration data and certification. The use of the W7 jet 
plate enables the removal of individual jets and the Micro-Orifice Collector (MOC) when 
these are found to create sonic (or critical) flow conditions in the instrument (i.e. situations 
where the air flow rate through the impactor cannot be increased given further increase 
of vacuum power). Notably, the unmodified NGI does not enable jet removal and high 
flow rate testing. To extend the flow limits of NGI and allow its operation outside the 
specific flow range for which it is calibrated [15–100 L/min; (Marple et al., 2003a; Marple 
et al., 2004; U.S. Pharmacopeial Convention, 2013)], MOC was replaced with a high flow 
internal filter holder containing an 81 mm diameter disposable type A/E glass fiber filter 
(Pall Corporation, Port Washington, NY) capable of complete aerosol capture. The 
programmable breath simulator ASL 5000-XL (a larger-volume version of the commercial 
model ASL 5000, redesigned for VCU by IngMar Medical, Pittsburgh, PA), was used in 
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this study to simulate the complete range of realistic IPs for Budelin Novolizer (Figure 5.2). 
Two vacuum pumps were used to generate constant air flow through NGI: a lower 
capacity ERWEKA vacuum pump VP 1000 (ERWEKA International, Annandale, NJ) for 
air flow rates ≤100 L/min, and a higher capacity 3-phase DOERR vacuum pump LR22132 
(Emerson Electric, St Louis, MO) for air flow rates >100 L/min.  
 
Experimental Setup and General Procedure 
The setup for characterizing the APSDs of drug exiting MT models, following 
deaggregation and dispersion under realistic inhalation conditions, is illustrated in Figure 
5.3. The NMI was placed atop the NGI-W7 impactor (noted as “NGI” in the following text), 
with its upper inlet connected to the MT model for receiving aerosol clouds from Budelin 
Novolizer, and side inlet connected to a compressed air source (with a pressure regulator 
and a flow control valve) for receiving dilution air. The vacuum pump was connected to 
the outlet of NGI, and depending on the PIFR of the test IP, either the lower capacity or 
higher capacity pump was selected to draw air through NGI at the designated flow rate 
(Table 5.2). The breath simulator was interposed between the NMI and compressed air 
source using a T-junction. While not strictly necessary, Parafilm® M (Bemis, Oshkosh, 
WI) over-wraps were used throughout to ensure airtight connections between apparatus 
components.  
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Figure 5.3. Experimental setup and apparatus used to measure aerodynamic particle 
size distributions of drugs exiting the MT model under realistic inhalation conditions for 
Budelin® Novolizer®. Equipment details are described in the text. 
 
Prior to each experiment, internal surfaces of the MT models and NGI plates were 
coated twice with Molykote® 316 silicone release spray (Dow Corning, Midland, MI) using 
procedures described by Hindle et al. to avoid particle re-entrainment after impaction 
(Hindle et al., 1996). After each spraying, excess coating solution was retained inside the 
MT model, and the model shaken regularly to ensure uniform internal surface coverage. 
The complete coating procedure took 30 minutes per coating, after which all solvents had 
evaporated. The apparatus was assembled as shown in Figure 5.3 except that prior to 
each test, a low-resistant digital flow meter SFM 3000 (Sensirion Inc., Westlake Village, 
CA) was connected at the mouth opening of MT, in place of the inhaler, to monitor the air 
flow rate entering MT with time. The vacuum pump was switched on to draw air through 
the MT into the NGI and air flow was adjusted until it reached the designated flow rate for 
the NGI in the chosen experiment (either 100 or 140 L/min in this study). The vacuum 
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flow was then held constant, and compressed air introduced as dilution air to the side port 
of NMI. This dilution air flow was adjusted until it balanced the vacuum flow through NGI 
to produce a flow meter reading at the entry to MT = 0±2 L/min. The breath simulator, 
programmed to create a chosen IP (Figure 5.2), was activated to draw air through MT 
into NMI while constant air flow was maintained through NGI. The designated IP was 
recorded at the mouth opening of MT to ensure that PIFR and V were within 2% of their 
designated protocol values (Table 5.1). Once this condition was met, the setup was 
accepted and the flow meter removed from the entrance to MT. Budelin Novolizer was 
then primed, inserted into the MT model and sealed with Parafilm® M, and a single IP 
used to  disperse and draw a budesonide dose through the system. After commencing 
the designated IP, the inhaler was removed from MT, and the compressed air source and 
vacuum pump switched off in sequence. The apparatus was disassembled after each 
dose, and budesonide was recovered by rinsing the inhaler (with drug cartridge removed), 
MT, NMI, NGI stages 1–7 and filter using known volumes of 70%/30%:methanol/water 
(v/v) and analyzed using high-performance liquid chromatography (HPLC). Budesonide 
assay was performed using Symmetry® C18 column (3.5µm, 4.6×100mm, Waters, 
Milford, MA), 69% methanol / 31% 0.1% (v/v) acetic acid buffer (v/v) as mobile phase 
(flow rate: 1.0 mL/min), and UV detection at 280 nm (2996 Photodiode Array Detector, 
1515 Isocractic HPLC Pump, 717 plus Autosampler, Waters). Injection volume was 100 
µL and calibration curves were linear in the range of 0.2–10.0 mcg/mL (r2 > 0.999). The 
limit of quantification (LOQ) = 0.025 mcg/mL.  
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Aerodynamic Particle Size Distributions of Budelin’s TLDin vitro 
The mixing inlet–cascade impactor system (Figure 5.3) and different VCU MT 
models (Figure 5.1) were employed to enable drug clouds to be withdrawn from Budelin 
Novolizer 200 mcg according to each of the designated IPs (Figure 5.2) so that the APSDs 
of drugs exiting MT (TLDin vitro) could be characterized under constant flow conditions. To 
evaluate the likely ranges of APSDs of Budelin’s TLDin vitro, the VCU-MTS, VCU-MTM, and 
VCU-MTL were paired with the small, medium and large IPs, respectively, for each 
inhalation condition (fast, moderate, slow). The NGI was operated either at 100 L/min if 
PIFR for the test IP was smaller than 100 L/min or 140 L/min if PIFR > 100 L/min. 
Combinations of MT models, IPs and NGI flow rates used for measurement of APSDs of 
Budelin’s TLDin vitro are summarized in Table 5.2. Because NGI is only calibrated in the 
flow range of 15–100 L/min (Marple et al., 2003a; Marple et al., 2004; U.S. Pharmacopeial 
Convention, 2013), additional experiments were performed to evaluate the data collected 
at 140 L/min. In practice, it was necessary to recalibrate the instrument at 140 L/min. To 
to do this, four MT-IP combinations where PIFR of the test IP < 100 L/min were selected 
from Table 5.2 (fast inhalation, small MT-IP and medium MT-IP; slow inhalation, medium 
MT-IP and large MT-IP). The same MT-IP combinations were employed to determine the 
apparent APSDs of TLDin vitro at the 140 L/min NGI flow condition given that the same 
budesonide aerosol should be generated under the same conditions, regardless of the 
change in NGI flow. In this way, the data collected at 100 L/min could be used as 
polydisperse aerosol calibration standards to compare with the data generated at 140 
L/min. All experiments were randomized. Single actuations were applied and five 
replicates were performed for each protocol.  
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Table 5.2. MT models, IPs and NGI flow rates used for measurement of APSDs of TLDin 
vitro for Budelin Novolizer. IPs (small, medium, large) for each of the inhalation conditions 
(fast, moderate, slow) in the literature (Newman et al., 2000) and as defined in Table 5.1 
and Figure 5.2.  
Inhalation Condition MT Model Inhalation Profile NGI Flow Rate (L/min) 
Fast VCU-MTS Small 100 and 140* 
VCU-MTM Medium 100 and 140* 
VCU-MTL Large 140 
Moderate VCU-MTS Small 100 
VCU-MTM Medium 100 
VCU-MTL Large 100 
Slow VCU-MTS Small 100 
VCU-MTM Medium 100 and 140* 
VCU-MTL Large 100 and 140* 
*The MT-IP combination was tested at both 100 and 140 L/min NGI flow conditions to 
evaluate the validity of APSD measurements of Budelin’s TLDin vitro at 140 L/min.  
 
Data Treatment 
The amount of budesonide depositing on inhaler, MT, NMI, NGI stages 1–7 and 
filter were calculated from the products of drug concentrations and sample volumes. 
Values for TLDin vitro were calculated as total amount of budesonide depositing on NMI 
and NGI, and compared with TLDin vivo reported in the gamma scintigraphy study 
(Newman et al., 2000) for each inhalation condition. The APSDs of TLDin vitro for 
budesonide exiting the MT model were analyzed in accord with USP (U.S. Pharmacopeial 
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Convention, 2013), where the cutoff aerodynamic diameters for NGI’s stages at a specific 
flow rate (Q ), 50,QD , were calculated using Equation 5.1: 
50, 50,
x
Q Qn
Qn
D D
Q
 
  
 
                                      Equation 5.1  
Where Qn  is the nominal flow rate (60 L/min) and 50,QnD  is the stage cutoff diameter at
Qn . USP’s values for 50,QnD  and the exponent x  (Table 5.3) are based on an archival NGI 
calibration that accords with NGI’s stage mensuration data and impaction theory in the 
flow range of 30–100 L/min (Marple et al., 2003a). To facilitate initial data analysis, 
Equation 5.1 was extrapolated so that values for 50,QD  could be calculated for both the 
100 and 140 L/min NGI flow conditions, assuming that the values for the exponent x  
were unchanged (Table 5.3). Apparent APSDs of Budelin’s TLDin vivo measured at 
different conditions were then compared by plotting the cumulative percent mass less 
than the stated cutoff diameter vs. the cutoff diameter of the corresponding stage ( 50D ) 
(Equation 5.2). Statistical analyses were performed for total recovered dose and total drug 
mass in NGI using one-way ANOVA and Student’s t-test at a significant level of 0.05 in 
JMP Pro 11 (SAS Institute Inc., Cary, NC). 
 50
    
 %     100%
   
Drug Mass Below Stage i
Cumulative Mass D of Stage i
Total Drug Mass in NGI
  

     Equation 5.2 
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Table 5.3. The cutoff aerodynamic diameters for NGI’s stages at the nominal flow rate 
(Qn ), 50,QnD , and the exponent x  in Equation 5.1 (U.S. Pharmacopeial Convention, 2013).  
Stage 50,QnD  x  
1 8.06 0.54 
2 4.46 0.52 
3 2.82 0.50 
4 1.66 0.47 
5 0.94 0.53 
6 0.55 0.60 
7 0.34 0.67 
 
Re-calibration of NGI’s Stage Cutoff Diameters 
While the theoretical value of the exponent x  in Equation 5.1 is 0.5 given “ideal” 
impaction theory (Reist, 1993), all impactors require experimental calibration corrections 
so it is not surprising that x  ranges 0.47 through 0.67 for NGI stages 1–7 in the flow rate 
range of 30–100 L/min (Table 5.3) (U.S. Pharmacopeial Convention, 2013). In order to 
employ NGI at a flow rate above this calibration limit (e.g. 140 L/min), it was necessary 
to: 
(a) Remove the last stage (MOC) from NGI to prevent flow limitation due to the flow 
through the MOC becoming critical or sonic; 
(b) Assess the validity of Equation 5.1 at 140 L/min with USP’s values for the exponent 
x  by comparing the APSDs of budesonide aerosols produced from Budelin under the 
same MT-IP conditions when drawn into NGI at both  air flow rates; 
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(c) Amend the values of 50D  for certain stages (perhaps by modifying the exponential 
term x  for those stages) at 140 L/min.  
The recalibration of a cascade impactor using polydisperse pharmaceutical 
aerosols was reported by Kotian et al. (2009) and a similar approach was employed here.  
Four sets of n = 5 cumulative percent mass undersize data obtained from the NGI at 100 
L/min from the experimental protocols described in Table 5.2 (fast inhalation: small MT-
IP, medium MT-IP; slow inhalation: medium MT-IP, large MT-IP) were used as calibration 
standards. Data were fitted using least square nonlinear regression analysis to determine 
best estimates for the mass median aerodynamic diameter (MMAD) and the geometric 
standard deviation (GSD) of each cloud by fitting the data to the cumulative lognormal 
distribution function (CDF) (Andrews, 1992; Kotian et al., 2009) shown in Equation 5.3: 
 0.5
1
100 0.5 0.5 log -
2 e
y ERF x MEAN

               
            Equation 5.3 
Where ERF  is the error function = 
 
2
0.5
1
log -
2
0.5
2 e x MEAN
e dx

          , and  MEANe  and e  are the 
MMAD and GSD of the lognormally distributed data. No weighting factors were assigned 
and the analysis was performed using MATLAB® R2012b (MathWorks, Natick, MA). The 
cumulative percentage of drug, y , depositing below the cutoff diameter, 50D , of each 
stage at 100 L/min, x , was fitted by allowing MEAN  and   to float in order to minimize 
the sum of squared deviations of the data from the line of best fit for each MT-IP 
combinations (Table 5.2). Best estimates of MMAD and GSD were tabulated for each 
product, alongside their 95% confidence intervals (CI) in accord with Kotian et al. (2009).  
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To recalibrate NGI at 140 L/min, the individual values for cumulative percent mass 
penetrating below each stage were tabulated for that flow condition. The curves of best 
fit for the NGI data at 100 L/min were assumed to also describe the NGI data at 140 L/min. 
Values for MMAD and GSD for each aerosol at 100 L/min were fixed at their best 
estimates following curve fitting, and solutions for the stage 50D  values at 140 L/min were 
then solved analytically using the cumulative lognormal distribution curves for each 
aerosol and MT-IP combination. This was performed in Microsoft Excel 2013 (Microsoft 
Corporation, Redmond, WA) by setting the value for the cumulative percent undersize ( y  
in Equation 5.3) to its experimentally determined value for the chosen MT-IP combination 
when tested with NGI flow = 140 L/min; the function was then solved for x  using the 
LOGNORM.INV function and the solution assigned to 50D  for the selected stage and data 
set. Mean values of each 50D  were calculated for each stage from the four separate 
calculations and assigned as the re-calibrated cutoff diameters for the NGI when operated 
at 140 L/min.  
 
5.3  RESULTS 
Mass Balance 
The mean total (SD) budesonide recovered from the deposition sites (mass from 
inhaler mouthpiece, MT, NMI + NGI) ranged from 222.1±7.6 to 240.5±21.9 mcg  showed 
no statistical differences (one-way ANOVA, p>0.05) across all testing conditions (Table 
5.4). This statement was true even through the combination of small MT and small IP 
resulted in greater inhaler retention and reduced delivered dose in all cases. The same 
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trend of reducing delivered doses was seen for Salbulin Novolizer (same inhaler, different 
drug and formulation) as shown in Figure 3.4.  
Table 5.4. Mean budesonide dose (±SD) collected from Budelin Novolizer 200 mcg 
inhaler, mouth-throat model (MT), Nephele Mixing Inlet (NMI), Next Generation Impactor 
(NGI) alongside the total recovered dose for different testing conditions. Total lung dose, 
TLDin vitro, was designated as the drug dose exiting the MT model, or the sum of the drug 
mass collected in NMI and NGI. Total recovered drug was calculated as the sum of drug 
dose collected from inhaler, MT, NMI and NGI. Data were presented as mean±SD (n=5). 
Drug deposition on NMI was <LOQ in most cases (noted as “0.0”).  
Experimental Protocol 
Budesonide Dose (mcg) 
Inhaler MT NMI NGI TLD Total 
Fast 
Inhalationa 
Small 
MT-IP 
100 
L/min 
78.0 
(17.6) 
117.6 
(22.2) 
0.0 
(0.0) 
36.1 
(5.2) 
36.1 
(5.2) 
231.7 
(17.7) 
Small 
MT-IP 
140 
L/min 
74.0 
(28.0) 
129.6 
(38.2) 
0.0 
(0.0) 
31.4 
(8.9) 
31.4 
(8.9) 
235.0 
(7.7) 
Medium 
MT-IP 
100 
L/min 
21.9 
(4.1) 
137.9 
(11.7) 
0.2 
(0.5) 
75.2 
(6.1) 
75.5 
(5.9) 
235.3 
(7.8) 
Medium 
MT-IP 
140 
L/min 
23.7 
(4.1) 
123.6 
(7.4) 
0.2 
(0.5) 
74.6 
(4.9) 
74.8 
(4.7) 
222.1 
(7.6) 
Large 
MT-IP 
140 
L/min 
21.6 
(9.8) 
114.9 
(8.0) 
0.5 
(0.7) 
89.3 
(9.9) 
89.8 
(10.5) 
226.3 
(13.6) 
Moderate 
Inhalationa 
Small 
MT-IP 
100 
L/min 
70.5 
(16.3) 
131.0 
(14.9) 
0.0 
(0.0) 
32.8 
(7.9) 
32.8 
(7.9) 
234.3 
(7.3) 
Medium 
MT-IP 
100 
L/min 
25.0 
(9.9) 
152.5 
(13.6) 
0.0 
(0.0) 
54.2 
(7.0) 
54.2 
(7.0) 
231.7 
(22.4) 
Large 
MT-IP 
100 
L/min 
22.2 
(3.4) 
150.6 
(18.7) 
0.0 
(0.0) 
67.6 
(8.1) 
67.6 
(8.1) 
240.5 
(21.9) 
Slow 
Inhalationa 
Small 
MT-IP 
100 
L/min 
62.4 
(28.1) 
162.2 
(35.3) 
0.0 
(0.0) 
12.2 
(2.9) 
12.2 
(2.9) 
236.7 
(10.5) 
Medium 
MT-IP 
100 
L/min 
18.9 
(3.2) 
174.1 
(11.8) 
0.0 
(0.0) 
42.3 
(6.1) 
42.3 
(6.1) 
235.2 
(18.5) 
Medium 
MT-IP 
140 
L/min 
25.1 
(8.6) 
172.8 
(7.2) 
0.2 
(0.5) 
37.0 
(2.5) 
37.2 
(2.9) 
235.1 
(4.9) 
Large 
MT-IP 
100 
L/min 
20.0 
(4.6) 
147.5 
(6.5) 
0.0 
(0.0) 
66.8 
(1.7) 
66.8 
(1.7) 
234.4 
(9.4) 
Large 
MT-IP 
140 
L/min 
20.3 
(7.1) 
154.7 
(7.2) 
0.5 
(0.7) 
56.9 
(4.4) 
57.4 
(4.9) 
232.3 
(6.2) 
aNewman et al. (2000) training conditions.   
Notably, the amount of drug collected in the NMI was <2% of TLDin vitro in all cases, 
consistent with the claims for the NMI (N. C. Miller, 1997; N. C. Miller et al., 2000) and 
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indicating that the addition of NMI to the NGI (Figure 5.3) had negligible effects on the 
data for particle size distributions of TLDin vitro. This observation was consistent with 
Olsson et al.’s findings (Olsson et al., 2010) and this again shows the advantage of NMI 
over the Electronic™ Lung approach (Burnell et al., 1998b) when seeking to couple 
realistic IPs with the constant flow conditions required for cascade impaction. The degree 
of IP control that proved possible with the apparatus and general method described in 
Figure 5.3 and associated text is illustrated in Figure 5.4.  
For experiments using the same MT-IP combinations tested at two NGI flow 
conditions (fast inhalation: small MT-IP, medium MT-IP; slow inhalation: medium MT-IP, 
large MT-IP), the flow rate vs. time profiles, or IPs, measured at the mouth opening of MT 
were indistinguishable and completely comparable for a selected inhalation condition, 
regardless of the change in NGI flow rates (Figure 5.4). Because aerosol generation and 
dispersion from Budelin is flow-dependent (de Boer et al., 2004), when the inhaler is 
tested using the same MT-IP combination, the budesonide clouds and drug doses 
collected from inhaler, MT, NMI and NGI should be comparable between the 100 and 140 
L/min NGI flow conditions within the dosing variations imposed by the product. This 
comparability was confirmed by the results from the small and medium MT-IP 
combinations tested under fast inhalation conditions (Table 5.4, Row 2–5), and the 
medium MT-IP combinations under slow inhalation conditions (Table 5.4, Row 11–12) 
that showed no statistically significant differences in mass distribution across the columns 
(e.g. for comparable MT-IP combinations). While small but statistically significant 
differences (Student’s t-test, assuming equal-variance, p<0.05) were observed for the 
collected mass in NGI between 100 and 140 L/min NGI conditions for the large MT-IP 
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combination (slow inhalation; Table 5.4, Row 13–14), this was only seen once and the 
variation was consistent with those reported for Novolizer (Munzel et al., 2005). It 
appeared reasonable to believe that budesonide aerosols, generated from Novolizer 
using the same MT-IP combinations, had comparable particle size distributions when 
tested in the apparatus shown in Figure 5.3, irrespective of whether the flow rate through 
the NGI was 100 or 140 L/min. 
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Figure 5.4. Comparison of inhalation profiles recorded at the entrance to MT under the 
same MT-IP combinations with NGI flow rates = 100 and 140 L/min, respectively.  
88 
 
In Vivo – In Vitro Correlations 
The method produced values for TLDin vitro (drugs recovered from NMI and NGI) 
that were comparable to those described previously following aerosol capture in upper 
airway models and filters (Delvadia et al., 2012) in spite of the fact that the method used 
to simulate the IPs (Chapter 4 and Figure 5.2) differed slightly from the technique reported 
for the Budelin Novolizer inhaler by Delvadia et al. (2012) and the large, fast IP utilized a 
value for V = 5.15 L (Table 5.1) in the present study. The results produced the IVIVCs 
shown in Figure 5.4 for the percent of the total recovered dose exiting MT, illustrating 
once more the importance of variations in mouth-throat geometry and breath profiles for 
aerosol drug delivery from Budelin Novolizer. For a selected inhalation condition, the 
extremes of lung deposition seen clinically appeared to correlate to the values for TLDin 
vitro seen between the large MT–large IP and small MT–small IP test configurations (Figure 
5.5). The in vitro lung doses determined using these test methods ranged from 11.5% to 
45.8% for fast inhalation, from 10.1% to 31.0% for moderate inhalation, and from 3.5% to 
31.2% for slow inhalation. These values are comparable to those reported by Delvadia et 
al. (2012) for the same inhaler where TLDin vitro ranged from 9.7% to 40.4% for fast 
inhalation, from 8.0% to 28.7% for moderate inhalation, and from 4.8% to 28.0% for slow 
inhalation. 
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Figure 5.5. Comparison of in vivo and in vitro total lung dose (TLD) as % total recovered 
drug dose (inhaler + MT + NMI + NGI) for Budelin Novolizer at fast, moderate and slow 
inhalation conditions. Both the in vivo (Newman et al., 2000) and in vitro data were 
presented as median (range) (n = 5). TLD values were calculated from the experiments 
where NGI was operated at 100 L/min except for the large MT-IP combination tested at 
fast inhalation which employed an NGI flow rate of 140 L/min.  
 
Aerodynamic Particle Size Distributions 
Deposition of TLDin vitro for budesonide within the NMI and NGI was determined for 
each of the MT-IP and NGI flow rate conditions described above (Tables 5.2) in replicate 
(n = 5). The mean results are shown in Table 5.5. Cutoff diameters for NGI stages were 
first calculated for both 100 and 140 L/min flow conditions using Equation 5.1 with values 
for x  taken from Table 5.3, and the results are shown in Table 5.6.  
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Table 5.6. Calculated cutoff diameters for NGI stages at 100 and 140 L/min flow rates 
calculated from Equation 5.1 and Table 5.3.  
Stage D50, 100L/min D50, 140L/min 
1 6.12 5.10 
2 3.42 2.87 
3 2.18 1.85 
4 1.31 1.11 
5 0.72 0.60 
6 0.40 0.33 
7 0.24 0.19 
 
Re-calibration of NGI’s Stage Cutoff Diameters 
For the four selected MT-IP combinations tested at both the 100 and 140 L/min 
NGI flow conditions (Fast Inhalation: small MT-IP, medium MT-IP; Slow Inhalation: 
medium MT-IP, large MT-IP), data were plotted as the cumulative percent of drug mass 
less than the stated cutoff diameter against the calculated stage cutoff diameters ( 50D ) 
from Table 5.6. While the same size distribution was expected and hoped for in the case 
of each selected MT-IP combination at the different NGI flow rates, the profiles shown in 
Figure 5.6 showed some discrepancies between the 100 and 140 L/min conditions for all 
cases, mostly related to deposition on stages 1 through 3 of NGI. The jets above those 
stages are associated with high Reynolds numbers (Re) and increasing airflow turbulence 
(Marple et al., 2003b). This suggested that the USP calibration (Equation 5.1) (U.S. 
Pharmacopeial Convention, 2013) failed to be applicable when calculating the stage 
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cutoff diameters at 140 L/min, necessitating experimental recalibration of the cutoff 
diameters.  
(a) Fast Inhalation / Small MT-IP
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(c) Slow  Inhalation / Medium MT-IP
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(d) Slow  Inhalation / Large MT-IP
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Figure 5.6. Apparent cumulative percent of drug mass under size vs. calculated stage 
cutoff diameters (Table 5.6) for budesonide collected in NGI following realistic aerosol 
testing in different MT models. Data are presented as mean±SD (n=5) for the four 
selected MT-IP combinations tested at the 100 and 140 L/min NGI flowrates.  
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The cumulative percent under size vs. stage cutoff diameter data for the four 
selected MT-IP combinations tested at 100 L/min were fitted to the cumulative lognormal 
distribution function (Equations 5.3–5.4) and results were shown in Figure 5.7. Values for 
coefficients of determinations ( 2r ) are greater than 0.997 for all cases, suggesting 
aerodynamic particle size of aerosols exiting MTs can be well described using the 
lognormal distribution model. Best estimation for MMAD ( MEANe ) and GSD ( e ), and their 
95% CIs, were summarized for each MT-IP combination in Table 5.7.   
 
Table 5.7. Mean values and 95% confidence intervals for MEAN ,  , MMAD ( MEANe ) and 
GSD ( e ) estimated from the curves of best fit (Equation 5.3) for the four selected MT-IP 
combinations when tested with NGI flow rate = 100 L/min.  
Experimental Protocol 
MEAN  
(95% CI) 
  
(95% CI) 
MMAD ( MEANe ) 
(95% CI) 
GSD ( e ) 
(95% CI) 
Fast 
Inhalationa 
Small MT-IP 
0.73 
(0.71-0.75) 
0.60 
(0.57-0.63) 
2.08 
(2.04-2.12) 
1.82 
(1.76-1.87) 
Medium MT-IP 
0.63 
(0.61-0.65) 
0.62 
(0.59-0.65) 
1.88 
(1.84-1.91) 
1.86 
(1.81-1.92) 
Slow 
Inhalationa 
Medium MT-IP 
0.93 
(0.91-0.95) 
0.62 
(0.59-0.65) 
2.52 
(2.47-2.57) 
1.87 
(1.81-1.92) 
Large  MT-IP 
0.82 
(0.80-0.84) 
0.64 
(0.62-0.67) 
2.27 
(2.23-2.30) 
1.90 
(1.86-1.95) 
aNewman et al. (2000) training conditions.   
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(a) Fast Inhalation / Small MT-IP (100L/min) (b) Fast Inhalation / Medium MT-IP (100L/min)
(c) Slow Inhalation / Medium MT-IP (100L/min) (d) Slow Inhalation / Large MT-IP (100L/min)
Figure 5.7. Cumulative percent of drug mass undersize vs. stage cutoff diameters for 
drugs collected in NGI following realistic testing. Data are presented as mean±SD (n=5) 
for the four selected MT-IP combinations tested at 100 L/min. Red circles are individual 
data points, while the black profiles are results of curve fitting to the cumulative lognormal 
distribution function (Equation 5.3). Coefficients of determination ( 2r ) were > 0.997 in all 
cases.  
 
 
 
0 1 2 3 4 5 6 7
0
20
40
60
80
100
Cut-off Diameter (m)
C
u
m
u
la
ti
ve
 %
 U
n
d
er
 S
iz
e
 
Data
Lognormal CDF
0 1 2 3 4 5 6 7
0
20
40
60
80
100
Cut-off Diameter (m)
C
u
m
u
la
ti
ve
 %
 U
n
d
er
 S
iz
e
 
Data
Lognormal CDF
0 1 2 3 4 5 6 7
0
20
40
60
80
100
Cut-off Diameter (m)
C
u
m
u
la
ti
ve
 %
 U
n
d
er
 S
iz
e
 
Data
Lognormal CDF
0 1 2 3 4 5 6 7
0
20
40
60
80
100
Cut-off Diameter (m)
C
u
m
u
la
ti
ve
 %
 U
n
d
er
 S
iz
e
 
Data
Lognormal CDF
95 
 
The curves in Figure 5.7 were generated according to Equation 5.3, to describe 
each budesonide APSD when characterized in NGI at 100 L/min. Calculated cutoff 
diameters ( 50D ) for stages 1–5 when NGI was recalibrated at 140 L/min are shown as the 
mean and standard deviations for the four selected MT-IP combinations in Table 5.8. 
Cutoff diameters for stages 6-7 are not listed as drug deposition on those stages could 
not be detected (washings resulted in budesonide mass < LOQ). The mean values for 
each stage were assigned as the re-calibrated 50D  values at 140 L/min, and the results 
were compared with the USP calibrated cutoff diameter (U.S. Pharmacopeial Convention, 
2013) in Table 5.9.  
 
Table 5.8. Re-calibrated NGI stage cutoff diameters ( 50D ) at 140 L/min for selected MT-
IP combinations. Data are presented as mean±SD (n=5). Drug deposition on stages 6 
and 7 was <LOQ in all cases. 
Stage # 
Small MT-IP 
(Fast)a 
Medium MT-IP 
(Fast)a 
Medium MT-IP 
(Slow)a 
Large MT-IP 
(Slow)a 
1 4.81 (0.30) 4.82 (0.13) 5.08 (0.34) 4.86 (0.03) 
2 2.42 (0.18) 2.48 (0.05) 2.49 (0.14) 2.44 (0.06) 
3 1.75 (0.16) 1.83 (0.04) 1.82 (0.10) 1.77 (0.05) 
4 0.98 (0.13) 1.06 (0.03) 1.02 (0.07) 1.01 (0.03) 
5 0.63 (0.02) 0.63 (0.02) 0.68 (0.01) 0.60 (0.02) 
6 NA NA NA NA 
7 NA NA NA NA 
aNewman et al. (2000) training conditions.   
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Table 5.9. Comparison of NGI’s extrapolated USP calibration (U.S. Pharmacopeial 
Convention, 2013) or cutoff diameters ( 50D ) at 140 L/min (assuming that Equation 5.1 
and Table 5.8 are valid) with the overall means for 50D  after recalibration (from Table 5.8).  
Stage # 
USP 50D  (µm) 
(Theoretical; 140 L/min)
Mean 50D  (µm) 
(Experimental; 140 L/min)
Experimental 50D
/Theoretical 50D  
1 5.10 4.89 0.96 
2 2.87 2.46 0.86 
3 1.85 1.79 0.97 
4 1.11 1.02 0.92 
5 0.60 0.63 1.05 
6 0.33 NA NA 
7 0.19 NA NA 
 
Aerodynamic Particle Size Distributions of Budelin’s TLDin vitro 
Aerodynamic particle size distributions of TLDin vitro, designated as drugs exiting 
the MT model following aerosol generation under realistic inhalation condition, were 
analyzed for all the MT-IP combinations shown in Table 5.2. The mean cumulative 
percent of budesonide depositing below 50D  for each stage was calculated and  plotted 
against the cutoff diameters using the archival USP calibration (U.S. Pharmacopeial 
Convention, 2013) when NGI flow = 100 L/min. In one case however, the high-flow IP 
protocol (large IP, fast inhalation) where NGI flow = 140 L/min, recalibrated cutoff 
diameters determined in the present study were applied (Table 5.9). No curve fitting was 
used to generate the results shown in Figure 5.8 for all three inhalation conditions. Values 
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for MMAD were calculated using linear interpolation for each MT-IP combination and data 
were summarized in Table 5.10. Perhaps the most important observation for Budelin’s 
budesonide aerosols was the variation seen in particle size distribution resulting from the 
different MT-IP combinations, where the apparent MMADs ranged from 1.79 to 3.26 µm 
across all test conditions (Table 5.10). The results suggested that in addition to total lung 
dose, the size distribution for drugs likely to enter the trachea also depends on the 
combined effects of each subjects’ MT geometry and inhalation profile. For Budelin, these 
effects were most pronounced for the slow inhalation condition (Figure 5.8) described 
clinically by Newman et al. (2000), where the mean values for MMAD varied from 2.17 to 
3.26 µm. For all three inhalation conditions, the large MT-IP combination invariably 
produced the smallest MMAD and the largest TLDin vitro, indicating that the best powder 
emptying and the best dispersion from Budelin occurred under large IP conditions. The 
amount of drug depositing on stage 1 was less than 10% of the total NGI dose in all cases, 
illustrating the high collection efficiency of the MT; MT appears to reduce the possible 
variations in APSDs significantly. There was also a lack of visually observable lactose 
deposition in the NGI, suggesting that at least the large lactose particles in the formulation 
were also captured by the coated MT models.  
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(a) Fast Inhalation
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(b) Moderate Inhalation
Cut-off Diameter (m)
0 1 2 3 4 5 6 7
C
um
ul
at
iv
e 
%
 U
nd
er
 S
iz
e
0
20
40
60
80
100
Large MT-IP
Medium MT-IP
Small MT-IP
(c) Slow Inhalation  
Figure 5.8. Cumulative percent of drug mass undersize vs. stage cutoff diameters for 
budesonide collected in NGI following realistic testing of Budelin Novolizer in the 
Apparatus shown in Figure 5.3. Data are presented as mean±SD (n=5) for (a) fast, (b) 
moderate and (c) slow inhalation conditions. NGI stage cutoff diameters were assigned 
according to USP (U.S. Pharmacopeial Convention, 2013) except for the high-flow IP 
protocol (large MT-IP, fast inhalation), where the NGI flow rate = 140 L/min and the re-
calibrated cutoff diameters shown in Table 5.9 were used to process the data.  
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Table 5.10. Mass median aerodynamic diameter (MMAD) for different MT-IP 
combinations. Data were presented as mean±SD (n = 5).  
 
MMAD (µm) 
Small MT-IP Medium MT-IP Large MT-IP 
Fast Inhalation 2.03±0.05 1.88±0.06 1.79±0.03* 
Moderate Inhalation 2.28±0.23 2.19±0.04 2.17±0.09 
Slow Inhalation 3.26±0.27 2.54±0.09 2.17±0.03 
*Calculated using cutoff diameters from Table 5.9.  
 
5.4  DISCUSSION 
The mixing inlet–cascade impactor system (Figure 5.3) allowed the aerodynamic 
particle size distributions of budesonide powder aerosols exiting MT models to be 
measured following testing of the DPI, Budelin Novolizer, according to realistic but 
different MT-IP conditions of use. A pre-requisite of the system was that the cascade 
impactor flow rate exceed the peak inhalation flow rate (PIFR) of the targeted breath 
profile; this to allow successful breath simulation through the inhaler and the MT model. 
Our previous clinical study (Chapter 4) showed that PIFR through an inhaler was 
dependent on the inhaler’s airflow resistance, and that PIFR may well exceed 100 L/min, 
the present upper limit of NGI’s calibration. Although the results described in Chapter 4 
were for healthy adults only, studies performed on asthma or COPD patients also show 
that PIFR values often exceed 100 L/min when inhaling through a powder inhaler (Azouz 
et al., 2015a; Azouz et al., 2015b; Virchow et al., 2014). Therefore, to allow a complete 
range of DPIs to be tested realistically, using the mixing inlet–cascade impactor system 
shown in Figure 5.3, impactors like NGI must be modified and, if necessary recalibrated 
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to allow their use under high flow rate conditions. While complete recalibration using 
monodisperse, nonvolatile aerosols may be desirable (Marple et al., 2003a; Marple et al., 
2004), for practical purposes, polydisperse pharmaceutical aerosols may also be used to 
estimate stage cutoff diameters outside the existing compendial specification range. This 
approach was shown to be successful previously (Kotian et al., 2009) and it also worked 
well in the present study. The largest difference between recalibrated cutoff diameters 
and USP calibrations (U.S. Pharmacopeial Convention, 2013) were seen for stage 2 (2.46 
µm vs. 2.87 µm; Table 5.7) where the magnitude of the error was the main source of the 
discrepancies seen in APSD profiles between the 100 and 140 L/min NGI flow condition 
for all selected MT-IP combinations (Figure 5.6). This may have been caused by the non-
ideal behavior of aerosols in NGI at high flow rates, where Re for stage 2 exceeds the 
generally desirable range of 500–3000 for impactor design (Marple et al., 2003b) 
(Calculated Re for stage 2 at 140 L/min= 6696).  
What should also be noted is that the DPI, Budelin Novolizer, as used in the 
present study, is a medium-resistance inhaler [airflow resistance = 0.0241 kPa0.5.L-1.min; 
(Delvadia, 2012)]. Other DPIs with lower resistances (e.g. Aerolizer®), can enable 
subjects to achieve a much higher PIFR when inhaling forcefully through the device 
(Chapter 2). As even higher flow rates (>140 L/min) may be required to enable realistic 
testing of low-resistance inhalers, a complete redesign of cascade impactors or some of 
their stages may be needed to ensure correct measurement of particle size distribution 
at high flow conditions using the setup described in Figure 5.3.  
The present study successfully coupled realistic in vitro testing (Chapter 3) with 
compendial cascade impactor methods (U.S. Pharmacopeial Convention, 2013). IPs 
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generated by breath simulation were re-producible at the mouth entrance of MT when air 
flow in the impactor is properly balanced with compressed air (Figure 5.4). Realistic MT 
models, when coated properly, proved to be highly efficient “preseparators” that captured 
large particles, thus eliminating the need to use an artificial preseparator before feeding 
an aerosol into the cascade impactor. The approach described here is different from that 
used elsewhere (Chrystyn et al., 2015; Goodey et al., 2014; Nadarassan et al., 2010; 
Yakubu et al., 2013), and standardization of the methods may be needed to facilitate 
application of realistic in vitro testing for inhaled drug products. Although other flow-
balancing devices, for example the Electronic Lung™ (Brindley et al., 1994; Burnell et al., 
1998b; Tarsin et al., 2006), may also be used to couple breath simulation with the 
constant flow needed for cascade impaction, yet the NMI was shown to minimize drug 
losses from the aerosol cloud once formed  (N. C. Miller, 1997; N. C. Miller et al., 2000) 
by allowing sheath air flow to be generated and introduced around the central aerosol 
cyclone to “protect” drug aerosols from interior device collisions and minimize wall losses 
(<1% total recovered dose was lost in NMI across all experiments reported in this chapter).  
An important observation in this study and the previously publications (Delvadia et 
al., 2012; Olsson et al., 2013) is that the large inter-subject variations in total lung dose 
seen in the gamma scintigraphy study for Budelin Novolizer (Newman et al., 2000) are 
most likely predictable (Figure 5.5) by using realistic in vitro testing that incorporates 
variations in human oropharyngeal geometry and the inhalation maneuver. The 
compendial cascade impactor method however, produced much smaller variations in fine 
particle fraction, FPF (designated as the percentage of particles likely to penetrate the 
lung, d<5 µm), with standard deviation <5% of label claim when Budelin was tested at the 
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flow rate equivalent to 4 kPa pressure drop (de Boer et al., 2004). Thus, the compendial 
test method fails to characterize the clinical variations in dose and aerosol delivery from 
powder inhalers like Budelin. Although FDA suggest that powder inhalers should be 
tested at “three flow rates [around the] reference labeled flow rate, and ±50% of the 
labeled flow rate” for the in vitro bioequivalent study (Saluja et al., 2014), in practice DPIs 
are usually tested at 30, 60 and 90 L/min during product development (Harris, 2015). This 
appears to be a gross oversimplification of the real situation as humans do not inhale at 
constant flow, and the three suggested flow rates cannot really represent the flow range 
that subjects were shown to produce in Chapter 4.  
Variations in regional drug distribution in the lung, usually described as P/C ratio 
[drug deposition in peripheral lung (P) to central lung (C) ratio] in the gamma scintigraphy 
study, were also reported for Budelin (Newman et al., 2000). We showed in the present 
study that the combination of different MT models and realistic IPs produced variable size 
distributions for drugs exiting MT models, and the effects were most pronounced for the 
slow inhalation condition (Figure 5.8). The results were consistent with the “critical 
condition” reported for Budelin (de Boer et al., 2004), where the  particle size distribution 
was seen to change significantly when the inhaled flow rate dropped below a certain 
threshold. This may partly explain the variations seen in the P/C ratios reported by 
(Newman et al., 2000). However, particle size distribution is not the only factor affecting 
aerosol deposition in the lung, many other factors like airway geometry and human 
inhalation maneuvers are also critical in determining the final destination of inhaled drug 
particles (De Backer et al., 2010; Farr et al., 1995; Newman et al., 1989). A better 
understanding of aerosol deposition in the airways, and the need to build IVIVCs for 
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regional drug distribution in the lung, require further studies using approaches like 
mathematical modeling [e.g. ICRP model (International Commission on Radiological 
Protection (ICRP), 1994)] or Computational Fluid Dynamic (CFD) simulations (Longest & 
Holbrook, 2012), as such measurement is beyond the present state-of-the-art for in vitro 
testing. A pilot study where realistic in vitro testing has been coupled with the modeling 
approach shown in this chapter will be described in Chapter 6.  
Demonstrating bioequivalence for locally acting drugs is always a challenge due 
to the difficulty in proving equivalent [drug delivery] at the “site of action” ("Code of Federal 
Regulations," 2015). For powder inhalers, FDA suggests in vitro bioequivalence be 
demonstrated between inhalers for single actuation content and aerodynamic particle size 
distribution (Saluja et al., 2014). While such approaches may be adequate to control batch 
to batch quality, the difficulty in correlating the in vitro (e.g. fine particle dose) and in vivo 
(e.g. drug dose penetrating the lung) data (Newman & Chan, 2008) make it challenging 
to predict clinical performance for the test product. The present work and previous 
publication (Delvadia et al., 2012) clearly show that IVIVCs can be achieved for total lung 
dose, and more importantly, for clinical variations seen in dosing. We believe that if such 
IVIVCs (mean and variations) can be demonstrated and validated in vitro, that in vitro 
predicted lung dose may be considered to be a surrogate for some in vivo bioequivalence 
studies. The approach may at least prove useful for drug developers to evaluate how a 
change in device design or formulation may affect in vivo lung dose, especially for drugs 
with low therapeutic windows. Although we have yet to demonstrate IVIVCs for regional 
drug distribution in the lung, the methods reported in this study, when used to determine 
the variations in particle size distribution for drugs entering the lung should provide a 
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foundation for future studies when assessing the relationships between particle size 
distributions, drug deposition in airways and the clinical effects produced by inhalers.  
 
5.5  CONCLUSION 
A new method was developed and evaluated to enable the prediction of variations 
in APSDs of TLDin vitro from Budelin Novolizer 200 mcg. This powder inhaler, that doses 
reproducibly when subjected to USP testing (de Boer et al., 2004; Delvadia et al., 2012), 
showed significant variations in lung dose in vivo due probably to variations in 
oropharyngeal (MT) geometry and the way that subjects inhaled. When realistic in vitro 
tests were conducted, IVIVCs revealed and confirmed the importance of MT geometry 
and IP variations. Coupling these realistic tests with cascade impactor methods to 
evaluate the APSDs exiting the MT models from Budelin Novolizer 200 mcg, showed that 
these methods were sufficiently precise to distinguish between the different aerosol doses 
and aerosol sizes likely to enter the trachea. There is no reason to believe that the same 
techniques used to study Budelin in this chapter cannot be extended to review the data 
for other powder inhalers that are also used clinically by patients with variable MT 
geometry and breathing patterns. The clinical importance of these observations requires 
further evaluation. 
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CHAPTER 6 
EVALUATING COMPUTATIONAL FLUID DYNAMIC (CFD) SIMULATIONS OF 
REGIONAL DRUG DEPOSITION FROM BUDELIN® NOVOLIZER® IN 
COMBINATION WITH REALISTIC IN VITRO TESTING TECHNIQUES  
  
6.1  INTRODUCTION 
The in vitro test methods described in Chapters 3–5 clearly enable drug 
development scientists to estimate the likely ranges of total lung dose (TLD) and the 
aerodynamic particle size distributions (APSDs) of those doses entering the trachea from 
DPIs like Budelin® Novolizer®. Even though an extensive primary and secondary 
literature exists that purports to relate regional deposition of aerosols to their APSDs in 
humans (International Commission on Radiological Protection (ICRP), 1994; Rostami, 
2009; Stahlhofen et al., 1989), and several groups have converted such deposition 
models into computer programs that in certain cases (W.H. Finlay, 2013), account for 
inhaler effects on mouth-throat (MT) deposition for a DPI, neither models nor programs 
can presently be used to predict regional drug deposition from powder inhalers. In part 
this is because the methods used to determine APSDs for powder inhalers fail to account 
for oropharyngeal geometry and variations in breath profiles; topics that have been 
examined and for Budelin Novolizer at least, addressed in the earlier chapters of this
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thesis. Even given the data for Budelin’s APSD from Chapter 5 however, existing 
deposition models fail to enable the prediction of regional lung deposition during a typical 
powder inhalation profile (IP). It follows therefore, that the detailed regional drug 
deposition in the lung from Budelin remains unknown in the sense that its dependence 
on aerosol characteristics and breathing maneuvers cannot readily be determined. 
Product development scientists can only make guesses about regional drug deposition 
using clinical studies such as those reported by Newman et al. (2000). Fortunately 
however, new CFD programs have recently been described by Longest et al. and Tian et 
al. who reported that by using lung models consisting of realistic geometries of the VCU 
mouth-throat (MT) model coupled to an airway model up to generation 15 (terminal 
bronchioles) it was possible to facilitate the prediction of regional drug deposition from 
DPIs (Longest et al., 2012a; Longest et al., 2012b; Tian et al., 2015a; Tian et al., 2011). 
Very recently, the CFD modeling technique from those authors was used with the APSD 
data determined and reported in this chapter to predict regional drug deposition for 
Budelin Novolizer in both the MT and lung regions (Tian et al., 2015a). Because of the 
importance of that work to this thesis (Tian et al., 2015a), the paper is reproduced in full 
in Appendix III. The authors showed that their CFD predictions were consistent with the 
regional deposition results reported by Newman et al. following a clinical gamma 
scintigraphy study in which the subjects were instructed to target a 99 L/min peak 
inhalation flow rate (PIFR) [referred to as fast inhalation in this chapter; (Newman et al., 
2000)] based on a selection of CFD model regions that were reported to be consistent 
with the imaging study. In this chapter, the CFD model and programming methods 
described by Tian and co-workers (Tian et al., 2015a) was applied with modifications and 
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evaluated for its ability to predict Budelin’s regional deposition and the possible variations 
in the results given different initial conditions for aerosol entry into the trachea in the form 
of values for TLDin vitro and APSDs of TLDin vitro coupled to their corresponding breathing 
maneuvers or IPs. This “hybrid method” eliminates the need to model deposition in the 
MT geometry, and thus simplifies some of the more complex aspects of the CFD predictions. 
The semi-empirical results for Budelin were compared with the theoretical values reported 
earlier (Tian et al., 2015a) and the clinical assessments (Newman et al., 2000).   
The motivation behind this study was to combine the new more realistic in vitro 
methods of predicting MT loss and TLD determinations developed in this dissertation 
together with CFD predictions of regional lung deposition to provide a more complete 
picture of dose distribution through the lungs.  In this approach, the relative strengths of 
the in vitro and CFD methods could possibly be maximized while minimizing the 
weaknesses.  The previous study of Tian et al. (2015a) demonstrated whole-airway CFD 
predictions of the aerosolized dose from a DPI with good agreement to in vivo data.  
Previous studies have also demonstrated good agreement between CFD predictions of 
MT depositional loss and in vitro predictions in identical geometries across a range of 
inhalers (Delvadia et al., 2013b; Longest & Hindle, 2009; Longest et al., 2012a; Longest 
et al., 2012b; Tian et al., 2011).  Perhaps the most complex region of the whole-lung CFD 
calculation of inhaler dose is the MT geometry due to the presence of highly turbulent 
flow and the need to include transient flow effects (Tian et al., 2011).  Furthermore, there 
are a number of difficult-to-define variables for inhaler aerosol simulations in the MT 
geometry, such as the exact emptying time course of a DPI for a given inhalation profile.  
In contrast, the in vitro techniques developed in this dissertation can directly predict MT 
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depositional loss and the particle size distribution entering the lungs on a realistic basis. 
This study explores a method in which in vitro experiments are used to predict the MT 
deposition fraction and APSD entering the lungs, and CFD simulations are then 
implemented to investigate regional lung deposition of that TLD.  By removing the MT, 
the CFD simulations are significantly simplified.  This reduction in complexity may enable 
the method to be more widely applied by scientists who do not specialize in CFD 
simulations.  However, it is known that complex airflow currents and turbulence arising 
from the presence of the inhaler and the MT geometry, including the larynx, can influence 
flow patterns and particle deposition in the conducting airways, potentially down to the 
6th generation (Xi et al., 2008).  The extent to which removal of the MT influences regional 
lung deposition predictions compared with previous CFD simulations (Tian et al., 2015a) 
and in vivo data (Newman et al., 2000) for a DPI aerosol is not known.  This study explores 
this newly proposed hybrid in vitro-CFD method with the aim of showing it to be a 
reasonably accurate new technique for predicting regional lung deposition of 
pharmaceutical aerosols. As demonstrated in previous studies, these new regional 
predictions of lung dose may possibly reveal important findings not available from current 
in vitro and imaging methods, such as the aerosol deposition fraction in the terminal 
bronchioles that are often involved with airway functional changes observed with asthma 
and COPD. 
 
 
 
109 
 
6.2  MATERIALS AND METHODS 
Initial Particle Size Measurements 
The APSDs from Budelin® Novolizer® 200 mcg (Meda Pharmaceuticals, Bishops 
Stortford, U.K.) were characterized using cascade impaction in three different ways: (a) 
a constant flow rate of 80 L/min (equivalent to a 4 kPa pressure drop across the device) 
was applied for 3 seconds; this method was used here to provide results for use in Tian 
et al.’s initial conditions for Budelin (Tian et al., 2015a); (b) a realistic breath profile or IP 
without an MT model or induction port was employed by linking the inhaler to the NGI via 
the Nephele Mixing Inlet (NMI; Model III; RDDonline, Richmond, VA); (c) three realistic 
breath profiles or IPs were used in the presence of the VCU medium MT model as 
described in Chapter 5. Experimental setups for the three different testing conditions are 
shown in Figure 6.1.  
Methods (a) and (b) were designed to directly measure the APSDs for drugs 
emitted from the Budelin inhaler. Method (a) provided the initial conditions for use by Tian 
et al. (2015a) who used the results for APSD to define the particle sizes of the 
polydisperse aerosols entering the MT geometry of their CFD model. Method (a) was a 
slight modification of the compendial approach (U.S. Pharmacopeial Convention, 2013), 
where Budelin was connected directly to the pre-separator in the absence of a USP 
induction port. An in-house manufactured adapter (Ten-to-One silicone rubber, Micro-
Mark, Berkeley Heights, NJ) was placed between the inhaler and preseparator to ensure 
airtightness of the system. The whole setup was flipped 90 degrees [i.e. preseparator 
placed horizontally and next generation impactor (NGI) vertically] to ensure correct inhaler 
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orientation. APSD was tested at 80 L/min to produce the 4 kPa pressure drop across the 
inhaler, following procedures described in USP (U.S. Pharmacopeial Convention, 2013). 
Method (b) added the NMI and dilution air supply between the inhaler and the NGI 
preseparator to enable the inhaler to be tested using a realistic IP. The primary purpose 
of the experiment was to determine the influence of the IP on this drug’s APSD from 
Budelin, given that compendial test conditions [Method (a)] do not employ a transient 
(variable) flow rate. The setup was kept similar to Method (a), but the NMI was placed 
between inhaler and preseparator, with its side port connected to the breath simulator 
(ASL 5000-XL, IngMar Medical, Pittsburgh, PA) and dilution air supplied at 100 L/min. 
Method (c) was designed to measure the size distribution for drug aerosols exiting the 
MT model (TLDin vitro), as described in Chapter 5. Methods (b) and (c) characterized the 
APSDs using realistic inhalation profiles for inhaler testing as described in Chapter 5. A 
schematic and the procedure for Method (c) was the same as that shown in Figure 5.3 
and associated text. The three medium IPs described in Table 5.1 and shown in Figure 
5.2 (orange curves; Chapter 5) were used for Method (c). These IPs are also shown in 
Figure 6.2 and they were simulated to represent the average inhalation maneuvers used 
by the human subjects under three different instruction protocols in the gamma 
scintigraphy study for Budelin (Newman et al., 2000). Only the medium IP for fast 
inhalation was used for Method (b) while the flow rate through NGI was maintained at 100 
L/min for both Methods (b) and (c).  
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(a) Constant Flow Condition (80 L/min) 
 
(b) Realistic IP without MT Model 
 
(c) Realistic IP with MT Model 
Figure 6.1. Experimental setup for measurement of aerodynamic particle size 
distributions (APSD) of drug aerosols delivered from Budelin® Novolizer® 200 mcg. (a) 
Constant flow condition (80 L/min); (b) realistic IP without MT model; (c) realistic IP with 
MT model. The latter is identical to the apparatus and procedures described in Chapter 
5.2.  
 
Next Generation Impactor Preseparator
Next Generation Impactor
Preseparator
Mixing Inlet
Mouth-Throat Model
Mixing Inlet 
Next Generation Impactor
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Figure 6.2. Inhalation profiles (IPs) simulated to mimic the average inhalation maneuvers 
used by subjects under three different instructions in the gamma scintigraphy study for 
Budelin (Newman et al., 2000). These medium IPs are identical to those described in 
Table 5.1 and shown in Figure 5.2 (Chapter 5). All three IPs were used for Method (c), 
while only the medium IP for fast inhalation (the blue curve) was used for Method (b). 
Experimental setups for methods (b) and (c) are shown in Figure 6.1.  
 
Prior to all experiments, internal surfaces of the MT model, preseparator stage, 
and NGI plates were coated twice with Molykote® 316 silicone release spray (Dow 
Corning, Midland, MI) to avoid particle reentrainment after impaction. Single doses were 
collected in each experiment and five replicates performed for each protocol;  budesonide 
deposition on inhaler, MT, NMI, preseparator, NGI plates and filter were collected using 
known volumes of 70%/30%:methanol/water (v/v), budesonide concentrations were 
determined using high-performance liquid chromatography (HPLC). The assay was 
performed using a Symmetry® C18 column (3.5µm, 4.6×100mm) and an HPLC system 
(Model 2996 Photodiode Array Detector, 1515 Isocratic HPLC Pump and 717 plus 
Autosampler; Waters Milford, MA) with 69% methanol / 31% 0.1% (v/v) acetic acid buffer 
(v/v) as mobile phase (flow rate: 1.0 mL/min), and UV detection at 280 nm. Injection 
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volume was 100 µL and calibration curves were linear in the range of 0.2–10.0 mcg/mL 
(r2>0.999). Statistical analyses were performed using one-way ANOVA and Student’s t-
test at a significance level of 0.05 in JMP Pro 11 (SAS Institute Inc., Cary, NC). 
 
CFD Simulation 
The original airway model and CFD methods, designed for simulating particle 
motion in the human respiratory tract after aerosol release from a powder inhaler, were 
reported by Tian et al. (2015a). Briefly, the model consisted of a complete upper airway 
geometry from MT to the third airway bifurcation (B3) followed by a stochastic individual 
path (SIP) model from B4 to B15 of the left lower lobe (Figure 6.3a) with aerosol 
introduction into the model simulated via an 0.6 cm diameter jet, as produced by the 
Budelin Novolizer mouthpiece. To facilitate CFD simulation and prediction of budesonide 
deposition from Budelin, the model was divided into four parts: MT, B1 to B3, B4 to B7, 
and B8 to B15; particles penetrating beyond B15 (terminal bronchioles) were shown 
based on calculations with deposition correlations to fully deposit in the alveolar airways. 
Airflow appeared to be turbulent in the MT and B1 to B3 regions for the Novolizer, while 
it transitioned to laminar flow in B4 to B15. In regions where turbulent flow was expected, 
a low-Reynolds number (LRN) k–ω model was applied to characterize the airflow (Tian 
et al., 2015a) (e.g. in MT through B3), where realistic, transient IPs were employed. In the 
lower airways, steady-state flow simulations were used with average flow = V/T (ratio of 
inhaled volume, V, to total inhalation time, T) condition was applied from B4 to B15. 
Polydisperse aerosols consisting of nine types of spherical, monodisperse particles with 
aerodynamic diameters equivalent to the midpoint of NGI’s stage cutoff diameters (D50) 
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at 80 L/min flow condition (preseparator, stages 1-7, and filter), were used to represent 
the budesonide particles delivered from Budelin Novolizer. The method then tracked 
particles in the airflows after their “injection” as polydisperse aerosols into the mouth inlet 
over a prescribed quick-and-deep (QD) inhalation profile lasting for 2.96 s.  Particles were 
released during the first 0 - 0.5 s of this inhalation profile, to simulate transient emptying 
of the inhaler.  During the simulation period, particle contact with the wall surface resulted 
in particle "deposition", and the wall contact location was recorded. Particle deposition 
data simulated in this way were then compared with the in vivo gamma scintigraphy data 
for Budelin (Newman et al., 2000) (Appendix I) by dividing the airway model into central 
(B1 to B7) and intermediate–peripheral (B8 to alveolar) regions (Tian et al., 2015a).  
The same CFD method, described briefly here and in detail previously (Tian et al., 
2015a) was also used in this chapter to track budesonide particles from Budelin Novolizer 
after their “injection” into the trachea as realistic APSDs known to exit MT, following 
testing according to Chapter 5. Three replicates were performed for each two-day 
simulation in this chapter. To couple the CFD simulation with the realistic in vitro test 
methods described in Chapter 5, where APSDs were measured at the exit of MT model, 
the original airway model and CFD methods (Tian et al., 2015a) were modified in the 
following ways:  
 
Airway Model 
MT and its geometry was removed from the original airway model (Tian et al., 
2015a) to allow CFD simulation starting from the trachea (Figure 6.3b). Theoretical 
“particle injection” began in this study at the trachea after which, CFD modeling used the 
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programming methods of Tian et al. (2015a). Particles were released into the trachea 
using a blunt spatial distribution pattern with a wall offset distance of 0.01 mm. 
 
(a) Original Model (Tian et al., 2015a) 
 
(b) Modified Model (This Study) 
Figure 6.3. Airway model (a) used for CFD simulations in Tian et al. (2015a), which began 
at the entry to MT via an 0.6 cm jet to represent the inhaler outlet. Simulations in this 
chapter used the modified model (b) and size distributions of TLDin vitro. Both models 
include a complete geometry of the airways from trachea to B3, and a stochastic individual 
path (SIP) model from B4 to B15 of the left lower lobe; in those respects, the model 
geometries were identical.  
 
 
Flow Conditions 
The quick-and-deep inhalation profile employed by Tian et al. (2015a) and applied 
in the trachea to B3 region of that study was refined and replaced by the IPs used to 
mimic the average inhalation maneuvers of the subject groups trained by Newman et al. 
(2000) (Figure 6.2) as advocated in Chapter 4 of this thesis. Accordingly, the steady-state 
(constant) airflow rate applied from B4 to B15 region by Tian et al. (2015a) (60.8 L/min; 
defined as V/T) was replaced by 63.0 L/min, 41.4 L/min, and 34.4 L/min corresponding to 
MT 
Trachea to B3
B4 to B15
Trachea to B3 
B4 to B15
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the average flow rates in the IPs for the fast, moderate, and slow inhalation conditions, 
respectively (V/T; Figure 6.2) consistent with the values for V reported by Newman et al. 
(2000).   
 
Polydisperse Particles for Injection  
The nine diameters of differently sized particles used in the simulations of Tian et 
al. (2015a) were replaced by eight monodisperse particle diameters with aerodynamic 
diameters equivalent to the midpoint of the upper and lower cutoff diameters of NGI’s 
stages at the 100 L/min flow condition (Table 6.1). In the absence of the preseparator 
[Method (c)], an upper size limit for particles depositing on stage 1 of the NGI had to be 
assumed; a value of 10 µm was assigned based on the D50 value for the NGI preseparator 
at 100 L/min. These particles sizes (Table 6.1) were used to represent the polydisperse 
assembly of drug particles entering the trachea during an IP. 4,000 particles were used 
from each of eight size bins (32,000 particles in total) and “injected" into the trachea inlet 
over a period of 0–1.0 seconds at an initial velocity = V/(T*A), where V/T was equivalent 
to the average volumetric flow rate of the test IP and A is the cross sectional area of the 
tracheal opening.  While Tian et al. (2015a) used 0–0.5 seconds for the particle injection 
period, this was extended in the present study because the “Air Classifier Technology” 
used by Novolizer was reported to prolong the inhaler’s powder dispersion and delivery 
time (de Boer et al., 2006).  
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Table 6.1. NGI’s stage cutoff diameters (D50) for the 100 L/min flow condition and the 
corresponding aerodynamic diameters used to simulate the polydisperse aerosol  
particles for “injection” at the tracheal inlet for CFD simulation in this study.  
 
In Vitro Particle Size Characterization 
(NGI at 100 L/min) 
Polydisperse Particles for 
CFD Simulation 
 
D50a 
(µm) 
Size Range 
(µm) 
Midpoint 
(µm) 
Aerodynamic diameter 
(µm) 
Stage 1 6.12 6.12-10.00b 8.06 8.06 
Stage 2 3.42 3.42-6.12 4.77 4.77 
Stage 3 2.18 2.18-3.42 2.80 2.80 
Stage 4 1.31 1.31-2.18 1.75 1.75 
Stage 5 0.72 0.72-1.31 1.02 1.02 
Stage 6 0.40 0.40-0.72 0.56 0.56 
Stage 7 0.24 0.24-0.40 0.32 0.32 
Filter 0.00 0.00-0.24 0.12 0.12 
aCalculated using USP calibration method (U.S. Pharmacopeial Convention, 2013) 
bThe upper bound was given by the D50 value for the preseparator at 100 L/min 
 
Analysis of Aerosol Deposition Data 
Particle counts depositing (e.g intersecting with the airway walls) in each of the 
regions [MT (Tian et al., 2015a), trachea to B3, B4 to B7, B8 to B15, and beyond B15 
(alveolar)] were generated using the CFD program and the techniques were described in 
detail by Tian et al. (2015a). Particle counts in each bifurcation were converted to mass 
fraction [defined as deposition fraction (DF) by Tian et al. (2015a)] of the injected “dose” 
by assuming that particle density and shape were size-independent and mass was 
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directly proportional to volume and diameter3. For example, the deposition fraction of 
particles in the trachea was given by: 
 
 
 4000
j j j
trachea
j j
m N CF
DF
m CF
 

 


                            Equation 6.1 
Where jm  is mass of a single particle of budesonide from size bin j  and jN  is the 
number count of the corresponding particles trapped by the trachea. Because an equal 
number of particles (4,000) were injected from each of the eight size bins, a conversion 
factor ( jCF ) was used to scale the number of particles in the actual APSD that should 
theoretically be injected; its value was given by: 
 
32000
4000
j j
j j
j
M m
M m
CF

                                     Equation 6.2 
Where jM  is mass fraction of budesonide with respect to the total mass of budesonide 
in the impactor that deposited at the corresponding NGI stage. Assuming particles were 
spherical, jm  was given by: 
 3
1
6j j
m d                                            Equation 6.3 
Where   is particle density. Geometric diameter, jd , was calculated from the 
aerodynamic diameter ( aejd ) for the corresponding particle (Table 6.1) from: 
 aejj
d
d

                                              Equation 6.4           
All airway generations were treated similarly and values for regional drug deposition in 
each airway segment calculated in the same way as described by Tian et al. (2015a).      
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6.3  RESULTS AND DISCUSSION 
Effects of Initial Conditions in the Original CFD Model (Tian et al., 2015a) 
The CFD model developed by Tian et al. (2015a) allows particle motion and 
deposition in the human respiratory tract following aerosol release from a DPI to be 
simulated based on principles of fluid mechanics and known particle deposition 
mechanisms (inertial impaction, gravitational sedimentation, and Brownian diffusion). 
Simulations and particle tracking for Budelin Novolizer in Tian et al. (2015a) include the 
jet at the inhaler mouthpiece (and retention in the inhaler) in addition to the deposition 
analysis for polydisperse particles injected into the mouth inlet of the MT and the airway 
model (Figure 6.3a). Table 6.2 shows an expanded form of Tian’s Table III (Tian et al., 
2015a) that enables the CFD results from the two different approaches to be compared 
with the average in vivo results from Newman et al. (2000). Stated most simply, the results 
shown in the right hand column of Table 6.2 (based on realistic testing of Budelin 
according to the medium simulated IP and an APSD for TLDin vitro (as the initial condition 
for drug entry to the trachea), showed that Tian et al.’s slight underestimation (relative 
percent difference between in vivo and CFD: 2.7%) of Budelin’s central lung deposition 
(Tian et al., 2015a) was further increased (new relative percent difference: 4.8%) by the 
approach described in this chapter in favor of intermediate and peripheral deposition.  
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Table 6.2. Deposition fractions (percent of aerosolized dosea) based on CFD predictions 
compared with the mean in vivo data for Budelin Novolizer (Newman et al., 2000) 
operated with a “QD waveform and PIFR of 99 L/min” as defined by Tian et al. (2015a) to 
mimic Newman’s mean PIFR (99 L/min) and V (3.13 L) for normal human subjects trained 
in fast inhalation. The QD waveform of Tian et al. (2015a) was replaced in the present 
study with the breath-simulated curve shown in blue in Figure 6.2; size distributions for 
TLDin vitro were determined exiting the VCU medium MT model using the same IP. 
Regional drug deposition data for the in vitro–CFD method are presented as mean (SD), 
n = 3.   
Deposition Regions 
In Vivo 
(Newman et al.)b 
CFD 
(Tian et al.) 
In Vitro–CFD 
(This Chapter) 
MP+MT 64.9 67.0 64.6 
Central Lungc (Trachea Excluded)d 12.1 9.0 6.9 (0.2) 
Intermediate and Peripheral Lunge 22.1 22.1 28.5 (0.2) 
Trachea–B3 (Trachea Included)  2.7f 1.3 (0.1)f 
B4–B7  8.2 5.6 (0.2) 
B8–B15  1.8 2.3 (0.3) 
Alveolar  20.3 26.2 (0.1) 
aAs reported in Tian et al. (2015a).  
bThe regional deposition reported by Newman et al. (2000) are percentages of the 
metered dose and therefore includes drug retained in the inhaler and not aerosolized. 
This fraction of the dose was not simulated during the CFD studies. In order to determine 
the in vivo deposition as a percentage of the aerosolized dose, the % radioactivity on the 
device was subtracted from the total recovered radioactivity to determine the total 
aerosolized dose and the regional deposition values were scaled as a percentage of this 
value. 
cThe central lung was defined as the B1–B7 region by Tian et al. (2015a). The same 
approach was applied in this chapter.  
dNewman et al. (2000) excluded tracheal deposition from their calculations for the lung 
because swallowing and esophageal radioactivity interfered with the results for tracheal 
deposition. 
eThe intermediate and peripheral lung was defined as B8–alveolar region by Tian et al. 
(2015a). The same approach was applied in this chapter. 
fTracheal deposition accounted for 1.9% and 0.0% of the metered dose for Tian et al. 
(2015a) and this study, respectively.  
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While the exact deposition result breakdown is shown in Table 6.2 for the lung 
regions of interest for this fast mode of inhalation, it is important to realize that the original 
CFD approach used by Tian et al. (2015a) extended from the mouthpiece of the inhaler 
using an aerosol APSD that was measured using the modified compendial method (U.S. 
Pharmacopeial Convention, 2013) described as Method (a) above, where aerosol 
generation and release was characterized from Budelin at a constant flow of 80 L/min for 
3 seconds. This was not the medium realistic inhalation condition for fast inhalation 
proposed for Budelin testing (Figure 6.2). For all passive DPIs, powder deaggregation is 
believed to be dependent on airflow, where the use of constant flow vs. a realistic IP may 
affect the APSD of the drug from the inhaler. In addition, the IP used for CFD simulation 
[“quick-and-deep”, or “QD” profile for Budelin Novolizer (Tian et al., 2015a)] was different 
from that proposed in Chapter 5.2 and employed here in realistic in vitro testing (Figure 
6.2, fast inhalation). Thus, before seeking to study the use of this combined in vitro–CFD 
approach further, it seemed prudent  to answer two important questions: (a) to what extent 
did the APSD exiting the inhaler change from the distribution seen under constant flow, 
when Budelin was tested with the realistic IP for fast inhalation as shown in blue in Figure 
6.2? and (b) how did the “QD” profile (Tian et al., 2015a) differ from the test IP employed 
in vitro in this chapter?  
The first question was answered by comparing budesonide particle size 
distributions from Budelin, after testing at the exit of the inhaler under constant flow 
conditions [80 L/min; Method (a); same data as those used in Tian et al. (2015a)] and 
variable flow [realistic IP; Method (b)]. Data are summarized in Figure 6.4.  
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Figure 6.4 Distribution (percent of metered dose) of budesonide from Budelin Novolizer 
when tested in accord with Method (a) and (b), respectively [constant flow (80 L/min) or 
the medium simulated IP for fast inhalation (Figure 6.2)]. Data are presented as mean±SD 
(n = 5). The data generated from Method (a) in this study was used for CFD predictions 
in Tian et al. (2015a). The NGI flow rate employed in Method (b) was 100 L/min. MP = 
inhaler mouthpiece; NMI = Nephele Mixing Inlet. Total drug mass collected before (MP + 
NMI/adapter) or within (preseparator + stages 1–7 + filter) the cascade impactor were 
statistically comparable (Student’s t-test, p>0.05) in both cases. Note that the cutoff 
diameters for each stage of NGI differ between the tests shown in this Figure because 
D50 values are a function of the air flow rate through NGI. 
 
There was no significant difference in the total mass fraction collected before (MP 
+ NMI/adapter) or within (preseparator + stages 1–7 + filter) the cascade impactor 
between the two methods (Student’s t-test, p>0.05). The data from the cascade impactor 
was processed according to USP (U.S. Pharmacopeial Convention, 2013) and plotted as 
cumulative % drug mass undersize to enable the APSDs determined at the different NGI 
flow rates to be compared. Figure 6.5 showed, for Budelin Novolizer that the APSDs for 
budesonide following testing using a realistic IP (Figure 6.2) or, a constant flow rate of 80 
L/min for 3 seconds produced results that were effectively identical (Figure 6.5).  
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Figure 6.5. Mean cumulative % mass under size (±SD; n = 5) vs. NGI stage cutoff 
diameters (D50) for drugs delivered from Budelin Novolizer at constant flow [80 L/min; 
method a; data used in Tian et al. (2015a)] and the test IP [Method (b)]. Size distributions 
are based on analysis of drug deposition within the NGI, and the cutoff diameters for 
NGI’s stages and the preseparator were adjusted during size analysis in accord with 
USP’s archival flow calibration (Marple et al., 2003a; U.S. Pharmacopeial Convention, 
2013).  
 
A further investigation compared the IP used by Tian et al. [“QD” profile; (Tian et 
al., 2015a)] to that used for realistic in vitro testing (Figure 6.2; fast inhalation) in this 
chapter. Figure 6.6 shows that the two IPs differed with respect to the air flow rate 
acceleration (linear vs. sinusoidal) but overall, the profiles were very similar.  This 
agreement is because both studies attempted to match the fast inhalation conditions of 
Newman et al. (2000), but with slightly different value assumptions and profile equations 
(e.g., linear vs. sinusoidal inhalation).  It is not clear from the data that Newman et al. 
provided which of these inhalation profiles is most correct. 
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Figure 6.6. IPs simulated to represent those used by subjects trained by Newman et al. 
(2000). The red curve was reproduced from the “QD” profile reported by Tian et al. 
(2015a); the blue curve was used for realistic testing in the in vitro study (Figure 6.2, fast 
inhalation).  
 
Based on these comparisons of Budelin’s APSDs and IPs used in testing, it 
seemed reasonable to assume that comparable CFD results should be generated for 
regional deposition within the lung if we were to replace the APSD and IP reported by 
Tian et al. (2015a) with those advocated for realistic in vitro testing in this thesis (fast 
inhalation; Chapters 5 and 6). The results in Table 6.2 however, show small but finite 
differences in the CFD results for the individual segments. Trachea to B3 and B4 to B7 
showed reduced deposition compared to the results of Tian et al. (2015a) while deposition 
in B8 to B15 and the “Alveolar” remainder were increased. The reduced deposition seen 
in the trachea itself [0.0% in the present study vs. 1.9% in Tian et al. (2015a); Table 6.2] 
likely points to the importance of particle trajectories at the tracheal entry point. In the 
present study, reduced particle impaction efficiencies were expected when particles were 
introduced vertically into the trachea compared to the flow curvature seen when the MT 
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was attached (Tian et al., 2015a). In addition, the exclusion of the larynx in Model (b) 
(Figure 6.3) may have eliminated the effects of the laryngeal jet on air turbulence and 
aerosol dynamics (Xi et al., 2008), resulting in an underestimation of aerosol deposition 
in the large airways. Another possible difference between the present study and that of 
Tian et al. (2015a) relates to the injection of particles in an accelerating transient flow over 
0.5 seconds (Tian et al., 2015a) vs. an accelerating and plateauing flow over 1.0 second 
(this study; see Figure 6.6). A difference that may also be significant relates to the 
assignment of particle sizes introduced into the two models to “represent” and compute 
the deposition of the polydisperse budesonide aerosols released from Novolizer. Because 
of the difference in NGI flow rates that must be used to size the aerosols leaving the 
inhaler [e.g. 80L/min; Method (a) in Tian et al. versus 100 L/min; Method (c) in realistic 
testing], the midpoint of the size bins used to represent large particles in each of the CFD 
simulations differed. The difference in individual particle mass between the CFD-assigned 
diameter for particles landing on stage 1 of the NGI at 100 L/min (this study) could be 
about 5/7 (8.063/9.153) of the individual particle mass that was used in Tian et al. (2015a) 
and this may be expected to influence computed values for upper airway deposition.   
 
APSDs of Budesonide Particles Entering Trachea 
Budesonide particle size distributions at the exit of the MT were measured with 
Method (c) using the three IPs shown in Figure 6.2. Those IPs were simulated to mimic 
the average inhalation maneuvers of subjects trained under the three different breathing 
instructions in the gamma scintigraphy study for Budelin Novolizer (Newman et al., 2000). 
The medium IP for fast inhalation (the blue curve in Figure 6.2) was selected to match the 
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flow condition used in the CFD simulation by Tian et al. (2015a); that IP and the 
associated APSD of the drug exiting MT were used as initial conditions for the modified 
CFD model to evaluate whether the predicted regional drug deposition results were 
comparable with those produced by Tian et al. (2015a)  as shown in Table 6.2. The 
medium IPs for moderate and slow inhalation (the orange and green curves in Figure 6.2, 
respectively) and their associated APSDs were used to further evaluate the method’s 
ability to predict variations in regional drug deposition in the lung. Because only the 
medium airway model is currently available for CFD simulation, the small and large IPs 
and APSDs of Budelin’s TLDin vitro produced from the small MT-IP and large MT-IP 
combinations (Chapter 5) were not studied or discussed in this chapter. 
APSDs of budesonide aerosols exiting the MT for the mean fast, moderate and 
slow inhalation conditions are summarized in Figures 6.7 and 6.8. The three medium IPs 
in Figure 6.2 produced significantly different results for budesonide mass depositing in 
MT and on NGI stages 1, 3, 4, 5, and 6 (one-way ANOVA, p<0.05; Figure 6.7). The data 
from NGI was also processed according to USP (U.S. Pharmacopeial Convention, 2013), 
and the cumulative percent mass under size vs. NGI’s stage cutoff diameters in Figure 
6.8 clearly illustrate the variations in the APSDs of drugs likely to enter the trachea across 
these inhalation conditions. Values for the mass median aerodynamic diameters (MMAD) 
ranged from 1.88±0.06 µm for fast inhalation, to 2.19±0.04 µm for moderate inhalation, 
and 2.54±0.09 µm for slow inhalation.  
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Figure 6.7. Distribution (percent of metered dose) of budesonide from Budelin Novolizer 
when tested in accord with Method (c) using IPs shown in Figure 6.2. Data are presented 
as mean±SD (n = 5). The NGI flow rate employed in this method was 100 L/min. MT = 
mouth-throat; NMI = Nephele Mixing Inlet. Significantly different values were observed for 
drugs depositing in MT and on NGI stages 1, 3, 4, 5, and 6 across the three inhalation 
conditions (one-way ANOVA, p<0.05).  
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Figure 6.8. Mean cumulative percent mass under size (±SD; n = 5) vs. NGI stage cutoff 
diameters (D50) for budesonide particles exiting MT when tested with Method (c) using 
IPs shown in Figure 6.2. Values for D50 (stage cutoff diameters) were plotted for the 100 
L/min airflow test condition in accord with USP’s archival flow calibration (Marple et al., 
2003a; U.S. Pharmacopeial Convention, 2013).  
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Aerosol Deposition Results  
Whole-Airway CFD Methods vs. Combined In Vitro–CFD Methods  
One purpose of this chapter was to evaluate whether the CFD model and 
programming methods developed by Tian et al. (2015a), in which deposition was also 
modeled in MT, could be modified and coupled to the realistic in vitro test methods 
described in Chapter 5. The main differences between the two methods were the aerosol 
particle injection site at which particle tracking begins and their associated APSDs, and 
the effects of the existence or absence of the laryngeal jet on air turbulence and flow 
profiles entering the trachea. Given the absence of significant differences between the 
aerosol that enters a theoretical MT from Budelin in Tian et al. (2015a) and that entering 
the model MT (Figures 6.4 and 6.5), as well as the use of comparable IPs in both cases 
(Figure 6.6), Tian et al.’s CFD predictions for MT deposition (Tian et al., 2015a) should 
compare well with those seen experimentally with the caveats noted in the discussion 
above. Indeed, the percent of the drug dose depositing in MT and the inhaler from both 
techniques appeared to be comparable with the in vivo results for fast inhalation as shown 
in Table 6.2. There were discrepancies however. The APSD data used in the CFD 
simulations in both cases is presented in Figure 6.9a where the difference between the 
curves should represent MT deposition; this experimental data, and the CFD data on file 
from Tian et al. (2015a) enabled computation of the CFD-predicted APSD for MT 
deposition that in turn enabled computation of the theoretical APSD entering the trachea 
according to Tian et al. (2015a) (Figure 6.9b; red curve). While the curves were broadly 
similar at aerodynamic diameters ≤9 µm, the discontinuity in the red profile at 
approximately 11 µm indicated the injection of almost 5% of the dose into the trachea as 
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large particles in Tian et al. (2015a). This difference in APSD entering the trachea 
between the two methods appeared to justify the experimental determination of both 
TLDin vitro and the APSD of the aerosols exiting MT and entering the trachea. This being 
said however, it is quite possible that variations within and between inhalers (as well as 
the use of the mixing inlet as a conduit to NGI) may also contribute to the apparent 
reduction seen in large particles exiting MT when realistic testing was employed. 
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 (a)      (b) 
Figure 6.9. (a) APSD data used in CFD simulations for fast inhalation by Tian et al. 
(2015a) and in this chapter (particles introduced into trachea). These data were produced 
experimentally using Methods (a) and (c) described above. (b) APSD data for aerosols 
exiting the MT model. In vitro–CFD results (blue curve) are identical to those shown in 
the left panel. Results from Tian et al. (2015a) (red curve) were computed from the CFD 
results of Tian et al. (2015a) by subtracting the predicted MT deposition for fast inhalation 
(Tian, 2015). Data are presented as the mean percent of the metered dose vs. the 
midpoint of the upper and lower stage cutoff diameters at the designated flow rates in the 
fashion of Tian et al. (2015a).  
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Variations in Regional Drug Deposition in the Lung  
To evaluate the ability of the in vitro–CFD method as a means of predicting 
variations in regional drug deposition in the airways, additional CFD studies were 
performed using different IPs and APSDs for Budelin’s TLDin vitro and introducing these to 
the trachea of the modified airway model (Figure 6.3b). IPs were simulated to mimic the  
subject groups’ moderate and slow inhalation conditions as described by Newman et al. 
(2000) (Figure 6.2); these IPs were paired with the mean APSDs produced using Method 
(c) [presented as the mean percent of the aerosolized dose depositing on a selected 
stage vs. the midpoint of the upper and lower stage cutoff diameters at the designated 
flow rates in the fashion of Tian et al. (2015a) as shown in Figure 6.10] and used as initial 
conditions for CFD simulations. Regional lung deposition results were compared across 
all three inhalation conditions (fast, moderate, slow) and also with the in vivo lung 
deposition data reported by Newman et al. (2000) in Figure 6.11 and Table 6.3. 
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Figure 6.10. APSD data for the CFD simulations used for fast, moderate and slow 
inhalation conditions. Data are presented as the mean percent of the aerosolized dose 
depositing on a selected stage vs. the midpoint of the upper and lower stage cutoff 
diameters at the designated flow rates in the fashion of Tian et al. (2015a). These 
experimental results were calculated from the data shown in Figures 6.7 and 6.8 and 
produced using Method (c).   
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          (a)                (b) 
Figure 6.11. Regional drug deposition in the lung model as predicted using the in vitro–
CFD approach for fast, moderate and slow inhalation conditions. Data are presented (a) 
as % total lung dose in vitro (TLDin vitro; ±SD; n = 3) and (b) as % aerosolized dose (±SD; 
n = 3) for budesonide from Budelin Novolizer depositing theoretically at trachea to B3, B4 
to B7, B8 to B15, and alveolar (>B15) regions of the modified lung model (Figure 6.3b). 
Significant differences were observed for the percent of TLDin vitro depositing in the B4 to 
B7, B8 to B15, and alveolar regions across the three inhalation conditions (one-way 
ANOVA, p<0.05).
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Budesonide aerosol deposition in trachea to B3, B4 to B7, B8 to B15, and alveolar 
(>B15) regions are summarized as %TLDin vitro in Figure 6.11a. For all three inhalation 
conditions, <5% of TLDin vitro deposited in trachea to B3, while the majority (>60% of TLDin 
vitro) deposited in the alveolar region. When comparing the regional deposition of TLDin vitro 
across the three inhalation conditions, significant differences were observed for B4 to B7, 
B8 to B15, and alveolar (one-way ANOVA, p<0.05), suggesting that the combination of 
subjects’ IPs and the associated APSDs in this study affected the regional drug deposition 
of the likely lung dose in each case. The effect was most pronounced for the fast 
inhalation condition, where much lower deposition was observed in B8 to B15 (and much 
higher deposition in alveolar) than those for the moderate and slow inhalation conditions, 
indicating the importance of the smaller aerosol produced during fast inhalation (Figure 
6.8). Aerosol deposition data are also presented as % aerosolized dose in Figure 6.11b 
and Table 6.3 to evaluate the likely variations in regional drug dose in the lung. In general, 
fast inhalation produced the highest theoretical deposition in trachea to B3, B4 to B7 and 
the alveolar regions, but the lowest deposition in B8 to B15 among these three inhalation 
conditions. When comparing these data with the in vivo lung deposition results (Newman 
et al., 2000), we again found that the combined in vitro–CFD approach [when coupled 
with the airway mapping technique developed by Tian et al. (2015a)] appeared to 
underestimate drug deposition in the central lung and overestimate delivery to the 
periphery. However, because the fraction of peripheral overlap of the central airways 
assigned by gamma scintigraphy is unknown, a direct comparison between CFD 
prediction and two-dimensional (2D) scintigraphy has limitations. Future studies may be 
needed therefore, before making firm conclusions about the validity of either of approach.  
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Overall, theoretical regional drug deposition predicted using in vitro results coupled 
to the modified CFD model [Figure 6.1c coupled with Tian et al.’s CFD programming 
method (Tian et al., 2015a) in the modified lung model] were compared with those 
reported by Tian et al. (2015a) for fast inhalation and the in vivo data of Newman et al. 
(2000) for fast, moderate and slow inhalation. For ease of comparison with Tian et al. 
(2015a), Table 6.2 and 6.3 were constructed in the fashion of (Tian et al., 2015a). Both 
methods produced comparable results with the in vivo deposition data for fast inhalation 
(Newman et al., 2000) for drug retention on the inhaler and MT (“MP+MT”). To compare 
the regional lung deposition results based on CFD simulation with the in vivo data, Tian 
et al. (2015a) defined B1 to B7 as the central lung and B8 to alveolar as the intermediate 
and peripheral lung and used these regions to compare to those defined by Newman et 
al. (2000).  This was based on using the lung division method of Newman et al. (2000) 
and applying it to the SIP CFD-based lung model. These same definitions were used in 
this chapter. The CFD methods used by Tian et al. (2015a) showed lower deposition in 
the central lung and higher deposition in the intermediate and peripheral lung than the 
published in vivo results (Newman et al., 2000) (Table 6.2), but a general trend of 
agreement between in vivo and in vitro–CFD results was seen to occur as the IP slowed 
from “fast” through “slow” inhalation (Table 6.3). Tian et al. (2015a) suggested that their 
underestimation of central lung deposition (which was within 10% relative error of the in 
vivo results) could be due to its overestimation by 2D gamma scintigraphy [because a 
significant fraction of the peripheral airways are captured in the central region by 
scintigraphy]. Their explanation is highly plausible. The “underestimation” of budesonide’s 
central lung deposition seen by Tian et al. (2015a) was magnified by the combined in 
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vitro-CFD approach described here, in large part because of the absence of air turbulence 
introduced by the laryngeal jet (Xi et al., 2008) and values assigned for the APSD of each 
TLDin vitro (Figure 6.9b and 6.10) as aerosols entering the trachea.  
In practice, the regional airway deposition of aerosols delivered from inhalers is 
known to be difficult to assess clinically. Extensive overlap between the central and 
peripheral airways can be expected when the three-dimensional (3D) lung geometry is 
projected onto the 2D plane in gamma scintigraphy studies. Schroeter et al. (2005) 
developed a 3D airway model using human morphological data and quantified the 
composition of different airways in the central, intermediate and peripheral lung (as those 
defined in gamma scintigraphy studies) by superimposing those regions on the planar 
view of their model. They found that over 18% of alveolar airways (>B17 in Schroeter et 
al.’s model) were captured in what appeared to be the central lung, and that these airways 
comprised about 80% of the total volume of airways in that region (Schroeter et al., 2005). 
Given that a large proportion of budesonide aerosols (>60% of TLD; Table 6.2) were 
predicted to deposit in the alveolar region (>B15) using both CFD methods discussed 
here, it appears to be necessary to account for a significant “peripheral fraction” appearing 
as central deposition when comparing results from CFD airway modeling with in vivo data 
from gamma scintigraphy.  
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6.4  CONCLUSION 
A new technique was developed and evaluated to combine the realistic in vitro test 
methods described in Chapter 5 and a CFD model to maximize the strengths of both 
approaches in predicting total and regional drug deposition in the lung. Results for 
theoretical regional drug deposition in the airways were evaluated for the powder inhaler, 
Budelin Novolizer 200 mcg, under three inhalation conditions using this hybrid in vitro–
CFD approach. Variations in results for drug deposition indicated that IPs and the APSDs 
of TLDin vitro appeared to affect drug deposition in the MT and airways of a model human 
adult respiratory tract. While future studies may be needed to incorporate variations in 
airway geometries across a population as well as effects of age and disease on those 
geometries, the combined approach appeared to show promise for predicting aerosol 
deposition in the lung. While changes in the inhalation profiles used by subjects using 
powder inhalers appeared likely to modify the dose of drug reaching the lung and its 
deposition across the airways, the model appeared to indicate that most of the dose from 
Budelin that escapes the MT region, was likely to reach beyond generation 15 into the 
lung periphery. This result indicated that the fraction of “peripheral deposition” that is 
usually reported in gamma scintigraphy studies is disproportionally low; a proportion of 
the counts usually attributed to deposition in the “central region” of the lung should be 
shifted to the periphery to allow for the presence of significant numbers of small 
(peripheral) airways that overlay the “central regions” in 2D lung scintigraphs.  
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CHAPTER 7 
SUMMARY AND CONCLUSIONS 
Realistic in vitro testing of inhaled drug products, coupling human mouth-throat 
(MT) models and inhalation profiles (IP) to allow drug aerosol generation from an inhaler 
and transport into the human respiratory tract to be mimicked under clinically-relevant 
conditions, has shown its potential in establishing in vitro–in vivo correlations (IVIVCs) for 
drug doses likely to enter the lung (TLD). The application of this approach however, 
remains challenging and scientists are left to decide which MT model(s) to choose and 
how to select representative IP(s). Furthermore, regional drug deposition in the lung 
remains unclear, although studies have shown that the deposition site of inhaled drugs 
may well be relevant to their therapeutic effects (Anderson & Newman, 2009; Usmani, 
2015; Usmani & Barnes, 2012; Usmani et al., 2005). This dissertation describes the 
continuing research to develop realistic in vitro performance test methods for dry powder 
inhalers (DPI), with efforts to standardize and improve the existing DPI test methods to 
(a) enable the use of realistic in vitro tests by drug development scientists and regulators, 
and (b) explore the truth about the ranges of the aerodynamic particle size distributions 
(APSD) of drugs that are likely to enter the lung (TLDin vitro) of healthy human adults from 
a marketed DPI. These goals were achieved through the four specific aims described in 
Chapter 2. In brief, these were: (i) select representative MT models for realistic in vitro 
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testing of DPIs; (ii) develop a general method for simulating the ranges of IPs for use with 
a DPI of known airflow resistance; (iii) develop methods for measuring APSDs of 
Budelin’s TLDin vitro across different ranges of IPs; (iv) couple computational fluid dynamic 
(CFD) simulations with realistic in vitro testing techniques to predict regional lung 
deposition of budesonide aerosols from Budelin® Novolizer®. All these aims were 
achieved and the results presented in Chapters 3–6 were consistent with the 
accompanying hypotheses (Chapter 2). 
The methods of selecting representative MT models for realistic in vitro testing 
were described in Chapter 3. Three main types of realistic MT models [the small, medium 
and large Virginia Commonwealth University (VCU) models, the small, medium and large 
Oropharyngeal Consortium (OPC) models, and the medium Alberta Idealized Throat 
(AIT)] were included in the study because those are commercially available and have 
been reported to produce IVIVCs with certain inhalers. The USP induction port was also 
included as a pharmacopeial control. A study was designed to evaluate the effect of MT 
model geometry on drug aerosol retention under realistic human inhalation conditions. 
This was accomplished by testing the eight, internally-coated MT models across a range 
of realistic IPs with Salbulin® Novolizer®. The models produced different values for TLDin 
vitro and most notably, the three medium MT models (VCU, OPC, AIT) did not show 
statistically comparable results. Interestingly however, the USP induction port produced 
comparable results with VCU and AIT models when tested with Salbulin in this study 
perhaps indicating some geometric similarities between those realistic MT models and 
the standardized USP induction port employed routinely for quality control of inhalers. 
Although we have yet to identify which medium MT is most “representative”, as these 
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models were designed based on different philosophies and no clinical lung deposition 
data for Salbulin are available for evaluating its in vitro properties, the study suggested 
that caution should be applied when using different MT models to predict TLDin vivo. A 
further implication of this study, and one that is perhaps more important, is that it may be 
necessary to incorporate both the variations in MT geometries and IPs when testing 
inhalers. The present study showed that the VCU and OPC models produced much larger 
ranges for TLDin vitro than the single medium AIT model and the USP induction port. Based 
on the previous studies (Delvadia et al., 2012; Olsson et al., 2013) that clinical variations 
seen in lung deposition could be accounted for by coupling the extremes of MT geometry 
with expected ranges of IPs, both the VCU and OPC models appeared to produce realistic 
variations in TLDin vitro. While the practical advantages of the VCU models overweighed 
their disadvantages for the purposes of this thesis, future studies may be needed to test 
these realistic MT models across different inhalation systems (e.g. MDIs, Respimat®) and 
formulations (e.g. solution-based vs. suspension-based MDIs), before selecting the most 
representative MT models. In addition, CFD simulations may be applied to further our 
understanding of the flow and aerosol behaviors in these different MT geometries.  
Chapter 4 describes the methods of selecting and simulating the range of 
representative IPs for use when testing a DPI with known airflow resistance. This study 
was designed to enable drug development scientists to select IPs for a new DPI a priori 
and predict inhaler performance in the clinic using realistic in vitro testing techniques. To 
achieve this goal, inhalation profile data from an existing VCU clinical trial (Delvadia, 2012) 
were reanalyzed, where a group of inhaler-naïve, mixed-gender, healthy human adults 
were trained (a) by leaflet reading and (b) by professional instruction to inhale through a 
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range of airflow resistances (R) typical of those used in commercial DPIs. Elaborate 
statistical analyses were performed by Delvadia (2012) and peak inhalation flow rate 
(PIFR) was found to have a linear correlation with 1/R, while time to reach PIFR (TPIFR) 
and inhaled volume (V) did not show significant correlations with R. Based on those 
analyses, three equations were derived for PIFR as a function of R from the pooled data 
to enable the 10, 50 and 90 percentile values to be predicted for a DPI of known airflow 
resistance for each training status. Because TPIFR and V were independent of R, their 10, 
50 and 90 percentile values could be selected from the cross-gender data regardless of 
the DPI resistance. These statistically-derived inhalation variables allowed representative 
IPs and their realistic variations to be simulated using sinusoidal equations derived from 
curve fitting of the subjects’ IPs (Chapter 4 and Appendix IV). The study provided a 
general method of selecting standard IPs for use in realistic in vitro tests of DPIs during 
the drug development process. Although the data analyses were based on profiles 
collected from healthy adults of both genders, and this was because clinical trial usually 
begins with healthy subjects or largely asymptomatic patients, the method is likely to be 
extended to select representative IPs and their likely variations for target patient groups 
(e.g. asthma patients, COPD patients) or age groups (e.g. pediatric patients, elderly 
patients). The data also showed clearly that professional training affected the subject 
group’s inhalation maneuvers. This was consistent with reports in the literature (Azouz et 
al., 2015a; Azouz et al., 2015b). To fully evaluate DPI performance in vitro, it may be 
necessary to include IPs representative of patients who are “insufficiently trained” in the 
sense that they are left to figure out themselves how to use their inhalers. In addition, IPs 
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for other inhalation systems (e.g. MDIs, MDIs with spacers, Respimat®) may need to be 
collected and generalized to standardize realistic in vitro tests for those inhalers.  
The selection of representative MT models and IPs enabled realistic in vitro test 
methods for DPIs to be developed further, to characterize the likely ranges of APSDs for 
TLDin vitro from Budelin® Novolizer® across different inhalation conditions (Chapter 5). 
The realistic in vitro test methods described in Chapters 3 and 4 were coupled to the 
compendial cascade impactor methods (U.S. Pharmacopeial Convention, 2013) by using 
the Nephele Mixing Inlet (NMI) supplied with dilution air to maintain constant airflow 
through a Next Generation Impactor (NGI). The modified test method enabled APSDs for 
the in vitro lung dose to be determined across a complete range of realistic IPs. To 
evaluate the method’s ability to predict inter-subject variabilities in total and regional lung 
deposition, the small, medium and large VCU MT models were paired with the three sets 
of small, medium and large simulated IPs to mimic those used by subjects in the gamma 
scintigraphy study used with the inhaler that became Budelin® Novolizer® (Newman et 
al., 2000). Because the NGI was operated outside its specific flow range, over which the 
archival calibration is known to function (15–100 L/min), additional studies were designed 
to assess the validity of the theoretical stage cutoff diameters when these were calculated 
according to USP at high flow rate. Four sets of MT-IP combinations were tested at 100 
and 140 L/min NGI flow conditions; the former was used as the calibration standard to 
recalibrate NGI’s stage cutoff diameters at 140 L/min by curve fitting. An important 
observation from this study is that Budelin Novolizer, the DPI known to deliver consistent 
doses when subjected to USP testing (U.S. Pharmacopeial Convention, 2013), showed 
significant variations in lung dose in vivo (Newman et al., 2000); when realistic in vitro 
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tests were conducted and variations in MT geometries and IPs were accounted for, the 
inter-subject variabilities in the in vivo lung doses were likely to be predicted. IVIVCs were 
observed for all three inhalation conditions and this again revealed and confirmed the 
importance of incorporating MT geometry and IP variations in realistic in vitro tests of 
DPIs. Further analyses of the APSDs of Budelin’s TLDin vitro showed that the size 
distributions of drug aerosols likely to enter the lung were also a function of both MT 
geometry and the subject’s inhalation maneuver; the largest variations in APSDs were 
seen for the slow inhalation condition, suggesting that the methods developed in the 
present study were sufficiently precise to distinguish between the different aerosol doses 
and the aerosol sizes likely to enter the trachea. There was no reason to believe that the 
same techniques could not be extended to review the data for other powder inhalers that 
are also used clinically by patients with variable MT geometries and breathing patterns. 
The biggest limitation of the present study was that the APSDs measured at the exit of 
the MT could not be compared directly with the regional lung deposition data from the 
clinical gamma scintigraphy study (Newman et al., 2000). Therefore, to explore the clinical 
importance of the results for APSD, an effort was made in Chapter 6 to predict regional 
drug deposition in the airways using computational fluid dynamic (CFD) simulations in 
combination with the in vitro testing techniques described in Chapter 5. It should be noted 
that the methods described in the present study are different from those used elsewhere 
(Chrystyn et al., 2015; Goodey et al., 2014; Nadarassan et al., 2010; Yakubu et al., 2013) 
and standardization of methods may be needed to facilitate application of realistic in vitro 
tests. Furthermore, some redesign of cascade impactors like NGI and/or their stages to 
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better enable aerosol characterization at high flow conditions may be required to enable 
other DPIs to be characterized across the range of realistic IPs.  
The last study of this dissertation (Chapter 6) was designed to explore regional 
lung deposition and its variation for Budelin Novolizer under three inhalation conditions 
using a new hybrid in vitro–CFD approach. To facilitate coupling of the realistic in vitro 
test methods described in Chapter 5 to CFD simulations, a published airway model and 
the CFD methods described by (Tian et al., 2015a) was modified to allow the values for 
APSDs of Budelin’s TLDin vitro and the associated IPs to be used as the initial conditions 
for CFD simulation at the tracheal opening. When comparing the regional deposition 
results produced using the hybrid in vitro–CFD approach with those from Tian et al. 
(2015a), small but finite differences were observed for the individual segments. This may 
be caused by differences in IPs between the two studies, as well as changes in particle 
injection time and particle trajectories at the tracheal inlet. Most likely however, the 
existence or absence of air turbulence introduced by the laryngeal jet, and differences in 
the APSDs of particles entering the trachea in both techniques appeared to produce 
differences in predicted regional deposition in the airways. The present study also showed 
that variations in IPs and the APSDs of TLDin vitro appeared to affect drug deposition in the 
airways of a model human adult respiratory tract; but regardless of the variations, most 
of the dose from Budelin that escaped the MT region appeared likely to reach beyond 
generation 15 into the lung periphery. The predicted regional deposition results using the 
in vitro–CFD approach were believed to be consistent with those reported in the gamma 
scintigraphy study (Newman et al., 2000), although our work demonstrated that a 
proportion of the counts usually attributed to deposition in the “central region” of the lung 
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should be shifted to the periphery to allow for the presence of significant numbers of small 
(peripheral) airways that overlay the “central regions” in two dimensional lung scintigraphs. 
It should be noted that the CFD model used by Tian et al. (2015a) and that used in the 
present study was designed to represent the “average” geometry of a healthy human 
adult. To further evaluate inter-subject variabilities in regional lung deposition, variations 
in airway geometries across a population may need to be incorporated. In addition, 
aerosol deposition patterns in the patient’s lung may be altered by changes in airway 
morphologies and physiologies (e.g. airway wall thickening, mucus hypersecretion, 
bronchoconstriction, etc.) caused by pulmonary diseases like asthma and COPD (Wang 
et al., 2014). An extensive study on the airway geometries of patients with different 
pulmonary diseases may be needed in future to generalize and select representative 
geometries for specific patient groups.  
Overall, the realistic in vitro test methods described in this dissertation allow total 
and regional drug deposition in the lung of healthy human adults and their inter-subject 
variabilities to be predicted for DPIs. Such methods may benefit both product 
development scientists and regulators as it produces more meaningful in vitro data than 
standard compendial tests (U.S. Pharmacopeial Convention, 2013). While efforts have 
been made to standardize and improve the existing realistic in vitro test methods, how to 
incorporate these methods into bioequivalence studies and guidance documents, and 
ease the development process for generic inhalers, remains to be discussed. More study 
and discussion of this topic and collaboration between different research groups and 
regulators appears to be needed. 
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APPENDIX I 
REGIONAL DRUG DEPOSITION FROM POWDER INHALERS: LUNG 
SCINTIGRAPHY STUDIES IN HEALTHY HUMAN ADULTS 
 
AI.1  INTRODUCTION 
A literature review was performed to identify clinical studies of inhalers in humans 
that provided aerosol drug deposition data according to well-characterized inhalation 
maneuvers that could feasibly be mimicked in vitro using realistic or “bio-relevant” tests 
and models; whence to compare the results of such tests and create in vitro–in vivo 
correlations (IVIVCs). This thesis was focused on assessing the likely regional deposition 
of budesonide from Budelin® Novolizer® 200 mcg based on that inhaler’s in vitro 
performance during realistic testing and subsequent computational fluid dynamics (CFD) 
modeling. Accordingly, the results were compared with the extensive work done by 
Newman et al. [1] on that inhaler using 2D gamma scintigraphy. This Appendix describes 
the process of selection and the merits of that study [1] from the broader aerosol drug 
deposition literature. 
In vivo lung deposition studies for orally inhaled drug products are usually 
performed using gamma scintigraphy studies or pharmacokinetic (PK) studies in which a 
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charcoal block technique to prevent drug absorption from the gastrointestinal (GI) tract. 
Although both approaches allow total lung dose (TLD) to be evaluated, regional drug 
deposition can only be characterized using gamma scintigraphy. To select representative 
inhaler(s) that enable the in vitro measured TLD and CFD predicted regional drug 
deposition results to be compared with the in vivo data, a literature review was initially 
performed to retrieve and evaluate gamma scintigraphy studies for dry powder inhalers 
(DPI), metered dose inhalers (MDI) and soft mist inhalers (SMI). The results of this are 
shown for DPIs in this Appendix.  
 
AI.2  METHODS  
A literature search of peer reviewed journals and conference proceedings was 
performed using Pubmed, Web of Science and RDDonline with the following keyword 
combinations and total results (dated to March 26, 2015): 
An “All Fields” search in Pubmed was performed for: 
(scintigraphy OR planar imaging OR 2D imaging OR two dimensional imaging OR 
lung imaging) AND (inhaler OR pulmonary drug OR inhalation drug OR respiratory 
drug OR aerosol OR lung deposition OR MDI OR DPI OR nebulizer) AND (human 
OR adult OR volunteer OR subject) AND healthy; a total of 387 references were 
found. 
A “topic” search in Web of Science was performed for: 
(scintigraphy OR planar imaging OR 2D imaging OR two dimensional imaging OR 
lung imaging) AND (inhaler OR pulmonary drug OR inhalation drug OR respiratory 
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drug OR aerosol OR lung deposition OR MDI OR DPI OR nebulizer) AND (human 
OR adult OR volunteer OR subject) AND healthy; a total of 204 references were 
found.  
A “keywords” and “title” search in RDDonline was performed for: 
scintigraphy; 62 references were found for “keywords” search and 8 references 
were found for “title” search.  
 
Initial screening of these articles was performed by reading all titles and abstracts, 
after which replicate references were discarded. 93 references were selected from the 
total and tabulated for individual reviews based on the possibility that they contained 
information where all of the following were reported: (a) lung deposition data in a group 
of healthy human adults following the use of radiolabeled formulations from inhalers 
described either within the reference itself or elsewhere, (b) inhalation profile (IP) 
variables used by the subjects in the study , and (c) pharmaceutical aerosol deposition. 
Many of the 93 references failed to provide aspects of this information and were rejected. 
However, 21 studies appeared to be promising for DPIs [1-21]. Data from those was 
tabulated and reviewed further.  
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AI.3  RESULTS AND DISCUSSION 
Inhalers, drugs, inhalation profile parameters and related gamma scintigraphic 
deposition data in healthy volunteers from the 21 possible DPI studies are compiled in 
Table 1. These studies covered the publication period 1992 to 2009. Notably, over half of 
the studies included in Table AI.1 (14 out of 21) were performed by Newman and 
colleagues who generally used standardized techniques; other research groups 
employed their own (alternate) methods to perform and assess lung deposition results 
[e.g. different attenuation factors, definition of lung regions of interest (ROI), etc.]. This 
was not surprising because the studies in Table AI.2 were performed before efforts were 
made to standardize methods in 2012 [2] when it was noted that experimentaldifferences 
in gamma scintigraphic techniques should be carefully considered when selecting 
inhalers for realistic in vitro tests, as cross-study comparisons may be needed to assess 
an resulting IVIVCs.  
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A closer look at the 21 possible studies in Table AI.1 showed that many were 
unsuitable for use when attempting to construct IVIVCs. Not all inhalers (or inhaler-drug 
combinations) were commercially available, and a lack of well described inhalation 
maneuvers and regional lung deposition data in some studies limited our choices further. 
In order to test the in vivo predictability of our methods the following additional criteria 
were established to define acceptable studies for the purpose of IVIVC comparisons: 
(a) Drug inhalers used in the gamma scintigraphy studies must be commercially 
available (to enable in vitro testing); 
(b) Validation of the labeling procedure should be described. In short, a comparison 
between the radiolabel and the drug in a standardized testing situation should 
ensure a comparable aerodynamic size distribution between the drug (from the 
unlabeled inhaler) and the label (from the labeled version); 
(c) Inhalation profile (IP) variables used by subjects in each study should be reported 
with statistics so that it is possible to simulate realistic IPs for in vitro testing. In 
short, values and statistics were required that described peak inspiratory flow rates 
(PIFR) and either total volume inhaled (V) or total inhalation time [before breath 
holding] (T). 
(d) Regional deposition data should be reported to describe the % of each lung dose 
deposited in well-defined lung regions (e.g. central, intermediate and peripheral);  
The references and data shown in Table AI.2 were selected for further 
consideration.   
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Selection of Budelin® Novolizer®  
The ASTA Medica DPI Device and formulation tested clinically by Newman et al. 
[1] became Budelin Novolizer and was marketed by Meda Pharmaceuticals in the EU. 
This thesis is focused on that device primarily because reference [1] had the advantage 
that Budelin was labeled and tested using a cross-over deposition study in the clinic that 
clearly showed the dosing variations and reginal drug deposition results after asking each 
volunteer to inhale at three different peak inspiratory flow rates. We expected to be able 
to see differences in deposition in vitro that resulted from similar variations in the breath 
profiles simulated to mimic each of Newman et al.’s 3 clinical study cohorts [1]. In practice, 
and in the future, however, it may well prove possible to test the IVIVCs by employing the 
data in references [1, 7, 8, 10, 15, 17, 18] that describe the deposition of drug from 
RelenzaTM DiskhalerTM (5 mg zanamivir, GlaxoSmithKline), Easyhaler® (200 mcg 
beclomethasone, Orion Pharma, U.K.), Eklira® Genuair® (322 mcg aclidinium, 
AstraZeneca, U.K.), Budelin® Novolizer® (200 mcg budesonide, Meda Pharmaceutics, 
U.K.), Pulvinal® (200 mcg salbutamol, Chiesi, Italy), Bricanyl® Turbohaler® (0.5 mg 
Terbutaline Sulphate, AstraZeneca, U.K.), and Pulmicort® Turbohaler® (100 mcg 
budesonide, AstraZeneca, U.K.) (Table IA.2). 
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APPENDIX II 
GEOMETRY OF THE MODIFIED VCU MOUTH-THROAT MODELS 
Three dimensional (3D) geometries of the original small, medium and large Virginia 
Commonwealth University (VCU) mouth-throat (MT) models are available at 
www.rddonline.com. These models were modified as shown below by adding a quick-fit 
adapter to allow an airtight connection between the MT and the Next Generation 
Pharmaceutical Impactor or NGI. Dimensions of the NGI quick-fit adapter were the same 
for all three MT models and the dimensions are shown in the figure below in mm. The exit 
of MT was centralized in the adapter in all cases. 
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APPENDIX III 
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APPENDIX IV 
CURVE FITTING METHODS FOR SIMULATING HUMAN INHALATION PROFILES 
AIV.1  INTRODUCTION 
Simulated inhalation profiles (IP) and equations described in Delvadia et al. [1-3] 
require the assignment of Thold, an arbitrarily defined variable, or time to maintain the peak 
inhalation flow rate. Delvadia et al. [1] held the value of Thold constant at 0.15 sec. In this 
thesis, a new process was proposed and published [4], which avoided the need to assign 
values to this variable. As a result, it was possible to advocate methods to simulate ranges 
of human IPs for DPI testing (Chapter 4) based solely on the clinical results from Delvadia 
[3] and a knowledge of the airflow resistance of the inhaler being tested. Essentially, the 
data presented in Delvadia [3] was reanalyzed in the present study in order to find optimal 
mathematical equations for IP simulation in the absence of Thold. 
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AIV.2  METHODS 
A variety of equations were assessed for their ability to describe the IPs presented 
in Delvadia [3]. Several different orders of polynomial equations and a combined 
exponential /sine equation 10 0( ) cos 2
k t tFR t A e A
T
      
 
 were explored and rejected 
because their parameters (e.g. A0, k1) could not be directly assigned to the variables with 
physical meanings in a typical IP such as that shown in Figure 4.4. Therefore, the 
equations described in Delvadia et al. [1] were used as the basis for this study, and curve 
fitting analyses were performed to define values for Thold in the hope that curve-fits would 
be no better in the case where Thold→0. These equations are rewritten below (Equations 
AIV.1–AIV.3) as initially defined in Delvadia [3] and integrated using Mathematica 9.0.1 
(Wolfram, Champaign, IL) to solve the relationship between T (total inhalation time) and 
Thold: 
( ) sin 0
2 PIFRPIFR
t
FR t PIFR t T
T
 
    
 
 Equation AIV.1
 ( ) PIFR PIFR HoldFR t PIFR T t T T       Equation AIV.2
  
    ( ) cos 2
PIFR Hold
PIFR Hold
PIFR Hold
t T T
FR t PIFR T T t T
T T T
  
        
 Equation AIV.3
 
Inhaled volume [V; area under the flow rate (FR) vs. time curve from t = 0 to t = T) 
can be described as a function of the peak inhalation flow rate (PIFR), time to achieve 
PIFR (TPIFR), time to maintain PIFR (Thold), and the total inhalation time (T) from: 
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0
( ) ( ) ( )
( )
30 60 30
PIFR HoldPIFR
PIFR PIFR Hold
T TT T
T T T
Hold PIFR HoldPIFR
V FR t FR t FR t
PIFR T PIFR T T TPIFR T
 


  
   
  
  
 Equation AIV.4
 
2
[ ( ) ]
60
Hold HoldPIFR T T T
V 
  
  Equation AIV.5
 
Or: 
60
( )
2 Hold Hold
V
T T T
PIFR

    Equation AIV.6
The real data in 10, 50, and 90 percentile FR vs. time profiles for all six resistances 
(red inhalation profiles in Figure 4.5 of Chapter 4) were used for curve fitting, and a total 
of 18 Text files [defined as an input format in MATLAB® R2012b (MathWorks, Natick, 
MA); 3 profiles for each resistance, 6 resistances in total) were created to store the FR 
vs. time data. In practice, each curve contained > 300 individual data points with a time 
interval of 0.005 sec. For each profile, values for PIFR were selected using the MAX 
function across all flow rates in Microsoft Excel 2013 (Microsoft Corporation, Redmond, 
WA), and the values for V under each IP were obtained by calculating the area under 
each curve trapezoidally. To facilitate curve fitting, values for TPIFR were fixed at three 
selected values: 0.276 sec, 0.493 sec, and 0.885 sec that corresponded to the 10, 50 and 
90 percentile values of the 240 TPIFR values from the trial population (Figure 4.5 of Chapter 
4). Non-linear least-squares curve fitting was then used with Thold floating in Equations 
AIV.1–AIV.3 to assess the goodness of fit for each data set. Combinations of PIFR, V and 
TPIFR that were employed at summarized in Table 1. All analyses were performed in 
MATLAB® R2012b. Examples of MATLAB scripts are shown in Figures AIV.1 and AIV.2.  
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Table AIV.1. Combinations of PIFR, V and TPIFR used to curve fit the 10, 50 and 90 
percentile IPs across six resistances. Each of the 18 inhalation profile data sets was 
analyzed for all three TPIFR conditions to determine the best estimate for the Thold.  
Resistance 
(kPa0.5 L-1 min) 
Profile 
PIFR 
(L/min) 
V 
(L) 
0.0462 
(Tube 1) 
10 Percentile 45.781 1.352 
50 Percentile 58.297 2.557 
90 Percentile 74.456 4.432 
0.0432 
(Tube 2) 
10 Percentile 52.556 1.389 
50 Percentile 65.564 2.694 
90 Percentile 78.977 4.369 
0.0344 
(Tube 3) 
10 Percentile 60.773 1.466 
50 Percentile 73.085 2.575 
90 Percentile 93.259 4.428 
0.0241 
(Tube 4) 
10 Percentile 76.887 1.43 
50 Percentile 98.160 2.723 
90 Percentile 126.241 4.64 
0.0200 
(Tube 5) 
10 Percentile 92.543 1.469 
50 Percentile 110.811 2.7 
90 Percentile 147.181 4.862 
0.0179 
(Tube 6) 
10 Percentile 95.286 1.435 
50 Percentile 122.947 2.733 
90 Percentile 162.254 4.773 
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Figure AIV.1. MATLAB scripts for defining functions used for curve fitting. The above 
example was shown for the 50 percentile profiles from Tube 4. Values for PIFR, V and 
TPIFR were assigned and THold was defined as the unknown (floating) parameter in each 
case.  
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Figure AIV.2. MATLAB scripts for curve fitting of Thold using non-linear least-squares 
approach. The above example was shown for the 50 percentile profiles of Tube 4. Data 
were imported as a matrix where “t” refers to inhalation time and “Q” refers to flow rate. 
“lsqcurvefit” function was used to perform non-linear least-squares curve fitting.  
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AIV.3  RESULTS 
Best estimates for Thold and the statistical parameters resulting from each of the 
profiles are summarized for the three tested TPIFR conditions in Tables AIV.2–AIV.4. The 
results showed that the best estimate for Thold was zero in 52 out of 54 cases. Only in two 
of 54 cases (10 percentile profile for Tube 1 in Tables AIV.2–AIV.3) was a small positive 
value for Thold seen to be a better estimate value than zero.  Based on these analyses, 
the finite variable choice of Delvadia [3] for Thold = 0.15 sec eliminated from Equations 
AIV.1–AIV.3 and the Equations AIV.7–AIV.8 shown below used for simulating human 
inhalation profiles in this thesis.  
( ) sin 0
2 PIFRPIFR
t
FR t PIFR t T
T
 
    
 
 Equation AIV.7
 
 
( ) cos
2
PIFR
PIFR
PIFR
t T
FR t PIFR T t T
T T
 
      
 Equation AIV.8
Equations AIV.7–AIV.8 are the same as those presented in the simulation in Chapter 4 
(Equations 4.7–4.8) and reference [4].  
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Table AIV.2. Best estimates for Thold and statistical parameters from curve fitting the 10, 
50 and 90 percentile profiles across six resistances (TPIFR = 0.276 sec; 10 percentile value 
in the total population). RMSE = root mean square error (used to measure the difference 
between predicted value and observed value); r2 = coefficient of determination (used to 
assess how well the data fit a model).  
Resistance 
(kPa0.5 L-1 min) 
Thold 
(Best Estimate; sec)
95% CI 
(Lower, Upper) 
RMSE r2 
0.0462 
(Tube 1) 
0.067 -0.029 0.163 6.79 0.751 
0.000 -0.076 0.076 4.84 0.880 
0.000 -0.084 0.084 7.33 0.857 
0.0432 
(Tube 2) 
0.000 -0.109 0.109 9.58 0.600 
0.000 -0.066 0.066 5.48 0.902 
0.000 -0.049 0.049 4.72 0.954 
0.0344 
(Tube 3) 
0.000 -0.090 0.090 9.33 0.669 
0.000 -0.052 0.052 5.57 0.932 
0.000 -0.067 0.067 8.31 0.888 
0.0241 
(Tube 4) 
0.000 -0.092 0.092 15.65 0.548 
0.000 -0.049 0.049 8.50 0.918 
0.000 -0.053 0.053 10.22 0.928 
0.0200 
(Tube 5) 
0.000 -0.129 0.129 29.24 0.047 
0.000 -0.053 0.053 11.13 0.897 
0.000 -0.040 0.040 9.57 0.958 
0.0179 
(Tube 6) 
0.000 -0.113 0.113 26.99 0.198 
0.000 -0.054 0.054 13.48 0.878 
0.000 -0.051 0.051 14.29 0.917 
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Table AIV.3. Best estimates for Thold and statistical parameters from curve fitting the 10, 
50 and 90 percentile profiles across six resistances (TPIFR = 0.493 sec; 10 percentile value 
in the total population). RMSE = root mean square error (used to measure the difference 
between predicted value and observed value); r2 = coefficient of determination (used to 
assess how well the data fit a model).  
Resistance 
(kPa0.5 L-1 min) 
Thold 
(Best Estimate; sec)
95% CI 
(Lower, Upper) 
RMSE r2 
0.0462 
(Tube 1) 
0.025 -0.020 0.071 3.22 0.944 
0.000 -0.050 0.050 3.24 0.946 
0.000 -0.087 0.087 7.78 0.839 
0.0432 
(Tube 2) 
0.000 -0.059 0.059 5.42 0.872 
0.000 -0.031 0.031 2.65 0.977 
0.000 -0.055 0.055 5.40 0.940 
0.0344 
(Tube 3) 
0.000 -0.046 0.046 5.01 0.905 
0.000 -0.021 0.021 2.35 0.988 
0.000 -0.064 0.064 8.05 0.894 
0.0241 
(Tube 4) 
0.000 -0.043 0.043 7.96 0.883 
0.000 -0.027 0.027 4.85 0.973 
0.000 -0.053 0.053 10.56 0.923 
0.0200 
(Tube 5) 
0.000 -0.079 0.079 19.75 0.565 
0.000 -0.019 0.019 4.33 0.984 
0.000 -0.036 0.036 8.76 0.965 
0.0179 
(Tube 6) 
0.000 -0.062 0.062 16.40 0.704 
0.000 -0.020 0.020 5.15 0.982 
0.000 -0.057 0.057 16.70 0.887 
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Table AIV.4. Best estimates for Thold and statistical parameters from curve fitting the 10, 
50 and 90 percentile profiles across six resistances (TPIFR = 0.885 sec; 10 percentile value 
in the total population). RMSE = root mean square error (used to measure the difference 
between predicted value and observed value); r2 = coefficient of determination (used to 
assess how well the data fit a model). 
Resistance 
(kPa0.5 L-1 min) 
Thold 
(Best Estimate; sec)
95% CI 
(Lower, Upper) 
RMSE r2 
0.0462 
(Tube 1) 
0.000 -0.070 0.070 5.11 0.859 
0.000 -0.102 0.102 6.76 0.765 
0.000 -0.116 0.116 10.79 0.690 
0.0432 
(Tube 2) 
0.000 -0.053 0.053 5.31 0.877 
0.000 -0.077 0.077 6.91 0.844 
0.000 -0.097 0.097 9.97 0.795 
0.0344 
(Tube 3) 
0.000 -0.072 0.072 8.57 0.721 
0.000 -0.077 0.077 9.09 0.818 
0.000 -0.093 0.093 12.33 0.753 
0.0241 
(Tube 4) 
0.000 -0.041 0.041 9.14 0.846 
0.000 -0.074 0.074 14.82 0.750 
0.000 -0.088 0.088 18.80 0.756 
0.0200 
(Tube 5) 
0.000 -0.040 0.040 12.72 0.820 
0.000 -0.068 0.068 17.08 0.758 
0.000 -0.075 0.075 20.12 0.816 
0.0179 
(Tube 6) 
0.000 -0.034 0.034 11.78 0.847 
0.000 -0.065 0.065 19.88 0.735 
0.000 -0.093 0.093 29.63 0.644 
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2. Wei X, Byron PR, Longest PW: Predicting variations in lung dose with different mouth-
throat models. In Respiratory Drug Delivery 2014. Volume III. Edited by Dalby R, 
Byron PR, Peart J, Farr SJ, Suman JD, Young PM, Traini D. River Grove, IL: DHI 
Publishing; 2014: 773-776. Available at www.rddonline.org 
3. Wei X and Byron PR: Predicting total lung dose in vitro (TLDin vitro) with different mouth-
throat (MT) models”. Poster presentation at the 2013 AAPS Annual Meeting and 
Exposition, San Antonio, TX, November 10-14, 2013, Poster R6184. Available at 
http://abstracts.aaps.org/published/ContentInfo.aspx?conID=43425 
c. Translated Articles and Book Chapters 
1. Li M, Yu X: Intellectual property protection and enforcement for pharmaceuticals in 
China: status and trends. In Respiratory Drug Delivery 2015. Volume I. Edited by 
Dalby R, Byron PR, Peart J, Farr SJ, Suman JD, Young PM, Traini D. River Grove, 
IL: DHI Publishing; 2015: In Publication. Available at www.rddonline.org (Chinese to 
English) 
2. Li M: Regulatory Requirements for Inhalers in China. In Respiratory Drug Delivery 
2012. Volume I. Edited by Dalby R, Byron PR, Peart J, Suman JD, Farr SJ, Young 
PM. River Grove, IL: DHI Publishing; 2012: 119-136. Available at www.rddonline.org 
(Chinese to English) 
3. Zhou D, R. Porter W, G.Z. Zhang G: Chapter 5 - Drug stability and degradation 
studies. In Developing Solid Oral Dosage Forms: Pharmaceutical Theory and 
Practice. Edited by Qiu Y, Chen Y, Zhang G, Liu L, and Porter W. San Diego: 
Academic Press; 2009: 87-124. (English to Chinese, Chinese version published in 
2013) 
4. Porter WR: Chapter 10 - Applied statistics in product development. In Developing 
Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. Edited by Qiu Y, 
Chen Y, Zhang G, Liu L, and Porter W. San Diego: Academic Press; 2009: 87-124. 
(English to Chinese, Chinese version published in 2013) 
 
213 
 
5. Yang Y, Yu LX: Chapter 12 - Oral drug absorption, evaluation, and prediction. In 
Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. Edited by 
Qiu Y, Chen Y, Zhang G, Liu L, and Porter W. San Diego: Academic Press; 2009: 87-
124. (English to Chinese, Chinese version published in 2013) 
6. Qiu Y: Chapter 17 - In vitro–in vivo correlations: fundamentals, development 
considerations, and applications. In Developing Solid Oral Dosage Forms: 
Pharmaceutical Theory and Practice. Edited by Qiu Y, Chen Y, Zhang G, Liu L, and 
Porter W. San Diego: Academic Press; 2009: 87-124. (English to Chinese, Chinese 
version published in 2013) 
7. Newman S: Chapter 1 - The background to pulmonary drug delivery in man. In 
Respiratory Drug Delivery: Essential Theory and Practice, Newman, S, Anderson, P, 
Byron PR, Dalby, R, and Peart, J, Richmond USA: RDD Online / Virginia 
Commonwealth University, 2009: 1-28. (English to Chinese, Chinese version 
published in 2011) 
8. Newman S: Chapter 2 - Aerosol properties and deposition principles. In Respiratory 
Drug Delivery: Essential Theory and Practice, Newman, S, Anderson, P, Byron PR, 
Dalby, R, and Peart, J, Richmond USA: RDD Online / Virginia Commonwealth 
University, 2009: 29-58. (English to Chinese, Chinese version published in 2011) 
d. Patent Application 
1. China Patent Application. Xi Q, Wei X, Chen L, Li J, Jin F. An injectable drug 
composition and preparation methods. Application #CN201010230586.2. Withdrawn 
on March 11, 2015.    
III. AWARDS 
2015 2015 Graduate Training /Travel Fund. Received at the 18th Annual 
Pharmaceutical Sciences Graduate Program Student Awards luncheon, May 
22, 2015. Virginia Commonwealth University, Richmond VA. 
2013 Joseph Schwartz Graduate Student Travel Award. Received on School of 
Pharmacy 16th Annual Pharmaceutical Sciences Research and Career Day, 
November 8, 2013. Virginia Commonwealth University, Richmond VA.  
 
 
